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ABSTRACT 
 The increasing healthcare burden of type 1 diabetes (T1D) makes finding 
preventive or therapeutic strategies a global priority. This chronic disease is 
characterized by the autoimmune destruction of the insulin-producing β cells. 
This destruction leads to poorly controlled blood glucose and accompanying life 
threatening acute and chronic complications. The role of viral infections as 
initiating factors for T1D is probable, but contentious. Therefore, my goal is to 
better characterize the effects of viral infection on human β cells in their function 
of producing insulin and to define innate immune gene responses in β cells upon 
viral infection. These aspects were evaluated in various platforms including mice 
engrafted with primary human islets, cultured primary human islets, β cells 
derived from human stem cells, and a human β cell line. Furthermore, the 
contributions of cell-type specific innate immune responses are evaluated in flow 
cytometry-sorted primary human islet cells. Taken together, the results from 
these studies provide insights into the mechanisms of the loss of insulin 
production in β cells during virus infection, and characterize the antiviral innate 
immune responses that may contribute to the autoimmune destruction of these 
cells in T1D. 
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CHAPTER I: INTRODUCTION 
1.1: The global impact of diabetes mellitus 
Type 1 diabetes (T1D) is a growing health issue worldwide. The incidence 
of T1D has increased over the past decades and is projected to continue on this 
trend1. The prevalence of the disease was 1.93 people per 1,000 in the United 
States population in 20092. In addition to the impact of this chronic disease on 
the quality of life, diabetes also presents a dramatic economic burden. In the 
United States, the estimated cost of all diagnosed diabetes was $176 billion in 
direct medical costs in 2012. As much as $69 billion is lost due to combined 
reduced work productivity and inability to work3. Despite advances in diagnosis 
and therapies for diabetes, this disease continues to place a significant burden 
on patients, families, and public health.  
1.2: Symptoms and complications of diabetes mellitus 
Diabetes mellitus causes chronic hyperglycemia and includes symptoms 
of frequent urination, increased thirst and increased hunger, as well as non-
specific symptoms of blurry vision, headache, and fatigue4. Diagnosis of diabetes 
mellitus is imperative to properly maintain blood glucose levels and prevent 
serious acute and chronic complications. A clinical diagnosis can be made with 
blood glucose measurements. Fasting blood glucose levels greater than 125 
mg/dL and non-fasting glucose greater than 200 mg/dL both indicate a 
hyperglycemic state. Additionally, an oral glucose tolerance test (OGTT) can be 
administered to test the physiological response to a bolus of glucose. A blood 
 2 
glucose measurement that is greater than 200 mg/dL 2 hours after an OGTT is 
indicative of diabetes. Additionally, glycated hemoglobin A1C (HbA1C), a marker 
of long-term glycemic control, can be utilized in diagnosis. Levels greater than 
6.5% are considered in the diabetic range5. A positive test for any of these tests 
would require further evaluation for the therapeutic regimen to be developed.  
Diabetes mellitus is associated with a variety of acute and chronic 
complications. The most common acute complication of diabetes mellitus is 
diabetic ketoacidosis. This occurs when diabetes leads to low levels of insulin, 
which increases breakdown of stored fatty acids in a process called lipolysis. The 
breakdown products of oxidative lipolysis in the liver are ketones, which can 
accumulate and cause metabolic acidosis. Diabetic ketoacidosis is a severe 
metabolic complication that can lead to coma and death6. Severe chronic 
complications arise from undiagnosed or poorly managed diabetes mellitus over 
a long period of time. Chronic diabetes mellitus is associated with atherosclerotic 
disease that affects the macro- and microvasculature. Perturbations in 
microvasculature blood flow leads to kidney damage, retinopathy, and peripheral 
neuropathy7. The prevention of acute and chronic complications of diabetes 
requires accurate diagnosis and careful management of the disease. 
Hypoglycemia is also a complication of diabetes and may result from skipping 
meals, high intensity exercise, or the improper administration of insulin or 
diabetes management drugs. In extreme cases a rapid drop in blood sugar 
causes anxiety, sweating, trembling, confusion, seizures, or even coma8.  
 3 
1.3: Diabetes mellitus is a heterogeneous disease 
In the late 19th century, physicians began to recognize two distinct forms 
of diabetes mellitus that require different forms of treatment9. Prior to the 
purification of insulin for therapeutic use, the two forms of diabetes presented 
with different progression and outcomes. The first form was characterized as a 
rapid wasting disease where the condition of patients declined over the course of 
months. The second form was associated with overweight, older patients with 
much slower progression that could often be prolonged through alterations in 
diet9. The isolation of insulin from canine islets of Langerhans followed by the 
administration of bovine insulin extracts in diabetic patients ushered in a new era 
of understanding of diabetes mellitus10. The response to insulin treatment 
became a differentiating factor to separate patients broadly into insulin-sensitive 
and insulin-resistant diabetes mellitus9: insulin-sensitive patients would respond 
similar to healthy individuals upon administration of a bolus of glucose followed 
by intravenous insulin. This led to the hypothesis that insulin-sensitive diabetes is 
due to the deficiency of insulin production11. Eventually the insulin-sensitive form 
of diabetes would be referred to as type 1 diabetes mellitus9. Currently the 
American Diabetes Association further divides this category based on etiology. 
Type 1A diabetes is immune mediated and type 1B diabetes is non-immune 
mediated12. The remainder of this thesis will focus on type 1A diabetes mellitus, 
and will be referred to as simply T1D.  
T1D is characterized by immune-mediated destruction of the insulin-
producing β-cells of the pancreas. The current view of the natural progression of 
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this disease is as follows. Environmental triggers that may occur in utero or early 
in life combine with a genetic predisposition to cause immune dysregulation in 
the form of autoreactive B and T cells. The destruction of β cells by 
autoantibodies and cytotoxic T cells occurs over the course of months or 
decades before changes in glycemic control are detectable13. A considerable 
proportion of β cells are destroyed before metabolic changes in insulin production 
are detectable. By the time of diagnosis, most patients retain only 10-20% of β 
cell function14. Patients with T1D usually present with general diabetes mellitus 
symptoms, but also experience weight loss and have higher incidence of 
ketoacidosis. Routine testing for T1D reveals elevated fasting glucose and a 
positive OGTT, with only mild increases in HbA1c15.  
1.4: Autoimmunity in T1D 
Autoimmunity in T1D is mediated by β cell autoantibodies and infiltration 
of the islets of Langerhans with immune cells that include cytotoxic CD8+ T cells. 
This infiltration of immune cells is referred to as insulitis. Antibodies commonly 
associated with T1D are directed against proinsulin (IAA), glutamic acid 
decarboxylase-65 (GAD65), tyrosine phosphatase (IA2), and zinc transporter 
ZnT8 (Slc30A8) 16. These autoantibodies are referred to collectively as islet cell 
antibodies (ICAs). Some of these proteins are also targets of autoreactive CD8+ 
T cells that mediate direct killing of the targeted β cells17,18.  
 The presence of autoantibodies IAA, GAD65, and IA2 is predictive of 
progression to T1D19. These autoantibodies develop sequentially, with IAA 
antibodies often presenting first. High affinity antibodies in patients are reactive to 
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residues in the N-terminal region (residues 8-13) of proinsulin20. Despite 
autoantibodies against GAD65 often developing after IAA antibodies, GAD65 
antibodies are still detectable several years before metabolic diagnosis of 
T1D21,22. While IAA is specific to T1D, GAD65 antibodies may be a more general 
marker of autoimmunity16. Detection of autoantibodies is a predictive marker for 
individuals who may progress to T1D and allows for early therapeutic 
intervention.  
In addition to autoantibody production, the T cell response against 
proinsulin could help explain the highly efficient destruction of β cells in the 
development of T1D.The high number of CD3+ T cells infiltrating the islets in T1D 
patients is evidence of T cells contributing to the progression of the disease23. T 
cells expanded from lymph nodes of T1D patients recognize a N-terminal epitope 
in proinsulin17. The N-terminal signal peptide and peptide cleavage site is 
recognized by CD8+ T cells from diabetic patients24. T cell responses against 
GAD65 are also detected prior to the onset of clinical diabetes22. T cells cloned 
from patients respond and proliferate in response to presentation of GAD65 
peptides 18. The combination of multiple T cell reactivity against β cell antigens 
further illustrates the highly focused autoimmune reaction against β cells.  
1.5: The current state of T1D therapies  
Insulin replacement therapy, first initiated in the 1920’s, remains the best 
therapeutic option for treating T1D. Advances have occurred in the production 
methods and formulations of insulin, improving pharmacokinetic profiles25. 
Additionally, the development of novel delivery systems of insulin pumps paired 
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with continuous glucose monitoring systems helps to maintain blood glucose in a 
more physiological range. Despite these advances, chronic complications of the 
disease still progress and the danger of hypoglycemic events due to improper 
insulin administration is real. This is especially true in younger patients where 
despite the use of insulin pumps, blood glucose is more variable than suggested 
guidelines to reduce complications26. 
The development of new drugs and therapeutics focuses on modulating 
either the autoimmune destruction of β cells or methods of increasing β cell 
mass. Current approaches for modifying the immune response in T1D aim to 
promote immune tolerance or modulate inflammatory responses. One method 
that showed early promise was vaccination with GAD65 antigen. This was 
thought to induce immune tolerance by reducing the number of autoreactive T 
cells. This strategy failed to prevent the loss of C-peptide or improve clinical 
outcomes in a clinical trial27. Another approach was non-specific suppression of T 
cell function. Suppression of T cells by treatment with the anti-CD3 therapy, 
Teplizumab, could reduce the autoimmune attack on β cells. This treatment helps 
maintain insulin production in newly diagnosed patients28. Several other T1D 
immune therapies are in various stages of development, but have variable effects 
on the maintenance of C-peptide production and have been reviewed15. These 
findings are encouraging, but non-specific immune suppression can leave 
patients susceptible to infections.  
More recently, T regulatory cells (Tregs) were used to suppress the 
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autoimmune destruction of β cells. In a phase I clinical trial, autologous Tregs were 
taken from patients and expanded in vitro. These Tregs were then transferred back 
into patients. This led to an increase in the numbers of long-lived Tregs, and the 
maintenance of C-peptide in several patients 29. This study is proof of principal 
that autologous Tregs can be used to modulate the immune responses in T1D 
patients without the broad depletion of T cells, which could leave patients 
immune compromised. While this new field of immune modulation to counteract 
autoimmunity is promising, the specificity and efficacy of the therapies must be 
improved to be considered a success.  
Immunotherapy approaches may address the autoimmune cause of T1D, 
but β cell mass is usually severely diminished at the time of diagnosis. Therefore, 
these treatments may not be enough to reverse the course of disease30. 
Regenerative and transplant approaches are being developed to replenish the β 
cell mass that is lost in T1D patients. In humans, β cell mass can be increased 
through β cell replication or transdifferentiation from other cells in the pancreas31. 
These processes may be targets for drug treatment to increase the number of β 
cells. β cell transplantation provides another possibility to increase β functional 
capacity. Allograft transplants of islet cells into the liver of T1D patients have 
some efficacy, with rates of insulin independence after transplant ranging from 
10-70%. However, allograft transplantation requires immune suppression to 
prevent the destruction of the engrafted tissue, and many of these drugs exhibit β 
cell toxicity32. New sources of β cells provide alternatives to allogeneic donor 
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tissue. β cells that are directionally differentiated from stem cells can restore 
glycemic control in diabetic mice, and provide new therapeutic opportunities33. In 
the future, autologous stem cells could be differentiated into β cells, allowing for 
autologous transplantation of β cells to increase insulin production capacity. Such 
therapies may need to be combined with immune modulators to stop the 
underlying autoimmune reactions to allow for these cells to survive long term.  
1.6: β cell functions in insulin production and release 
Glucose is absorbed in the intestines and rapidly crosses into the blood 
stream. These sugars are delivered to all cells of the body though circulation to 
provide energy or for storage as glycogen. Circulating glucose levels are tightly 
regulated by the secretion of insulin from β cells. Insulin is a hormone that signals 
cells to increase their uptake of glucose, increase the synthesis of glycogen and 
triglycerides, and suppress hepatic glucose output from gluconeogenesis34. 
These activities act together to reduce blood glucose and increase glycogen 
stores. The control of insulin function incorporates gene transcription, protein 
processing, and control of release. In addition to signaling for the release of 
stored insulin, hormones from the gut trigger increased insulin biosynthesis35. In 
humans, insulin is encoded by a single gene36. Insulin is translated as a single 
polypeptide that is processed into two polypeptide chains joined by disulfide 
bridges37. Insulin is retained in secretory granules until the cell senses high 
concentrations of glucose to stimulate their release. Deficiencies in any of these 
steps can lead to poor control of blood glucose homeostasis, which is detrimental 
to the normal function of many organ systems.  
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β cells respond to increased blood glucose by releasing insulin stores, and 
increasing insulin biosynthesis (Fig. 1.1). Sensing of increased blood glucose by 
β cells is mediated through import of glucose by the glucose transporter 2 
(GLUT2) and the sensing of intracellular glucose by glucokinase (GK)38,39. GK 
mediates the transition of glucose to glucose-6-phosphate and is the rate-limiting 
step in glycolysis40. The metabolism of glucose increases mitochondrial ATP 
synthesis, which initiates the closure of ATP-regulated potassium channels. This 
causes plasma membrane depolarization and the opening of voltage-gated 
calcium channels41. The resulting increase in cytosolic calcium triggers the 
release of insulin granules that are poised for release at the cell surface42. These 
effects of increased glucose metabolism also trigger activation of insulin gene 
expression though the stimulation of the insulin promoter43.  
Insulin biosynthesis begins with the regulation of insulin gene expression. 
Tissue specificity and control of insulin gene expression is controlled by the 
region 5’ of the coding region. This region allows for positive and negative 
regulation in response to physiological stimuli through the binding of transcription 
factors or repressors44. The 5’ flanking region of the insulin gene contains 
positive regulatory motifs for cis-acting elements and trans-activating factors. 
Several of these factors increase their activity in the presence of glucose, which 
could contribute to the increased insulin gene expression in response to 
glucose45. 
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 Insulin gene transcription is also negatively regulated through the activity 
of several proteins. BETA3 can inhibit E box-mediated insulin expression by 
inhibiting the function of E box-activating transcription factors53. The JNK-
activated transcription factor c-Jun can inhibit insulin transcription through 
binding to E154. This could indicate a role of reduction of insulin transcription in 
response to oxidative stress or the presence of pro-inflammatory cytokines. The 
transcription factor c/EBPβ can also reduce insulin transcription by directly 
binding to factors that bind to the enhancer region of the insulin gene55.  
Insulin is translated as preproinsulin in the rough endoplasmic reticulum, 
and is co-translationally converted to proinsulin by the cleavage of the signal 
sequence56. To allow for the glucose-stimulated secretion, insulin must be sorted 
into the regulated secretory pathway of the trans-golgi network. Proinsulin is 
sorted and incorporated into immature dense-core granules to allow for regulated 
release57. The maturation of these granules includes three steps. The first is the 
acidification of the granules58. The second is the cleavage of proinsulin to insulin 
and C-peptide through proteolysis by two proprotein convertases, PC1/3 and 
PC2. The final step in maturation is the removal of nonspecific components of the 
granule including the clathrin protein coat59. These mature insulin granules exist 
as two populations in β cells. The readily releasable pool is pre-docked to the 
plasma membrane with a calcium-dependent fusion complex to allow for first 
phase insulin secretion60. The second pool allows for the prolonged second 
phase of insulin release61. Upon release of insulin from β cells, insulin enters 
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portal circulation and following first pass through the liver, then enters into the 
systemic circulation.  
1.7: Evidence for genetic factors in T1D 
Similar to the heterogeneity of the clinical presentation of diabetes, many 
genetic factors can contribute to diabetes. The complexity of genetic factors is 
highlighted by studies in monozygotic twins. In twin cohorts under the age of 40, 
the concordance between siblings is around 50%. In contrast, the concordance is 
near 90% in cohorts older than 40 years62. The low concordance in the younger 
group highlights the multifactorial nature of the development of T1D.  
Many factors may contribute the development of T1D, and polymorphisms 
at several distinct genetic loci are identified as risk factors. Many non-
synonymous single nucleotide polymorphisms (SNPs) are associated with the 
development of the disease. While the contributions of individual SNPs to the risk 
for developing the disease may be small, different combinations of SNPs 
contribute to the overall risk for an individual. SNPs in human leukocyte antigen 
(HLA) genes, the insulin gene, and non-HLA immune genes are associated with 
the development of T1D.  
Associations of HLA genes with other autoimmune diseases prompted the 
search for HLA genes that contribute to T1D. HLA proteins are expressed on the 
surface of all nucleated cells in the case of the class I major histocompatibility 
complex (MHC), while class II MHC HLA expression is restricted to antigen 
presenting cells on certain types of immune cells. HLA genotypes can account 
for half of the familial clustering of T1D63. Linkage analysis studies identified the 
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6p21 chromosomal region as a genetic susceptibility locus, which initially 
implicated the MHC genes64. This region confers the highest genetic risk for T1D. 
The class II MHC genes, HLA-DR and HLA-DQ, are the most important genetic 
factors and account for approximately 40% of genetic risk for T1D65. Individual 
HLA alleles only contribute modestly to the risk of T1D, but the combined odds 
ratio (O.R.) for all HLA genes together is quite high (O.R. >6.5)66. People with 
two predisposing haplotypes have the greatest risk. The most common risk 
genes are DRB1*0301 (DR3) which often associates with DQA1*0501-
DQB1*0201 (DQ2) and DRB1*0401 or DRB1*0401 (DR4) with DQA1*0301-
DQB1*0301 (DQ8). Protection from T1D is conferred by the HLA-DR2 in 
association with DQB1*060267. 
In addition to HLA genes, SNPs in other genes also contribute to T1D 
susceptibility. Interestingly, β cells themselves express mRNA of >80% of the 
T1D candidate genes, which highlights the role that β cells themselves play in the 
development of the autoimmune attack68. Polymorphisms in the INS gene are 
associated with T1D69. The rs7111341 SNP has one of the most significant 
associations of all the non-HLA risk SNPs70. This association could help explain 
the production of IAA autoantibodies produced in T1D.   
Among the non-HLA SNPs are many genes that are involved in innate 
immune signaling in the production of antiviral interferon responses69,71. The 
SNPs in the innate immune double stranded RNA (dsRNA) sensor, MDA5, that 
decrease its function are associated with protection from T1D72. Tyrosine kinase 
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2 (TYK2) mediates signaling of the type I IFN receptor and SNPs that decrease 
its function are associated with T1D protection. The SNP rs2304256:C>A 
decreases the interaction with the type I interferon receptor (IFNAR1) and 
decreases downstream signaling73,74. TYK2 phosphorylates signal transducer 
and activator of transcription (STAT) to promote the production of interferon 
stimulated genes. SNPs that decrease the function of inhibitory genes of STAT 
function are associated with increased risk of T1D. PTPN2 is a phosphatase that 
inhibits STAT function, and the rs45450798 SNP accelerates progression to T1D 
after the appearance of autoantibodies75. USP18 suppresses STAT driven gene 
production76. The contributions of IFN-I signaling in the context of viral infection 
and contribution to T1D development will be discussed more below and outlined 
in Figure 1.3.  
1.8: Evidence for environmental factors in T1D 
While it is clear that HLA and non-HLA genes contribute to the 
development of T1D, inheritance of high-risk genotypes does not completely 
predict the development of T1D. Therefore, it is possible that these genetic 
variants increase susceptibility to environmental factors that trigger the 
development of the disease. Seasonal incidence and spatial clustering studies 
provided some of the earliest evidence for the potential contribution of 
environment in the development of T1D. Seasonality of T1D incidence is a 
phenomenon first described in 1926 with an increase of cases identified during 
the winter months in Minnesota77. This finding is replicated in a worldwide survey 
of T1D incidence with peak incidence in October through January78. It is unclear 
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from these studies what causes the seasonal incidence. Factors of diet (cows 
milk proteins, vitamin D deficiency), toxins (streptozotocin and nitrites), 
psychological factors have been reviewed79. 
In addition to seasonal variations in T1D incidence, spatial clustering of 
the onset of T1D occurs on both large and small scales. A number of small-scale 
clusters of T1D incidence have also been reported. A cluster of 27 new cases 
was reported in 1986 in one county in England80. Several clusters of family 
members being diagnosed with T1D in a short time frame, often following or 
coinciding with enterovirus infections have been reported (reviewed here81). In 
one case, simultaneous infection of monozygotic twins with enterovirus resulted 
in both siblings developing T1D82. These cases are rare, but they highlight the 
potential combinatorial nature of T1D, combining the predisposing genetic factors 
of family members with a simultaneous exposure to environmental triggers. 
Differences in T1D incidence that varies based on country cannot be entirely 
attributed to racial or ethnic variations between affected countries or regions83. 
Taken together this epidemiological evidence points to environmental factors as 
potential precipitating factors for T1D in genetically predisposed people.  
Epidemiologists have also tried to link environmental exposures of diet, 
toxins, and infections with T1D through case-control studies. In a population 
based, case-control study of 217 T1D patients and 258 control subjects were 
surveyed about consumption of cow’s milk, breastfeeding habits, and infections 
three months prior to the onset of diabetes. This study found that breast feeding 
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for greater than 3 months is associated wit a protective effect (O.R. 0.66), while 
consumption of cow’s milk before three months of age are associated with an 
increased risk (O.R. 1.52). Reports of an infection three months prior to T1D 
onset is a risk factor for developing T1D (O.R. 2.92)84. While these results are 
encouraging for a link between environmental factors, retrospective studies can 
introduce unintended bias in the study and are difficult to identify causality.  
To mitigate the shortcomings of case-control studies, several countries 
have established large-scale prospective studies to identify environmental factors 
contributing to T1D. In the Finnish Type 1 Diabetes Prediction and Prevention 
Study (DIPP), newborns are screened for HLA risk alleles HLA-DQB1*02/*0302 
or *0302/x (where x refers to alleles other than *02, *0301, or *0602). 
Longitudinal samples are taken from these patients every 3-6 months in the first 
2 years of life and then 6-12 months thereafter. Children are screened for the 
formation GAD65, IAA, and IA2 autoantibodies. Post-hoc analysis of birth cohort 
for enterovirus antibodies and viral RNA were both found more commonly in 
children that developed T1D compared to those who did not85,86. Similar results 
were observed in the Diabetes and Autoimmunity Study in the Young (DAISY) in 
children followed prospectively in Colorado. The presence of enteroviral RNA in 
the serum was detected more commonly in children who developed T1D83,87.  
Other prospective studies found no association between enterovirus 
infection and the development of T1D. In the German BABYDIET study, 150 
children who had genetic or familial risk for T1D were followed longitudinally with 
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blood and stool sample collection every 3 months for the first 3 years of life, and 
yearly thereafter. Infections and clinical symptoms were also logged daily for the 
first year. In a follow-up study, samples from 22 children who developed T1D and 
82 who did not were evaluated for viral RNA. There was no difference in the 
detection of enterovirus RNA between these groups88. Differences in these 
studies could be attributed to heterogeneity in the study design, specifically the 
sampling frequency for viral RNA. Since viral RNA is rarely detected 3 months 
after infection, viremia may have gone undetected in studies with longer 
sampling intervals. The differences in the findings highlight the difficulty in 
establishing a causal link between enterovirus infection and T1D. The contrasting 
findings in these studies of these prospective studies make the contribution of 
enteroviruses to the development of T1D a contentious issue.  
1.9: Further evidence for enterovirus infection 
Viral infections are a common environmental insult and they can have 
both short and long-term consequences. Infections with cytomegalovirus89, 
Epstein-Barr virus90, mumps virus91,92, rotavirus93, and rubella virus94 have all 
been implicated in the development of T1D. The most evidence has accumulated 
for infections with enteroviruses as a precipitating factor for the development of 
T1D. Serology against enteroviruses, viral proteins in tissue, viral RNA, and 
isolation of enteroviruses from recent onset T1D patients provide compelling 
evidence for the etiologic role of enteroviruses in T1D. Associations are 
described for all six coxsackievirus B (CVB) serotypes, and several echovirus 
and enterovirus species (see review95).  
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One of the initial observations that linked virus infection with T1D was the 
increased incidence of T1D following seasonal enterovirus epidemics96. 
Furthermore, neutralizing antibodies against CVB4 in newly diagnosed T1D 
patients can be detected97. Other enteroviruses are also linked to the 
development of T1D. Following an echovirus outbreak in Cuba, autoantibodies 
were detected in patients that recovered from the infection98. A virus antibody 
survey for neutralizing antibodies against all 6 CVB serotypes indicates a link 
between antibodies against CVB1 and the development of T1D99. Additionally the 
presence of anti-CVB1 can be used to predict the development of T1D100. 
Neutralizing antibodies are more common against a CVB4 strain that establishes 
persistent infections in children with T1D and there is an association with higher 
antibody titers with the GAD65 autoantibodies101. Despite these trends of 
antibodies against enteroviruses in T1D patients, these studies are contentious 
due to the lack of matched HLA risk alleles in control samples102. 
Enteroviral proteins are detected in pancreatic tissue specimens from 
individuals with T1D. Enterovirus viral protein 1 (VP1) is detected in the β cells of 
recent onset T1D patients more often than in control samples by 
immunohistochemical staining103. In a follow-up study, reactivity for VP1 was 
found in 20% of recent onset T1D patients. The presence of viral proteins also 
correlates with increased expression of the viral response protein, protein kinase 
R (PKR)104. The presence of viral protein does not necessarily indicate active 
replication in these samples.  
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Detection of viral RNA may be transient in patients and limited by the 
acute phase of viral replication. This complicates the association of viral infection 
with the development of disease. Other aspects of the progression of T1D 
pathogenesis that obscure the association with viral infection include variability in 
autoimmune development and presentation of clinical manifestations. Despite 
these potential difficulties in associating the presence of viral RNA with T1D 
progression, several studies established a correlation. Detection of enterovirus 
RNA sequences is associated with the presence of islet autoantibodies105. 
Furthermore, enteroviral RNA is detected more often in prediabetic children prior 
to the increase in autoantibodies against GAD65106. Enterovirus RNA is most 
common in the 6 months preceding the first autoantibody positive sample107. 
Viral RNA is also detected in peripheral blood mononuclear cells (PBMCs) in 
recent onset T1D patients108. A meta-analysis of 24 case-control studies found a 
clinically significant association between the presence of viral RNA or proteins 
with the development of both islet autoimmunity (O.R. 3.7) and T1D in humans 
(O.R. 9.8)109. 
In addition to the detection of viremia prior to the development of T1D, 
virus has also been isolated from these patients. Mice infected with a clinical 
sample of CVB4 isolated from a child with diabetic ketoacidosis was able to 
promote the development of hyperglycemia in these mice110. CVB isolated from 
pancreas biopsy samples taken from six living patients with newly diagnosed 
T1D failed to amplify in vitro, so these viruses may replicate poorly111.  
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Taken together, there is substantial evidence for the presence of 
enteroviral infection prior to the development of T1D. However, a direct causal 
link between viral infection and the development of T1D is elusive. This is partly 
due to limitations in the detection and identification of viral infection and the 
poorly defined timing between the initiation and clinical onset of T1D. The first 
limitation is the transient nature of the production of viral RNA or proteins. The 
absence of viral proteins in some T1D patients highlights the difficulty of linking 
viral infections to the development of T1D. Even if a persistent infection is 
established, viral replication may be below the limit of detection or viral proteins 
may not be actively produced. The undefined timeframe between the putative 
precipitating factor and the presence of clinical T1D diagnosis further complicate 
establishment of a causal relationship. The intervening time may be from months 
to years in some cases and involve the contributions of multiple initiating factors. 
A better understanding of the mechanisms mediating the dysfunction of β cells 
upon viral infection and their contributions to innate immune signaling will help to 
develop methods to determine their role in the initiation of T1D.  
1.10: Enteroviruses in human disease 
The Picornaviridae family of viruses is a genetically diverse group of non-
enveloped, positive sense, single stranded RNA viruses that cause a range of 
disease in humans. The genera of viruses in this family that are associated with 
human disease include Enterovirus, Hepatovirus, Parechovirus, Cardiovirus, and 
Kobuvirus112. Species in the Enterovirus genus that infect humans are HEV-A, -
B, -C, -D and rhinovirus-A, -B, -C. These species include important human 
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pathogens polioviruses, coxsackievirus A (CVA), coxsackievirus B (CVB), 
echoviruses, other enteroviruses, and rhinoviruses113. While these viruses cluster 
together on a genetic basis, their replication and disease presentation are 
diverse. So historical groupings based on phenotypic manifestations in infected 
mice are still useful. For example, CVA and CVB can be separated based on 
their pathogenicity in humans and animals. CVA viruses affect skeletal and heart 
muscle and induce flaccid paralysis in mouse models. In contrast, CVB tropism is 
much broader in mouse tissue. CVB infects the central nervous system, liver, 
exocrine pancreas, brown fat and striated muscle and cause spastic paralysis113.  
Enterovirus (EV) infection is usually transmitted fecal-orally. The virus 
begins replication in oropharyngeal and intestinal mucosa. After crossing the 
intestinal barrier, the virus travels to the lymph nodes, which allows progression 
to overt viremia114. Enteroviruses can be detected in stools for up to 3-4 weeks 
post infection, although in some cases they can be detected 2-3 months after 
infection. The incubation period is between 2-30 days for symptoms to 
develop114. Most EV infections are asymptomatic, but this varies wildly based on 
the type and strain of virus. EV infections are among the most common viral 
infections in the United States with an estimated 10-15 million symptomatic 
infections each year115. Incidence of reported EV infections has seasonal 
variation with a sharp increase in cases during late summer and autumn months. 
Among the EV infections reported from 1970 to 2005, CVB serotypes were often 
associated with fatal outcomes. Specifically, CVB4 infections have the highest 
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risk of death compared to other EV serotypes. Outbreaks of CVB4 are rare116. 
CVB infections cause a wide range of disease from asymptomatic to mild 
symptoms of fever, summer cold, and rash to severe outcomes like myocarditis, 
meningitis, and pancreatitis117. CVB frequently infects the CNS of newborns and 
infants and is responsible for >85% of aseptic meningitis cases118. CVB also 
causes fulminant pancreatitis, which leads to exocrine pancreas insufficiency119. 
Viruses in this family are also associated with the development of T1D as 
outlined above, but this association remains controversial. 
While CVB infections are usually acute and self-limiting, there is some 
evidence that persistent viral infections do occur. CVB RNA can be found in heart 
tissue months after infection120. This may be associated with 5’-terminal deletions 
in the genome that allow for slower replication121.  
1.11: Enterovirus replication  
Genomic RNA in the Picornaviridae family varies in length from 7 to 8.8kb 
and has stereotypical genetic organization. A 5’ untranslated region (5’ UTR) is 
followed by a protein coding region and a 3’ UTR. The protein-coding region 
encodes for a polyprotein that is proteolytically cleaved by viral proteases during 
and after translation122. This processing yields four structural proteins (VP1-4) 
that comprise the capsid and seven nonstructural proteins (2A-C and 3A-D) that 
have various other functions in viral replication123. These are outlined in Figure 
1.2. 
The terminal UTRs provide structural motifs required for viral replication 
that allow transcriptional and translational regulatory factors to bind. The 5’ UTR 
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contains structural elements that are important for translation. This includes an 
internal ribosomal entry site (IRES) that is required for the initiation of cap-
independent translation of the viral polyprotein. The IRES recruits transactivating 
factors such as polypyrimidine tract-binding protein 1 (PTBP1) that recruits 
ribosomes to the viral RNA124. Additionally, the 5’ UTR is covalently linked to The 
VPg (3B) protein and facilitates priming for transcription of the viral RNA 
dependent RNA polymerase (RdRp)125,126. Furthermore, the 3’ UTR also contains 
important regulatory features including a pseudoknot structure and a polyA 
tail127,128. The mutations and deletions in the UTRs can modulate viral replication 
efficiency and persistence121.  
Viral entry of CVB viruses into host cells is mediated primarily through 
binding to the coxsackievirus and adenovirus receptor (CAR)129. CAR is a 
transmembrane member of the tight junction protein family, so access 
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of the virus to CAR in polarized tissue may be limited130. Some CVB serotypes 
can bind to the co-receptor, decay activating factor (DAF), which delivers the 
virus to CAR to overcome the limited availability of the receptor in polarized 
cells131. Internalization of the virus bound to CAR is cell type dependent, but is 
sufficient for the initiation of uncoating132. Internalization is mediated through 
caveolin and is independent of clathrin133,134. Uncoating and viral RNA release 
from the virion is mediated through conformational changes that involve the loss 
of VP4 that allows for the formation of a pore135. While this is the main entry 
mechanism for CVB4, other CVB serotypes may utilize other receptors or 
alternate mechanisms136.  
Upon entry and release of the genomic RNA, viral translation is initiated 
through the cap independent mechanisms described above. The polyprotein is 
rapidly co- and post-translationally cleaved into 11 individual proteins, and some 
intermediates that have independent functions. Cleavage of the polyprotein is 
mediated by self-activated viral proteases 2A and 3C, which are both 
chymotrypsin-like proteases123. Most cleavages of the polyprotein occur at 
defined glutamine-glycine junctions122. These proteases are also important in 
modulating the host cell to promote viral replication. They inhibit host mRNA 
translation by directly cleaving eukaryotic translation initiation factors, eIF4GI and 
eIF5B137,138 and cleavage of polyA-binding protein (PABP)139. The precursor 
protein 3CD contains a nuclear localization signal (NLS) that allows for transport 
into the nucleus, where it can cleave TATA-box binding protein and other host 
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factors to further inhibit host transcription140,141. Furthermore, 2A can disrupt 
nucleo-cytoplasmic trafficking through cleavage of components of the nuclear 
pore complex142. In addition to suppression of host gene transcription, viral 
proteases also modulate immune activation. 3C suppresses innate immune 
signaling by cleavage of MAVS and TRIF proteins143. All of these protease 
activities modulate host proteins to optimize the intracellular environment for 
efficient viral replication.  
Replication of the viral genome occurs through the RdRp activity of the 3D 
protein. 3D utilizes the VPg attached to the 5’ end of the genome as a primer to 
initiate transcription125,126. This is a highly error prone polymerase, which 
incorporates 1-2 errors per genome copy144. 3D is also capable to template 
switching in a form of “replicative recombination.” This is thought to 
simultaneously ensure the stability of the genome, while also introducing 
additional variation.  
The release of mature CVB virions from infected cells is not completely 
understood, but the viral protein B2 increases plasma membrane permeability, 
which could facilitate virion release145. Other potential mechanisms are direct 
lysis of infected cells or through the initiation of apoptosis146. Along with these 
mechanisms of virion release, viral RNA can be transferred to adjacent cells 
through phosphatidylserine-containing vesicles147. Viruses likely utilize a 
combination of these mechanisms depending on the cell-type and immune 
response to the viral infection. 
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1.12: Innate immune recognition of pathogens 
The innate immune system is a broad category of non-specific protective 
factors against pathogens. These include anatomical barriers like the skin and 
tightly associated epithelial tissues of the lungs and digestive tract. There are 
also cell intrinsic sensors that detect the presence of pathogens that are used to 
recruit cells of the innate immune system. These specialized immune cells 
include natural killer (NK) cells, monocytes, polynuclear phagocytes, and 
eosinophils. These cells all respond broadly to tissue injury or cytokine 
responses to pathogens. Some of these cells act as intermediaries between the 
innate and adaptive immune system by processing pathogen antigens for 
presentation to B and T cells in lymphatic tissues. These cells are referred to as 
antigen-presenting cells (APCs). The interplay between innate immune signaling 
and presentation of antigen can aid in efficient clearance of pathogens. But 
detrimental effects are possible in the case of inefficient immune response or 
excessive immune response. Inefficient immune response can allow for 
continued replication of the pathogen and pathogenesis to occur. Inefficient 
clearance of low virulence pathogens can also result in a persistent infection. On 
the other hand, excessive immune responses can cause immune pathology. 
Interestingly, both inefficient clearance and excessive immune response are 
associated with the development of autoimmunity and will be further discussed 
below. Here I will focus on the cell intrinsic mechanisms in the response to viral 
infections.  
In mammals, recognition of viral infection begins with cellular pattern 
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recognition receptors (PRRs) that recognize stereotypical pathogen-associated 
molecular patterns (PAMPs). Detection of viral PAMPs is mediated through three 
families of PRRs, namely the Toll-like receptors (TLRs), the retinoic acid 
inducible gene 1 (RIG-I) like receptors (RLRs), and the NOD-like receptors 
(NLRs). The cell localization of these PRRs facilitates recognition of the virus at 
various stages of replication.  
TLRs are type I transmembrane glycoproteins that are expressed in a cell 
type-specific manner. TLRs are expressed in immune cells including dendritic 
cells (DCs), macrophages, B cells, and NK cells. They are also expressed in 
non-immune cells including some fibroblasts, endothelial, and epithelial cells. 
Cell surface TLRs can recognize components of the viral envelope or capsid 
during virus attachment or endocytosis. TLRs 1, 2, and 4-6 are localized on the 
cells surface and recognize either viral proteins or lipids. Intracellular vesicle 
localization of TLRs in endosomes, lysosomes, and endoplasmic reticulum can 
detect viral components released during uncoating or through degradation of 
virions in endosomes. TLRs 3, 7, 8, and 9 are primarily localized in these 
endocytic compartments and sense nucleic acids. Upon formation of endocytic 
vesicles, fusion with these TLR-containing vesicles allows for recognition of 
endocytic cargo148.  
Upon interaction of TLRs with their cognate ligands, downstream 
activation is mediated through adaptor proteins. The toll-interleukin receptor 
(TIR) domains of adaptor molecules, myeloid differentiation primary response 
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gene 88 (MyD88) and TIR-domain-containing adaptor-inducing interferon-β 
(TRIF) interact with the TIR domains of activated TLRs. All TLRs, except for 
TLR3, initiate proinflammatory cytokines in macrophages and DCs through 
MyD88 activation of NF-κB. TLR3 and TLR4 recruit TRIF to activate NF-κB or 
IRF3, which induces the production of proinflammatory or IFN-I respectively149. 
These responses can depend on the TLRs and adaptor proteins that are 
expressed in different cell types.   
The three members of the RLR family are expressed in the cytosol of most 
cells, and detect genomic nucleic acids or replication intermediates of viruses. 
Members of the RLR family include DExD/H helicases melanoma differentiation 
factor 5 (MDA5, encoded by the gene IFIH1), RIG-I, and laboratory of genetics 
and physiology 2 (LGP2)149. RIG-I and MDA5 both share similarity in their protein 
structure, with an RNA helicase domain, and two caspase activation and 
recruitment domains (CARDs). They also have a repressor domain that 
suppresses the activity of the CARD domains in the inactive conformation150. 
RIG-I recognizes the ends of both dsRNA and ssRNA in the presence of a 
5’triphosphate151,152. In contrast, the dsRNA ligand for MDA5 is less well defined. 
MDA5 signaling occurs upon recognition of dsRNA that is 1-2kb in length153. 
MDA5 cooperatively binds internally to long dsRNA which results in the formation 
of filaments that contribute to downstream signaling154. This signaling cascade is 
outlined in Figure 1.3. The activation of both RIG-I and MDA5 allows the CARD 
domains to interact with the mitochondrial antiviral signaling (MAVS) protein. 
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Activated MAVS induces the transcription of type I IFN (IFN-I) genes through 
phosphorylation of IRF3 or the activation of proinflammatory cytokines through 
NF-κB155.  
Signaling from both TLRs and RLRs converge on the production of 
interferons (IFNs). The IFN family includes three classes of related cytokines, 
type I IFN (IFN-I), type II IFN (IFN-II), and type III IFN (IFN-III). The IFN-I group 
includes thirteen different INF-α types, along with IFN-β, IFN-ε, IFN-κ, and IFN-ω. 
Members of this group all signal through the IFN-I receptor (IFNAR). IFN-II only 
contains one member, IFN-γ. This cytokine signals through the IFN-II receptor 
(IFNGR)156. IFN-III is composed of three members, IFN-λ1 (IL-29), IFN-λ2 (IL-
28A), and IFN-λ3 (IL28B). These signal through the IFN-III receptor (IFNLR) 
which is composed of a heterodimer of IL-28 receptor–α (IL-28Rα) and 
IL10Rβ157. Upon the activation of the receptor by dimerization, IFNAR and 
IFNGR are autophosphorylated and activate their associated with members of 
the Janus activated kinase (JAK) family. The phosphorylated JAK proteins, 
including tyrosine kinase 2 (TYK2) and Janus-associated kinase 1 (JAK1), then 
phosphorylate signal transducer and activator 
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of transcription (STAT) proteins, which leads to their dimerization and 
translocation to the nucleus. STAT proteins promote the transcription of genes 
that can mediate various biological processes to inhibit viral replication158.  
1.13: Activation of innate immune signaling by CVB 
Cell surface TLRs contribute to the recognition of CVB infections. TLR4 is 
best known for its role in sensing lipopolysaccharide during bacterial infections, 
but it also contributes to sensing of viral infections159. TLR4 contributes to CVB4 
sensing in the pancreas and the production of cytokines. This interaction is likely 
to occur on the surface and does not require replication as inactivated by 
ultraviolet light activates TLR4 signaling. It is unclear how CVB4 directly interacts 
with TLR4160.  
Intravesicular TLRs also mediate sensing of CVB infections. The 
activation of these receptors requires an acidic environment, which is usually 
provided by the maturation of endosomes161. TLR3 senses CVB replication 
intermediates in the form of dsRNA. The synthetic dsRNA mimetic, 
polyinosinic:polycytidylic acid (poly(I:C)), also acts as a ligand for this receptor 
when it is transfected into cells162. TLR3 knockout mice are highly susceptible to 
CVB3 infection and have more severe pathology163. TLR7 and TLR8 both 
recognize ssRNA164. Human cardiac inflammatory responses are largely 
dependent on TLR7 and TLR8 in CVB infections165. Despite the importance of 
TLR signaling, it is unclear if these receptors are activated during viral entry or at 
later stages in replication. In plasmacytoid DCs, TLR7 is only activated when 
CVB is bound to virus-specific antibodies166. While later RNA replication 
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intermediates in the cytoplasm are sequestered from the endosomal TLRs, there 
could be a role for autophagy in delivering viral RNA to TLRs in endosomes. CVB 
infection prompts the formation of autophagy-associated double-membrane 
structures, and blocking autophagy in CVB3 infection of HeLa cells reduces viral 
replication167. It is unclear if these autophagosomes contact and mature with 
endolysosomes to allow for the activation of TLRs.  
Because of their cytoplasmic localization, the RLRs are in a prime location 
for sensing CVB replication. Replication intermediates include dsRNA and higher 
order RNA complexes due to the strand switching ability of the viral protease 3D. 
RIG-I does not contribute to the response to CVB, as mice lacking RIG-I are not 
more susceptible. This is because CVB lacks the required 5’-tripohspate on RNA 
due to the covalent linkage of the VPg protein on the 5’end125,151. Knockout of 
Ifih1 in mice renders them more susceptible to pancreatic and hepatic necrosis 
upon infection with CVB3. MDA5 contributes to controlling the early infection 
through the production of IFN-I in infected mice168.  
1.14: Contributions of innate immune signaling in the development of 
autoimmunity 
The early stages of T1D are characterized by the infiltration of immune 
cells into the islets of Langerhans and are called insulitis. Insulitis is initiated by β 
cells producing cytokines and chemokines in response to viral infection to recruit 
immune cells to the site of infection. Macrophages and DCs sample antigens in 
the area of local inflammation and present autoantigens to CD4+ T helper cells. 
This occurs through the presentation of autoantigens through class II MHC 
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molecules to the T cell receptor on CD4+ T cells. The resulting activated Th1 
helper T cells mediate the production of cytotoxic CD8+ T cells, which ultimately 
infiltrate the islets and specifically kill β cells. In line with this hypothesis, 
infiltrating macrophages and DCs in recent onset T1D patients produce 
inflammatory cytokines TNF-α and IL-1β169. This contributes to the local 
inflammation of the islets. Additionally, in early stages of insulitis, the dominant 
infiltrating immune cells are CD8+ cytotoxic T cells and CD86+ macrophages23. 
Despite being early in the process of insulitis, the presence of CD8+ T cells in 
these tissues indicates this is already late in the development of cellular 
autoimmunity. Evidence for the early contributions of innate immune signaling 
that contribute to the ultimate autoimmune disease are discussed below.  
Innate immune signaling is important for the development of T1D. These 
immune responses are likely the result of environmental triggers like CVB 
infection, and mediate the development of autoimmunity through their 
interactions with the adaptive immune system. Recently it was shown that β cells 
express >80% of the T1D candidate genes, so this means they are likely playing 
an active role in the development of autoimmunity68. Multiple lines of evidence 
implicate a signaling cascade that involves the cytosolic dsRNA sensor, MAD5 
followed by the production of IFN-I and the downstream production of cytokines 
like CXCL10 in the progression of β cell dysfunction and development of T1D. 
This signaling cascade links the initial viral insult to the cytokine production that 
recruits monocytes and DCs to initiate insulitis in the beginning stages of T1D.  
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SNPs in IFIH1, the gene encoding MDA5, are associated with T1D. A 
genome-wide association study (GWAS) uncovered a protective association with 
the minor allele of the SNP rs1990760 for T1D72. This common SNP leads to an 
amino acid substitution of threonine for alanine at position 946, but functional 
studies indicate that protein function is maintained170. The rs1990760 SNP does 
correlate with a reduction of IFIH1 mRNA171. Four additional rare variant SNPs in 
IFIH1 are also associated with protection against T1D. One causes a non-sense 
mutation resulting in a truncated mutation (rs35744605), two are at essential 
splice sites (rs35337543 and re35732034), and the fourth is at a highly 
conserved isoleucine at position 923 (rs35667974) that decreases the function of 
the protein172,173. Collectively, these mutations follow the trend that lower IFIH1 
expression is protective for the development of T1D (Fig. 1.3). This would likely 
correlate with less IFN-I production and lower expression of downstream 
cytokines. In support of this hypothesis, mice with reduced levels of MDA5 
induce a Treg profile as opposed to an effector T cell response174. These 
associations need to be explored more directly in human cells in in the context of 
viral infections.  
In contrast to these rare protective mutations, risk alleles of IFIH1 
(rs2111485) increase the 5 year progression rate to T1D 31% compared to 11% 
for the protective alleles have been described175. Expression of these risk alleles 
is associated with development of autoantibodies targeting β cells75. 
Furthermore, risk of developing T1D is associated with higher expression of 
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IFIH1 in PBMCs171. MDA5 signaling in DCs stimulate CD4+ T-cell proliferation, so 
higher expression of IFIH1 could potentially drive autoimmune progression176. 
Immunoreactive IFN-α is detectable in β cells in T1D patients177. 
Additionally this expression of IFN-α coincides with the presence of enteroviral 
proteins in β cells in pre-diabetic or diabetic donors103,104. IFN-α mRNA is 
expressed at higher levels in islets of T1D patients compared to controls178. In 
patients with T1D, 70% had elevated levels of IFNα in their plasma179. 
Furthermore, two studies highlight an IFN-I signature of associated genes that is 
detectable prior to the development of autoantibodies in blood of children 
genetically at risk180,181. The contribution of IFN-α expression either prior or soon 
after the development of diabetes is consistent with the role of IFN-α as important 
co-factor in development of Th1 immune reaction and can contribute to 
development of autoimmune disease182. In patients receiving recombinant IFN-α 
therapy for hepatitis C virus infection increases T1D risk by 10-18-fold183,184. 
Collectively, these studies point to an important role for IFN-I, which is a major 
response component of viral infection, in the development of T1D.  
The C-X-C motif chemokine 10 (CXCL10) is an IFN-inducible cytokine that 
is highly expressed in CVB-infected primary human islets and contributes to the 
development of autoimmunity. CXCL10 interacts with CXCR3 chemokine 
receptors on immune cells and mediates a cytotoxic T cell response through Th1 
helper T cells185. The development of cytotoxic T cells through Th1 help is 
important for clearance of intracellular pathogens. Serum concentrations are 
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higher for CXCL10 in T1D patients and those at risk for developing T1D186. 
CXCL10 is highly expressed in β cells in pancreas tissue from T1D patients and 
CD3+ cells bearing the cognate receptor, CXCR3, are also present187. In a 
mouse infection model in which lymphocytic choriomeningitis virus causes 
diabetes, inhibition of CXCL10 signaling blocks the development of autoimmune 
diabetes188. In addition to its role in recruiting immune cells, CXCL10 can also 
induce reduce the secretion of insulin in response to glucose and induce β cell 
apoptosis through a feedback loop that involves TLR4189,190.  
The data presented above support the model of β cell autoimmunity 
presented in Figure 1.4. Viral infection of β cells causes local cytokine production 
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that includes IFN-I, CXCL10, and eventually class I MHC hyperexpression. 
These signals in combination with genetic predisposition to develop 
autoimmunity due to class II MHC leads to the break through of central tolerance. 
APCs activate Th1 T cell responses through class II MHC, which then help 
produce autoreactive CD8+ T cells. These activated, autoimmune T cells then 
mediate autoimmune destruction of β cells.  
1.15: Prevailing mechanistic theories on the viral contribution to T1D 
development 
Development of autoimmunity in T1D occurs in the form of humoral and 
cellular immunity. Autoantibodies and autoreactive cytotoxic T cells are both 
present prior to the diagnosis of diabetes19. Several theories connect the putative 
viral trigger to the development of T1D. These include molecular mimicry, epitope 
spreading, bystander activation, and the “fertile field” hypothesis. While some of 
these mechanisms are controversial they are not mutually exclusive and may be 
acting in combination to potentiate the autoimmune reaction.  
Molecular mimicry is the idea that an immune epitope is shared by the 
pathogen and the host, which results in a cross-reactive immune response. 
Sequence homology is shared between the viral 2C non-structural CVB protein 
(aa 32-47) and the T1D associated autoantigen GAD65 (aa 247-279) 
(PEVEKEK)191,192. Humoral and cellular responses against GAD65 are detected 
prior to the onset of clinical diabetes22, and autoantibodies are positive several 
years before diagnosis21. Despite the attractive nature of this hypothesis, the 
experimental evidence is lacking. In infections of mice with various strains of 
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CVB4, autoimmunity was only induced when a transgenic autoreactive T cell was 
introduced, indicating bystander activation, not molecular mimicry193. Additionally, 
T cells clones for GAD 247-280 generated from T1D patients failed to react with 
the mimicry epitope derived from 2C from CVB194.  
Epitope spreading is the concept that infection releases sequestered 
antigens which could be presented to the adaptive immune system in draining 
lymph nodes, and failure of central tolerance results in autoimmunity193. In line 
with this hypothesis, the cytolytic infection of β cells by viruses leads to a 
cytotoxic immune response195. More pathogenic strains increase viral response 
and increase autoimmunity98. Also SNPs that are associated with protection of 
T1D temper the antiviral response75,173. The presence of viral proteins in patients 
shows that only 5% of endocrine cells are positive for VP1, but despite this low 
infection rate of endocrine cells, there is overexpression of class I MHC in all β 
cells104. This expression of class I MHC in the context of local inflammation from 
infected β cells recruits cytotoxic CD8+ T cells that mediate β cell killing. The local 
cytokine profile includes IFN-α, IFN-β, IFN-γ, TNF-α and IL-1β196.  
Bystander activation is the idea that autoreactive T cells could be 
activated independently of the T cell receptor in some scenarios. Secretion of 
proinflammatory cytokines by infected cells or resident macrophages and 
dendritic cells could initiate activation of circulating naïve islet-specific T cells. 
Viral infections may result in the impaired activation of self-reactive T cells 
through a T cell receptor independent mechanism in genetically predisposed 
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individuals through a distinct cytokine profile197. In support of this hypothesis, 
autoimmunity could be triggered through activation of transgenic autoreactive T 
cells by viral infection193. Targeted expression of IL-2 or IL-12 in the β cells of 
mice to promote the proliferation of T cells failed to initiate T1D198. These 
conflicting results indicate that factors other than just the cytokine profile are 
needed to activate naïve T cells. However, viral infection does not strictly meet 
the definition of bystander activation, where cytokines alone are activating naïve 
T cells. In this case, viral antigens or host proteins released during cell lysis 
provide antigens that may bypass peripheral tolerance in the presence of strong 
cytokine signaling.   
The “fertile field” hypothesis combines one or more of the above 
mechanisms into a single paradigm. The main idea is that conditions of the 
intensity of infection, immune history, and mass of potentially autoreactive T cells 
exist at the same time and anatomical location. Molecular mimicry or bystander 
activation may prime the accumulation of low numbers of autoreactive T cells in 
initial infections. Once this field is sufficiently fertile, the right infection can 
overcome the thresholds of immune tolerance and develop full autoimmune 
destruction of cells. Complications in identifying causative agents in this 
paradigm are that priming events might be separated from the activating events 
by substantial amounts of time and may involve heterologous agents199.  
1.16: Working toward better understanding of the role of viruses in T1D 
Despite the increasing evidence for correlations between enterovirus 
infections and the development of T1D, a causal relationship is elusive. A causal 
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role of enterovirus infection in T1D could be strengthened by understanding how 
viruses suppress β cell function and initiate antiviral responses in these cells. 
Further insights into both of these processes could facilitate the development of 
improved therapeutic or preventive treatments to stop the development of 
autoimmunity against β cells. 
Currently, the timing of sampling and lack of prognostic markers limit the 
early diagnosis of T1D prior to development of autoantibodies. Identification of 
genetic changes in β cell functional genes or innate immune responses could be 
used as earlier and more long-lasting markers for viral initiation of autoimmunity. 
Earlier markers provide the possibility to intervene with immunoregulatory or 
virus suppressing drugs to stop the development of autoimmunity. Ideally, a 
specific innate immune profile or a single gene marker could be identified to 
predict the progression to T1D. These markers may also allow for better 
associations between viral infection and T1D if they are more specific to viral 
responses that lead to the disease. In order to identify better markers for the 
initiation and progression of T1D, a better understanding of the basic processes 
of viral infections of human β cells is necessary. However, the inability to directly 
evaluate these processes in the context of human infections requires the use of 
specific models for infections of human β cells described below.  
In the following chapters, I will utilize a variety models to address two 
overarching goals. The first determining the mechanisms involved in the loss of  
insulin production and secretion that occurs in CVB-infected β cells with a 
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potential role for changes in PDX1 localization after CVB infection. The second is 
characterizing the key innate immune signaling pathways with a focus on IFN-I 
and CXCL10 and identifying the cell types involved in the production of these 
responses (Fig. 1.5). An overview of the models presented in this thesis is 
described in Table 1.1. I will describe effects of CVB4 infection on both β cell 
function and innate immune signaling in immunodeficient mice engrafted with 
primary human islets in Chapter II, and in cultured primary human islets, stem 
cell-derived human β cells (SC-β), and a human β cell line, EndoC-βH1, in 
Chapter III. In Chapter IV I will explore the effects of CVB4 infection on PDX1 
localization and β cell function that may contribute to decreases in insulin 
production in EndoC-βH1 cells. Finally in Chapter V, I will describe cell type 
differences in innate immune signaling in flow cytometry-sorted cells from 
primary human islets. 
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CHAPTER II: VIRAL INFECTION OF ENGRAFTED HUMAN ISLETS LEADS 
TO DIABETES 
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2.1: Abstract 
 Type 1 diabetes (T1D) is characterized by the destruction of the insulin-
producing β cells of pancreatic islets. Genetic and environmental factors both 
contribute to T1D development. Viral infection with enteroviruses is a suspected 
trigger for T1D, but a causal role remains unproven and controversial. Studies in 
animals are problematic because of species-specific differences in host cell 
susceptibility and immune responses to candidate viral pathogens such as 
coxsackievirus B (CVB). In order to resolve the controversial role of viruses in 
human T1D, we developed a viral infection model in immunodeficient mice 
bearing human islet grafts. Hyperglycemia was induced in mice by specific 
ablation of native β cells. Human islets, which are naturally susceptible to CVB 
infection, were transplanted to restore normoglycemia. Transplanted mice were 
infected with CVB4 and monitored for hyperglycemia. Forty-seven percent of 
CVB4-infected mice developed hyperglycemia. Human islet grafts from infected 
mice contained viral RNA, expressed viral protein, and had reduced insulin levels 
compared with grafts from uninfected mice. Human-specific gene expression 
profiles in grafts from infected mice revealed the induction of multiple interferon- 
stimulated genes. Thus, human islets can become severely dysfunctional with 
diminished insulin production after CVB infection of β cells, resulting in diabetes.  
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2.2: Introduction 
Animal models are helpful for understanding virus-induced diabetes but 
have translational limitations for human disease. For example, coxsackievirus 
and adenovirus receptor (CAR), the receptor for CVB, is expressed within human 
islets, but not mouse islets109,119,129,200, and infection of C57BL/6 mice with CVB3 
or CVB4 does not result in diabetes (unpublished data). NOD mice have been 
used to extensively assess the parameters of viral infection on T1D, although a 
critical mass of autoreactive T cells rather than direct viral insult appears to 
accelerate progression to diabetes during CVB infection201,202.  
Given these inherent limitations, we used the NOD/ Lt-Prkdcscid 
IL2rgtm1WJL (NSG) mouse203 to study the effects of CVB infection in 
transplanted human islets. NOD mice express multiple alleles that alter the 
function of the innate and adaptive immune system204,205. The severe combined 
immunodeficiency (scid) mutation results in a complete absence of T and B 
lymphocytes. The addition of a targeted null mutation in the interleukin (IL)-2 
receptor common γ-chain fully disrupts NK cell development, further reducing 
innate immune responses, and facilitating the engraftment of human cells and 
tissues206. Hyperglycemia was induced either by administering streptozotocin 
(STZ) or diphtheria toxin (DT) to NSG mice transgenically expressing the human 
DT receptor (DTR) under the control of the rat insulin II promoter (the NOD/ Lt-
Prkdcscid IL2rgtm1WJLTg(Ins2-HBEGF)6832Ugfm/Sz strain [abbreviated as 
NSG-Tg(RIP-DTR)]). Hyperglycemic mice were engrafted with human islets to 
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restore normoglycemia and then were infected with CVB4. Our goal was twofold: 
1) to assess viral replication and persistence in human islets in vivo; and 2) to 
assess for the development of hyperglycemia. Our results indicate that CVB4 
directly invokes the dysfunction of human β cells, providing insights into the early 
events that precipitate T1D.  
 
2.3: Results 
2.3.1CVB4-Infected Mice Engrafted With Human Islets Develop Diabetes  
β cells of the native pancreas were disrupted by treating NSG mice with 
STZ (experiment 1) or by injecting NSG-Tg (RIP-DTR) mice with DT 
(experiments 2 and 3). Given the extended kinetics of experiment 1, ablation of 
native mouse β cells was changed to the DTR method, mitigating the possibility 
of mouse β cells contributing to glucose homeostasis, which can occur with 
STZ207,208. After a hyperglycemic state was confirmed, human donor islets were 
transplanted into recipient mice to restore normoglycemia. Three independent 
transplant studies were performed with human islets from donors characterized 
in Table 2.1. Mice were injected with CVB4 or saline control (mock infected). The 
target end point of the study was the development of diabetes. At the end of the 
study, mice were sacrificed, and  
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Table 2.1: Demographic characteristics of human islet donors of engrafted 
islets 
 Donor 1 Donor 2 Donor 3 
Age, years 55 55 29 
Gender (M/F) M F M 
Ethnicity n.r. White Hispanic/Latino 
Body weight, kg 85.0 109.1 87.3 
BMI, kg/m2 28.4 39.9 27.5 
Time in culture* 16 h 28 h 20 h 
HLA n.r. n.r. 
Class 1 – A: 2, 11 
Class 1 – B: 7, 51 
Class 1 – C: 7, 15 
Class 2 – DR: 8, 15 
Abbreviations: BMI, body mass index; n.r., not recorded. *Refers to the amount 
of time that the human islets were cultured following isolation until shipment to 
our laboratory.
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tissues were harvested for analysis. Figure 2.1 summarizes survival data for the 
three studies, and provides the numbers of animals per group plus information on 
animals that died prematurely and the possible causes of death. Mice that died 
prematurely were excluded from the final analysis.  
In the first experiment, three of the six (50%) infected mice that survived 
greater than 21 days post-infection (dpi) developed diabetes (Fig. 2.2, A-top 
panel). Mice became hyperglycemic between 21 and 25 dpi, while no mock-
infected control mice (n = 5) developed diabetes over the course of the 
experiment (log-rank P = 0.08). CVB4 also induced diabetes in experiments 2 
and 3, although the kinetics of disease was prolonged. In experiment 2, two of 
four infected mice (50%) that survived greater than 35 dpi became diabetic (Fig. 
2.2, A-middle panel) (log-rank P = 0.005). In experiment 3, progression to 
diabetes was similar to that in experiment 2, with two of five (40%) infected mice 
surviving greater than 35 dpi becoming diabetic (Fig. 2.2, A-bottom panel) (log-
rank P = 0.09). Because of the small sample size and the few infected mice that 
developed diabetes, time to diabetes data were combined across experiments to 
develop a more stable estimate of the difference between the infected and 
control mice. Seven CVB4-infected mice developed diabetes with a mean time to 
diabetes of 28 days, while no control mice developed diabetes (log-rank P = 
0.0002). The percentage of mice remaining normoglycemic is plotted against 
time (Fig. 2.2, B). 
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n=5, mock-infected, n=5, CVB4-infected. Error bars in C-E show the S.E.M. *, 
P<0.05; **, P<0.01; Student’s t-test. 
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The peak nonfasting blood glucose value for each mouse over the 
experimental observation period was assessed and was significantly higher on 
average for CVB4-infected mice compared with mock-infected mice. Mock-
infected mice had normal mean blood glucose measurements with an average of 
87.5mg/dL, and were tightly controlled (standard deviation (SD) of 14.2 mg/dL). 
CVB4-infected mice had a higher average non-fasting glucose of 137.3mg/dL 
with much more variability (SD of 113.1 mg/dL). Comparing blood glucose levels 
between CVB4-infected and mock-infected mice with generalized estimating 
equation models revealed an increase of 81.7 mg/dL in CVB4-infected mice 
compared with the mock-infected mice (P = 0.018) in experiment 1, an increase 
of 77.5 mg/dL in the infected mice in experiment 2 (P = 0.0001) and an increase 
of 32.0 mg/dL in the infected mice in experiment 3 (P = 0.07).  
Human insulin and C-peptide levels were compared in terminal serum 
samples from infected versus control nonfasted mice (Fig. 2.2, C & D). These 
values were normalized to the terminal serum glucose measurement to account 
for glycemic variability in nonfasted mice. Lower values were observed in 
infected mice compared with control mice, but no differences were noted 
between hyperglycemic and normoglycemic infected mice. Insulin (INS) gene 
expression in the human grafts was quantified using NanoString. In each 
experiment, INS gene expression was significantly lower in CVB4-infected mice 
compared with controls (Fig. 2.2, E). A threefold decrease was observed in INS 
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gene expression in grafts from CVB4-infected mice compared with controls (Fig. 
2.6, A). In contrast, glucagon (GCG) expression ratios were not significantly 
impacted (Fig. 2.6, B). Thus, regardless of whether overt hyperglycemia was 
detected, significant decreases in both human C-peptide and insulin levels were 
detected in CVB4-infected animals. Across the three experiments, negative 
correlations were observed between peak blood glucose values and INS gene 
expression (Spearman ρ = 20.39, P = 0.04). Additionally, negative correlations 
were observed between peak blood glucose values and terminal serum human 
C-peptide values (ρ = 20.45, P = 0.01).  
2.3.2: Grafts From Infected Mice Show Decreased Insulin  
Histopathological examination of grafts from both CVB4-infected and 
mock-infected mice revealed intact islets without infiltrating inflammatory cells in 
grafts (Fig. 2.3, A). A moderate degree of fibrosis was present. Insulin-specific 
immunohistochemical stains revealed a decrease in the number of insulin-
positive cells in the islets from infected mice compared with those from control 
mice (Fig. 2.3, B). Glucagon-specific stains did not reveal glucagon depletion in 
the grafts of CVB4-infected mice (Fig. 2.3, C). Immunofluorescent staining for 
insulin and glucagon revealed similar trends (discussed below, see Fig. 2.4, D). 
Examples are shown from a CVB4-infected mouse that ultimately became 
diabetic, but the histopathological appearance of grafts from diabetic and 
nondiabetic CVB4-infected mice were similar overall. Histopathological changes
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(A) H & E staining on sections of human islet grafts from a representative mock-
infected control (left panels) and a CVB4-infected diabetic mouse (right panels) 
from 49 dpi (Experiment 2). In both grafts, islets are surrounded by fibrosis and 
surrounding renal cells appear intact. In the CVB4-infected mouse (right panel), 
degenerative changes are present throughout the engrafted islets. Individual 
cells are shrunken with karyorrhexis and hypereosinophilic cytoplasm, and 
vacuolar degenerative changes are abundant (arrowhead). (B) 
Immunohistochemical staining for insulin. ~50% of the graft is positive for insulin 
in the CVB4-infected mouse (right panel) compared to >75% in the control 
mouse (left panel). (C) Immunohistochemical staining for glucagon. ~75% of the 
graft is positive for glucagon in the CVB4-infected mouse (right panel) compared 
to ~50% in the control mouse (left panel). For images in A-C scale bars represent 
500 µm and final magnification is 40X (insets in A are at 400x magnification). (D) 
Blinded histopathology scoring of human islet grafts from all available mice: 
n=16, Mock-infected normoglycemic; n=8, CVB4-infected normoglycemic; and 
n=5, CVB4-infected hyperglycemic. Insulin immunostain, percent positive cells. 
0=0%, 1=25%, 2=50%, 3=75%, 4=90%. (E) Glucagon immunostain, percent 
positive cells. 0=0%, 1=25%, 2=50%, 3=75%, 4=90%. (F) Degeneration of 
implanted cells. 0=none, 1=minimal, 2=mild, 3=moderate, 4=marked. (G) Fibrosis 
of the implanted cells. 0=none, 1=minimal, 2=mild, 3=moderate, 4=marked. *, 
P<0.05; **, P<0.01; ****, P<0.0001; Student’s t-test. No differences were 
observed in scores between infected normoglycemic versus hyperglycemic mice.
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were quantified for insulin, glucagon, cell degradation, and fibrosis by blinded 
scoring of sections from all available animals (Fig. 2.3, D–G).  
2.3.3: CVB4 Infection Persists in Human Islet-Engrafted Mice  
Diabetes did not develop in any infected mice until at least 3 weeks post-
infection. Viral RNA was present in mouse serum throughout the course of 
experiment 1 (Fig. 2.4, A). Plaques were recovered from terminal serum of 
CVB4-infected animals, indicating the presence of replication-competent virus 
(Fig. 2.4, B). Viral RNA was readily detected by NanoString from the terminal 
human graft samples (Fig. 2.4, C). Viral copy numbers were highest in the first 
experiment, which corresponds with the more rapid time to diabetes compared 
with the other two experiments. Replicating virus was also present in terminal 
host tissue samples; examples from experiment 2 include heart (1.3 ± 0.6 × 106 
pfu/g, n = 4), pancreas (7.0 ± 4.0 × 106 pfu/g, n = 4), and the nongrafted kidney 
(4.3 ± 2.1 × 106 pfu/g, n = 4).  
To establish that human β cells were infected with CVB4, 
coimmunofluorescence staining was performed on human islet graft sections 
using antibodies against insulin, glucagon, and enterovirus viral protein 1 (VP1). 
VP1 was readily detected in all graft samples from CVB4-infected mice at various 
time points; examples from 41 and 49 dpi (Fig. 2.4, D) as well as 7 dpi (Fig. 2.4, 
E) are shown. Notably, VP1 and insulin colocalized frequently, indicating that β 
cells were infected with CVB4. Not all VP1-positive cells were positive for insulin, 
however, suggesting that other cell populations within human islets can be
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infected mice (41 and 49 dpi). VP1 is green, glucagon blue, and insulin red. 
Images were acquired with a 40X objective. Scale bars represent 75 µm. (E) VP1 
is present in insulin-producing cells in grafts of CVB4-infected mice. Samples 
from an experiment in which grafts were specifically planned for harvest at 7 dpi 
are shown. VP1 is absent from the graft of a mock-infected control mouse (top 
panel). VP1 and insulin co-localize in a graft from a CVB4-infected mouse 
(bottom panel, arrowheads). Images were acquired with a 63x objective. Scale 
bars represent 50 µm.
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infected with CVB4. Since exocrine and pancreatic ductal cells can be 
transplanted along with human islets, we sought to determine whether these cells 
support viral replication.  
Exocrine cells, which stain positive for amylase, were infrequently 
observed in the grafts, and no evidence of VP1 localization was noted (Fig. 2.5, 
A). Similarly, CK19-positive pancreatic ductal cells did not colocalize with VP1 
(Fig. 2.5, B).  
Immunofluorescent staining revealed a significant decrease in the insulin-
to-glucagon signal ratio in grafts of infected mice versus control mice. In 
experiment 2, the insulin-to-glucagon signal ratio was 0.74 ± 0.16 in grafts from 
CVB4-infected mice (n = 4) compared with 3.99 ± 0.92 in mock-infected controls 
(n = 6, P = 0.02, Student t test). This result was consistent with observations for 
insulin and glucagon by immunohistochemical staining (Fig. 2.3, B-C).  
 
2.3.4: Profiling of Gene Expression in Human Islet Grafts  
Human graft gene expression levels after infection were assessed using a 
NanoString platform with species-specific probes. Combined gene expression 
profile results for 100 genes from graft samples are summarized in Fig. 2.6, A 
and B as fold change over the mock-infected animals. INS gene expression was 
significantly lower in grafts from CVB4-infected mice compared with those from 
the mock-infected controls (Fig. 2.2, E). Expression values of somatostatin (SST) 
and pancreatic duodenal homeobox-1 (PDX1), which regulates transcription of 
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INS and SST, were also significantly lower in the grafts of CVB4-infected mice 
relative to those of mock-infected mice.  
Numerous genes in the type I IFN pathway, including CXCL10, MX1, 
OAS2, CCL5, IFIH1, and DDX58, were significantly induced in the grafts of 
infected mice (Fig. 2.6, B). A moderate but significant increase was observed for 
TXNIP, which encodes thioredoxin-interacting protein and is induced by ER 
stress through the protein kinase RNA-like ER kinase (PERK) and inositol-
requiring enzyme 1 (IRE1) pathways. Expression for DDIT3, which encodes 
CHOP, a multifunctional transcription factor in the ER stress response, was 
significantly increased. IL-1β gene expression was significantly decreased, 
although absolute values in samples were consistently low. 
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2.4: Discussion 
We describe a model in which NSG mice with induced hyperglycemia are 
transplanted with human islets and successfully used for studying the viral 
induction of diabetes. Sustained infection with a prototypical strain of CVB4 is 
accompanied by reversion to hyperglycemia. Interestingly, the final diabetic state 
appears to result from a loss of human islet insulin production rather than overt 
islet destruction. Despite the possibility of resident immune cells being engrafted 
with the human donor islets, this model provides an environment largely devoid 
of T cells and antibodies. The absence of an intact immune system in this model 
provides a new, unobscured view of how viruses can directly initiate diabetes. 
The diabetic state is most likely a direct consequence of viral infection of human 
cells that harbor CAR. To our knowledge, this aspect of human specificity has not 
been previously achieved in other in vivo models of viral induction of diabetes. In 
contrast, other models of virus-induced diabetes depend on the contributions of T 
cells. For example, β cell destruction is T cell dependent during the acceleration 
of diabetes in viral infection of aged NOD mice209 and in the Kilham rat virus 
infection model in BBDR rats210. 
Interexperimental variability was observed using several metrics for 
evaluating diabetes. Fluctuations in blood glucose measurements for some 
CVB4-infected mice were noted, but were not entirely unexpected given that 
glucose levels were randomly obtained from nonfasted animals with concurrent 
viral disease. Time to the development of diabetes also varied between 
 67 
experiments. The human islets used for engraftment in each experiment were 
obtained from distinct donors, and differences in the condition of the islets upon 
transplantation could explain some experimental heterogeneity. Variations in the 
course of human T1D can be attributed to a multitude of genetic and 
environmental factors that have only been partially characterized. Despite the 
different genetic backgrounds of the primary human islets and limited sample 
sizes, strong patterns in gene expression were noted in islet grafts and in ex vivo 
cultured islets after infection (see Chapter III).  
The prolonged course of progression of human islet engrafted mice 
infected with CVB4 to hyperglycemia was somewhat surprising. The lytic nature 
of CVB4 in other cell types and the rapid deterioration of mice infected at high 
doses indicate that this virus is quite pathogenic. However, these results fit well 
with reports that the development of T1D is prolonged over an indeterminate time 
period of months to years. Additionally they mesh well with the observations of 
seasonality of both viral infection and T1D incidence. Enterovirus incidence 
peaks in late summer months into autumn116. T1D incidence is the highest in the 
winter months78. So if viral infections in the late summer months are causing the 
development of T1D over the course of several months, this would fit well with 
the observed T1D peak in winter. However, this association is tenuous and since 
the time period of the development of T1D is poorly understood, this is only 
speculation.  
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Significant changes in gene expression were observed for endocrine 
genes, type I IFN-associated genes, and T1D susceptibility genes. The 
endocrine genes INS, SST, and PDX1 had the greatest fold decreases in gene 
expression in both the engrafted islets and ex vivo-cultured islets. PDX1 
regulates the expression of both INS and SST; and protects against apoptosis, 
autophagy, and susceptibility to ER stress211-214. Interestingly, persistently 
infected cultures of a ductal-like cell line with CVB4 have diminished PDX1 
expression after several weeks of infection215, which provides insights for our 
model. The expression of type I IFN–associated genes, including OAS2, MX1, 
CCL5, and TLR3, was increased. The presence of a type I IFN signature in 
individuals genetically at risk for T1D prior to the development of autoantibodies 
was recently highlighted181. CXCL10, an IFN-stimulated gene, had the highest 
fold induction of expression in both in vivo and ex vivo studies. CXCL10 recruits 
immune cells at inflammation sites and has been proposed to contribute to the 
pathogenesis of many autoimmune diseases, including T1D216,217. T1D 
susceptibility gene expression for IFIH1 and HLA-A was significantly higher after 
infection. We previously reported168 that IFIH1 mediates IFN responses after 
CVB infection. Single nucleotide polymorphisms in IFIH1 that could diminish the 
type I IFN response after viral infection are associated with protection from 
T1D72,172. The marked increase in the expression of HLA-A in grafts after 
infection is consistent with class I MHC hyperexpression described in patients 
with T1D218.  
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Human islet-engrafted mice developed diabetes several weeks after 
infection, during which time replicating virus was readily detected. CVB can 
cause prolonged infection in immunocompetent mice. Vella and Festenstein219 
reported that CVB4 infection led to persistent infection in the majority of 10 inbred 
mouse strains. Persistent enteroviral infections have been described in 
immunodeficient humans, particularly those with agammaglobulinemia (for 
review, see Galama220). Prolonged coxsackievirus antigen shedding was 
described in a patient with agammaglobulinemia, corresponding to a lack of 
neutralizing antibody221. Additionally, B cell-deficient mice infected with CVB3 
exhibit persistent viral production up to 45 dpi222, and CVB3 persistence has 
been reported in SCID mice223. Mounting evidence exists that coxsackievirus can 
establish persistent infections in astrocytic cells and ductal cells of the 
pancreas215,224. In our study, we performed dual staining for VP1 and CK19 to 
determine whether ductal cells were acting as a viral reservoir. We did not detect 
any colocalization, although others have detected viral RNA from primary ductal 
cells, which is more sensitive than VP1 staining215. Identification of additional 
human cells that can be persistently infected could provide insights into relevant 
viral reservoirs.  
The ability to investigate the long-term consequences of viral infection 
could provide new insights into the homeostatic balance between mechanisms of 
β cell function and death. The human islet engraftment model may reflect the 
earliest stages of the onset of virus-related diabetes prior to the development of 
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autoimmune responses. Many features are reminiscent of cases of fulminant 
T1D, characterized by rapid onset of hyperglycemia and ketoacidosis resulting 
from accelerated β cell failure. Tissue studies reveal the presence of enterovirus 
in pancreatic islet cells as well as increased expression of innate immune 
sensors, CXCL10, and type I IFN in β cells and infiltrating immune cells225,226, 
underscoring the importance for innate immune signaling pathways. Additionally, 
this model mirrored many key pathological features found in tissues of recent 
onset T1D patients. There is characteristic expression of IFN-I227 and associated 
cytokines like CXCL10187, and hyperexpression of class I MHC218.  
Infection models using humanized mice that include reconstitution of 
components of the human immune system will yield further insights into the 
pathogenesis of virus-induced diabetes, revealing specific contributions of both 
innate and adaptive immunity.  
2.4.1: Conclusions 
Mice with glucose homeostasis under the control of engrafted primary 
human islets revert to hyperglycemia after infection with CVB4. This 
hyperglycemia is due to the loss of insulin production of engrafted β cells at the 
level of both mRNA and protein. This loss of INS gene expression upon CVB4 
infection is a key marker for β cell dysfunction. Furthermore, the infection of 
engrafted primary human islets initiates a robust innate immune response. The 
IFN-I and cytokine expression profile is characterized by the robust expression of 
downstream ISGs, CXCL10, MX1, CCL5, and IFIH1. The following chapters will 
use these findings to evaluate various models of cultured primary human islets.  
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2.5: Materials and Methods 
2.5.1: Mice  
Mice were maintained in accordance with the Institutional Animal Care 
and Use Committee of the University of Massachusetts Medical School. NSG 
male mice, 12–14 weeks old, received a single intraperitoneal injection of 160 
mg/kg STZ to induce hyperglycemia (blood glucose >250 mg/dL on 2 
consecutive days). B6CBA-Tg(Ins2-HBEGF)6832Ugfm mice, in which the rat 
insulin II promoter drives β-cell–specific expression of the DTR, were provided by 
P. Herrera (University of Geneva, Geneva, Switzerland). This transgene was 
backcrossed using a marker-assisted speed congenic approach to the NSG 
strain background (i.e., NSG-Tg[RIP-DTR])228,229. Female NSG-Tg(RIP-DTR) 
mice, 12–16 weeks old, were given 40 ng DT by intraperitoneal injection. 
Nonfasting blood glucose levels were monitored with a glucometer. To enhance 
survival after the induction of diabetes was confirmed, mice were given LinBit 
insulin pellet implants (LinShin Canada Inc.) until human islets were available for 
transplant.  
2.5.2: Human Islet Transplantation  
Human islets were obtained from the Integrated Islet Distribution Program 
under protocols approved by the Institutional Review Board of the University of 
Massachusetts Medical School. A total of 3,000 islet equivalent units were 
transplanted under the subrenal capsule of each mouse, as previously 
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described203. For each experiment, islets obtained from single, distinct human 
donors were used. Mice were allowed to recover from the surgery for 2 weeks to 
allow for graft revascularization and for normoglycemia to be restored.  
2.5.3: Mouse Infections  
Mice were intraperitoneally injected with normal saline solution (control) or 
1 × 104 plaque-forming units (pfu) of the prototypical CVB4 laboratory strain JVB 
(catalog # VR-184; American Type Culture Collection) grown in HeLa cells230. 
Nonfasting blood glucose levels were measured at least twice weekly. Additional 
blood samples were obtained weekly for viral RNA extraction. Mice were killed if 
they displayed gross signs of illness (e.g., ruffling, hunching), and the native 
mouse pancreas and the human islet graft were harvested for RNA and 
histopathology. Serum, pancreas, heart, liver, spleen, and contralateral kidney 
were harvested for viral titers. Plaque assays were performed using previously 
described methods168.  
2.5.2: PCR  
Viral RNA was extracted from serum using the QIAamp Viral RNA Mini kit 
(Qiagen) and cDNA generated using the High Capacity cDNA Reverse 
Transcriptase Kit (Applied Biosystems) followed by quantitative PCR using the 
Platinum Quantitative PCR SuperMix-UDG Kit (Life Technologies). Enterovirus-
specific primers and probe were used for quantification of viral RNA105. A 
standard curve was established using the EGFP-CVB3 plasmid as a template (a 
gift from L. Whitton, Scripps Research Institute, La Jolla, CA)231.  
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2.5.4: Histopathology and Immunohistochemistry  
Antigen retrieval was performed on paraffin-embedded sections with 
Retrievagen A Solution (BD Biosciences), and endogenous biotin was blocked by 
Dual Endogenous Enzyme Blocking Reagent (Dako). Guinea pig antibody to 
insulin (Dako) or rabbit antibody to glucagon (Abcam) was added and detected 
with the EnVision Dual Link Kit (Dako) followed by staining with DAB Solution 
(Dako). Samples were counterstained with hematoxylin. A veterinary pathologist 
scored histopathological changes by blinded scoring of sections.  
2.5.5: Immunofluorescence  
Antigen retrieval was mediated at 98°C for 45 min in formalin-fixed, 
paraffin-embedded sections. Sections were blocked with PBS containing 1% 
BSA and 5% normal goat serum, then incubated with the following primary 
antibodies overnight: guinea pig antibody to insulin (1:150; Dako); rabbit antibody 
to glucagon (1:50; Dako); mouse antibody to VP1, clone 5-D8/1 (1:50; Dako); 
rabbit antibody to cytokeratin 19 (CK19) (1:500; Abcam); and/or rabbit antibody 
to amylase (1:400; Abcam). Sections were incubated with the following 
secondary antibodies for 1 h at 1:1,000 dilution: Alexa Fluor-594 goat antibody to 
guinea pig IgG; Alexa Fluor-647 donkey antibody to rabbit IgG; and Alexa Fluor-
488 goat antibody to mouse IgG (catalog #A11076, #A31573, and #A11029, 
respectively; Life Technologies). Sections were mounted with ProLong Gold 
Antifade Re- agent with DAPI (Life Technologies). Immunofluorescence was 
imaged on a Leica SP8 confocal microscope and quantified using FIJI software 
(version 1.48p) using automatic thresholding followed by the measure area 
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function232. Wide-field images were acquired using a Nikon Eclipse Ni-U 
microscope with a X4 plan objective using NIS-Elements imaging software 
(version 4.13). High-magnification wide-field images were acquired with a X40 
plan objective using QCapture Pro software (version 5.1).   
2.5.6: Gene expression profiling of engrafted islets  
A portion of the human islets that were engrafted in mice were collected at 
the time of sacrifice from all available animals. TRIzol reagent (Life 
Technologies) was used for RNA extraction from the tissue.  A multiplex 
hybridization assay (NanoString) allowed for direct measurement of mRNA 
copies without the need for amplification. Probes were designed to target human 
genes in a species-specific manner. The NanoString CodeSet #1 (NSCS1) 
included type I IFN, cytokines, apoptosis, endocrine, endoplasmic reticulum (ER) 
stress, T1D-associated loci, and other human genes, plus seven housekeeping 
genes for normalization of data. A probe for a conserved CVB sequence 
targeting the same region as the quantitative RT-PCR primer was included105. 
One hundred nanograms of RNA extracted from tissue was hybridized, 
processed, and analyzed per the manufacturer’s procedure. Data were 
normalized using the nSolver Analysis Software (version 1.1). Fold changes in 
gene expression were the ratio of normalized gene expression in CVB4-infected 
samples versus those in mock-infected samples. Averages of fold changes were 
calculated by averaging the log10 of the fold change followed by a transformation 
of 10x. Values <1 were transformed by -1/x. For experiment 2, only five of seven 
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samples from mock-infected mice were analyzed because of space constraints 
on the NanoString assay.  
2.5.7: Statistical Methods  
To compare repeated blood glucose measurements between treatment 
groups within an experiment, generalized estimating equations were used to 
adjust for the inherent correlation among the measurements within each mouse. 
The significance of the regression coefficients was assessed using standard z 
tests. The relationship between the maximum glucose level and the number of 
insulin copies and C-peptide level was assessed using Spearman 
(nonparametric) correlation coefficients with Fisher transformation. The onset of 
diabetes within and across experiments was compared using Kaplan-Meier 
product-limit estimates and the log-rank statistic. To assess the significance of 
the fold-change of gene expression, a standard one-sample t test was used to 
determine the significance compared with zero. SAS (version 9.3) was used for 
all analyses. 
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CHAPTER III: COMPARISON OF CVB INFECTION IN CULTURED PRIMARY 
HUMAN ISLETS AND IN HUMAN Β CELL LINES  
 
Glen R. Gallagher, Robert W. Finberg, and Jennifer P. Wang 
 
Contribution Summary: 
G.R.G. designed and performed the experiments and helped to analyze the data 
and write the manuscript. R.W.F. helped to design the experiments. J.P.W. 
helped to design experiments, analyze data, and write the manuscript. 
 
Figure 3.1 is reprinted from the Diabetes article PMID: 25392246
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3.1: Abstract 
 Immunodeficient mice with induced hyperglycemia and engrafted with 
primary human islets reverted to hyperglycemia following infection with CVB4. 
This in vivo model provides important insights into β cell dysfunction upon CVB4 
infection under physiological conditions, but the early effects of viral infection in 
human islets were not interrogated. Short-term culture of primary human islets, 
which are permissive to CVB4 infection, is possible and allows for evaluation of 
gene expression changes over a time course. Given that insulin gene expression 
decreases in primary human islets following CVB4 infection, cultured human 
islets can be used to define infection-specific pathways important in influencing 
insulin. Similarly, gene expression of innate immune genes can be interrogated. 
Human β cells derived by directed differentiation of stem cells (SC-β) provide a 
model for studying the effects of CVB4 infection of human β cells. Furthermore, 
the EndoC-βH1 cell line provides a pure β cell population in which changes in 
gene expression after CVB4 infection can be studied. The results presented here 
indicate that both of these sources of β cells are permissive to CVB4 infection. 
Although inconsistencies were observed in insulin gene expression between 
cultured primary human islets and SC-β and EndoC-βH1 cells, all three sources 
of β cells had robust innate immune responses to CVB4 infection. Therefore, 
these other cells may provide new options for studying the nature of innate 
immune signaling in β cells.  
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3.2: Introduction 
3.2.1: Overview 
Studies with mice engrafted with human islets provide benchmarks for the 
viral contributions to triggering T1D. This model provides the advantage that 
human islet gene expression changes associated with hyperglycemia can be 
monitored in vivo. However, the dynamic processes that lead to the development 
of β cell dysfunction and hyperglycemia are difficult to study due to the technical 
complexity and cost of this model. Determining the underlying regulation of viral 
replication, how antiviral responses are initiated, which cell types contribute to 
the immune signaling, and how these processes contribute to β cell dysfunction 
are all challenging in vivo. To relieve these constraints, I turned to cultured β cells 
from either primary human islets, stem cells directionally differentiated into β 
cells, and a human β cell line. Identifying the pathways involved and the key 
mediators of β cell dysfunction that cause a decrease in insulin production and 
innate immune antiviral responses provide opportunities to develop interventions 
to prevent the progression to overt, autoimmune T1D.  
Cultured primary human islets are a convenient replacement cell type for 
studying the effects of viral replication. In addition to infections of cultured 
primary human islets, new advances in directed differentiation of stem cells into 
pancreatic endocrine cells (SC-β), and the introduction of previously unavailable 
human β-cell lines offer new tools for studying viral infection in even more 
controlled conditions. 
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3.2.2: Cultured Primary Human Islets  
Cultured primary human islets are becoming more readily available and 
provide a platform for studying viral replication and host responses in a controlled 
experimental setting. Currently there are two main sources of primary human 
islets. The first is the not-for-profit Integrated Islet Distribution Program (IIDP), 
which is coordinated by the City of Hope National Medical Center and sponsored 
by the National Institute of Diabetes and Digestive and Kidney Diseases. The 
second are commercial sources that include Prodo Laboratories, Lonza, and 
ZenBio. These sources provide primary human islets derived from healthy 
donors for use in basic research. Since these cells are in a culture format, there 
is greater flexibility in experimental design and greater ability to control for the 
virus dose and timing of infection. This provides the opportunity to further dissect 
the interactions between enteroviruses and islet cell function. Cytopathic effects 
of viral infection can be directly observed by microscopy, supernatants can be 
sampled for insulin release or cytokine production, and islets can be harvested 
for RNA to measure gene expression changes. However, a major limitation of 
cultured primary human islets is the inability to culture the cells for long periods of 
time. Despite this caveat, this system provides a convenient method of 
evaluating early changes in β cell function or immune gene expression.   
3.2.3: Enterovirus infection of cultured primary human islets affects β cell 
function  
Similar to the insulin insufficiency of primary human islets engrafted in 
mice, infections of cultured primary human islets also exhibit signs of β cell 
dysfunction upon viral infection. Factors of viral replication efficiency, cytotoxicity, 
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and β cell tropism may all contribute to the ability of a virus to cause β cell 
dysfunction and therefore its diabetogenic potential. Cultured primary human 
islets are permissive to infections of various viruses in the enterovirus genus due 
to the presence of viral receptors. Poliovirus, Coxsackie A virus (CVA), 
Coxsackie B virus (CVB), echovirus and various enterovirus strains all 
productively replicate in primary human islets233,234. While most of these viruses 
exhibit lytic replication with considerable cytopathic effect (CPE), CVA serotype 9 
replicates with no apparent CPE233. In addition to developing CPE after 
enterovirus infection of cultured primary human islets, β cells exhibit defects in 
glucose-stimulated insulin secretion234,235. However, this is not always the case. 
CVA serotype 9 replicates in cultured primary human islets without affecting 
insulin content or secretion in response to glucose234. However, the mechanisms 
of the suppression of insulin secretion after enterovirus infection have not been 
investigated. A better understanding of the kinetics of gene expression changes 
after enterovirus infection may elucidate the underlying mechanisms.  
3.2.4: Gene expression changes after enterovirus infection in cultured 
primary human islets 
In addition to CPE and β cell functional studies, cytokine production and 
gene expression changes in infected primary human islets could provide insights 
into the diabetogenic potential of strains of CVB4. CVB4-JVB infection of cultured 
primary human islets induces IFN-α production200. Infected islets similarly 
produced IP-10 (CXCL10) and other IFN stimulated genes (ISGs) in response to 
infection236. While the production of these immune responses has been identified 
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in cultured islets, the contributions of different cell types to the overall response 
are difficult to identify. If the antiviral response is different in β cells than other 
infected cell types, this could tip the balance from viral clearance to the 
development of autoimmunity. Therefore, understanding both the genes involved 
in the antiviral response and the cell types that mediate the response could 
provide insights into autoimmunity directed at β cells.  
3.2.5: New models of human β cells 
While the availability of cultured primary human islets enables the 
investigation of the interactions between human islet cells and viruses that was 
previously impossible, these cells still have a number of restrictions including 
limited availability, variability in donor genetics, limited viability in culture, and 
high cost. Newly available sources of human β cells mitigate some of these 
limitations.  
One newly available source of human β cells is SC-β cells. These cells are 
derived from pluripotent stem cells that are directionally differentiated to a 
endocrine phenotype through well-timed treatments with cocktails of small 
molecule agonists and growth factors33. The majority of these cells are insulin-
producing β cells, but other hormone positive cells are also represented in the 
cell clusters, including glucagon-producing α cells. These cells are responsive to 
glucose stimulation and in theory have minimal batch-to-batch genetic variability 
because they are differentiated from clonal progenitor cells.  
Another human β cell platform, EndoC-βH1 cells, provides the advantage 
of monotypic culture of only insulin-producing β cells. This cell line was produced 
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by the transduction of the SV40 large T-antigen into human fetal pancreas tissue. 
These cells were expanded by engrafting them into SCID mice followed by 
recovery of the cells. Recovered cells were then transduced with hTERT to 
further immortalize the cells, followed again by engraftment into SCID mice. The 
resulting cells were then used to establish the clonal, functional, human β cell 
line237. Use of this cell line eliminates the paracrine effects of other cell types 
during infection. Since all of the cells are phenotypically similar prior to infection, 
infections of these cells helps to define the cell-intrinsic effects of virus on human 
β cell gene expression and function.  
3.2.6: Goals 
The goals of this chapter are as follows: 1) compare the gene expression 
changes in engrafted and cultured primary human islets following CVB4 infection 
to identify important β cell regulatory pathways and antiviral responses that 
contribute to the hyperglycemia observed in vivo, 2) evaluate the kinetics of gene 
expression changes in CVB4-infection of cultured primary human islets at 6, 24, 
48, and 96 hpi, 3) compare gene expression in cultured primary human islets 
upon infection with CVB4 or stimulations with poly(I:C) or poly(dA:dT) at 24 hpi, 
4) evaluate viral replication in SC-β cells and assess expression of hallmark 
genes identified in human islet studies, and 5) measure CVB4 replication and 
CPE in EndoC-βH1 human β cells and evaluate gene expression changes upon 
infection.  
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3.3 Results 
3.3.1: Gene expression profiling in cultured human islets at 48 hpi 
Cultured islets from three different human donors were independently 
challenged with CVB4. At 48 h post-challenge, supernatants were harvested and 
cells were processed for RNA to assess gene expression using the same 
NanoString probes used for experiments in Figure 2.6 (NSCS1) (Fig. 3.1, A and 
B). Significant changes in gene expression were observed in CVB4-infected 
samples compared with those from controls. The greatest decreases were again 
seen with INS, SST, and PDX1, although statistical significance was achieved 
only with INS (P = 0.034, 0.071, and 0.056, respectively, Student’s t test). 
CXCL10 had the highest increase in gene expression, however statistical 
significance was not reached (P = 0.08, Student t test). Increases in expression 
were observed for numerous type I IFN response genes, including OAS2 and 
MX1, as well as TLR3 and IFNB1. Interestingly, GCG gene expression was not 
significantly changed. Low levels of IFN-β and IFN-α were detected in 
supernatants from cultured human islets 48 h post-challenge with CVB4 or the 
MDA5 agonist poly(I:C) (Fig. 3.1, C). 
The gene expression in CVB4-infected cultured primary human islets at 48 
hpi has many similarities with the gene expression observed in infections of 
engrafted primary human islets in mice at an average of 38 days post infection. 
Gene expression is similarly increased in both engrafted and cultured primary 
human islets for ISGs CXCL10, MX1, OAS2, and IFIH1 (Fig. 3.2, A). However, 
there are some differences in IFN gene expression. This may be due to the 
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Human IFN-β and IFN-α were measured by ELISA from supernatants of human 
islets challenged with either CVB4 (1e6 pfu/100 IEQ) or poly(I:C) (100 µg/ml) for 
48 h. *, P < 0.05, Student’s t test. Error bars indicate the S.E.M. (D) Human islets 
from an independent donor were infected with eGFP-CVB3 (1e6 pfu/100 IEQ). A 
subset of the virus-infected cells is insulin-positive by immunofluorescent staining 
(arrowhead). eGFP-CVB3 is green, insulin is red, DAPI is blue. Co-localization of 
CVB3 and insulin is yellow. Scale bar represents 75 µm.
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differences in the kinetics of the antiviral response. In cultured primary human 
islets at 48 hpi, IFNB1 and IFNG increase 8.15 and 13.34-fold, respectively, but 
their gene expression is not increased in engrafted primary human islets at the 
much later time points (Fig. 3.2, B). Differences in expression of other genes in 
the engrafted human islets during this persistent infection may highlight 
regulatory pathways of interferon genes in persistently infected tissues. Despite 
the drastic differences in the time scale of the experiments with engrafted and 
cultured primary human islets the three genes with the greatest decreases in 
gene expression are INS, PDX1, and SST in both cases (Fig. 3.2, B). Therefore, 
infections of cultured primary human islets with CVB4 provide a comparable 
surrogate platform for the mouse model given similarities in gene expression 
changes despite the large differences in time scales.  
3.3.2: Virus tropism in cultured primary islets 
Cultured primary human islets are composed of a mixed cell-type population, so 
cells that are infected may be different from the cells that produce the IFN-I and 
inflammatory gene responses detected in Figure 3.1, A-C. It is also possible that 
the reduction in INS gene expression is mediated through a paracrine effect from 
viral response to cells that are infected nearby. In order to confirm the tropism of 
CVB for insulin-producing β cells in human islets, eGFP-expressing CVB3 was 
used to infect dispersed cultured human islets in vitro. Insulin-positive cells were 
detected using immunofluorescence staining and visualized by confocal 
microscopy (Fig. 3.1, D). eGFP and insulin frequently colocalized, providing 
further evidence that human β cells are infected with CVB. However, some cells 
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heatmap, are sorted in decreasing order for the engrafted human islets for genes 
with increased expression (A) or decreased expression (B). Fold changes are 
indicated for each gene for each conditions. Scale from -10-fold decrease in blue 
to 10-fold increase in red. Genes mentioned in the text are highlighted with an 
asterisk.
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that were infected did not stain positively for insulin production. So cells other 
than β cells are permissive to CVB infection and may contribute to IFN-I and 
cytokine response in primary human islets.  
3.3.3: Kinetics of gene expression changes in primary human islets after 
infection with CVB4 
Measuring changes in gene expression at different time points after 
infection with CVB4 can provide insights into the pathways involved in changes in 
islet function genes. Early changes in gene expression can identify factors 
involved in mediating the later phenotypic changes in β cell function. To identify 
early changes in gene expression, I profiled changes at 6, 24, 48, and 96 hpi with 
CVB4 in primary human islets from a single donor using a revised panel of genes 
in a second NanoString CodeSet (NSCS2 - see Materials and Methods for 
details).  
Over this time course, viral gene copies increase steadily between 6 and 
48 hpi with a 0.6-log increase in viral gene copies occurring over this timeframe. 
This increase indicates productive viral infection in cultured primary human islet 
cells. Between 48 and 96 hpi a modest 0.23-log decrease in viral copies was 
observed (Fig. 3.3, C), which may be secondary to the innate immune response 
suppressing further replication. Alternatively, the replication capacity of these 
cells is exhausted by this time point. 
At 6 hpi with CVB4, only four genes had a greater than 3 fold change 
compared to mock treated primary human islets (Fig 3.3, A). These genes were 
CXCL10, IFNE1, CXCL11, and IFNA16 (in order of highest to lowest fold 
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challenged islets compared to uninfected islets) were sorted by the average fold 
change across all time points in descending order and displayed as a heatmap 
for genes that (A) increased after infection or (B) decreased after infection. Gene 
expression of selected endocrine genes, genes involved in β cell function, or 
innate immune response are plotted as relative copies with media controls in 
black and CVB4-challenged islets in red at 6, 24, 48, and 96 hpi for (C) CVB 
genome, (D) INS, (E) GCG, (F) PDX1, (G) PCSK1, (H) SLC2A2, (I) IFNA6, (J) 
IFNB1, (K) CXCL10, and (L) ISG15. Dotted line represents the limit of detection 
for the NanoString assay ~15 copies.
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change). IFNE1 has low total gene counts that are near the level of background, 
but the gene counts for the other three genes are robust at this time point. At 24 
hpi, many more changes in gene expression after CVB4 infection are observed. 
28 genes have a greater than 3-fold increase, and 12 genes have a greater than 
3-fold decrease in expression. Genes that are among the most increased at 24 
hpi include the IFN-I genes IFNB1 and IFNA16 and the IFN-III gene IFNL3. This 
correlates well with the expression of ISGs CXCL10, IFIT2, ISG15, CXCL11, and 
MX1 that also have increased expression at this time point (Fig. 3.3, A). Most of 
the genes with a greater than 3-fold decrease at 24 hpi are involved in islet cell 
function and include genes involved in β cell function and insulin secretion, 
specifically SLC2A2, MAFA, IAPP, INS, PCKS1 and PDX1 (in order from highest 
to lowest fold change) (Fig. 3.3, B).  
By 48 hpi, 23 genes with a greater than 3-fold increase, and 15 genes with 
a greater than 3-fold decrease are detected. The patterns are similar to results 
presented in Figure 3.1. By 96 hpi, the number of genes with a greater than 3-
fold change are 58 genes increased and 6 genes decreased.  
To better visualize the changes in gene expression over time in either 
mock or CVB4-infected primary human islets, I plotted the measurements for 
selected genes involved in islet cell function or antiviral response that for each 
time point. Similar to previous experiments (Fig. 3.1), INS expression is 
dramatically decreased in CVB4-infected islets. INS expression drops 
precipitously between 6 and 24 hpi and continues to decrease until 96 hpi, while 
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mock infected islets have only a slight reduction in INS expression by 96 hpi (Fig. 
3.3, D). GCG gene expression is slightly increased in CVB4-infected islets (Fig. 
3.3, E). Genes involved in insulin production and secretion, PDX1, PCSK1, and 
SLC2A2 are decreased upon infection with CVB4. (Fig. 3.3, F-H). IFN genes are 
expressed in response to CVB4-infection (Fig. 3.3, I-J). Congruent with the 
expression of IFN genes, ISG expression for CXCL10 peaks at 48 hpi (Fig. 3.3, 
K). Similarly ISG15 expression reaches peak levels at 48 hpi and is among the 
genes with the highest difference in gene expression between CVB4-infected 
cells and mock at all time points (Fig. 3.3, L).  
3.3.4: Gene expression changes in primary human islets infected with 
CVB4 or stimulated with poly(I:C) or poly(dA:dT) 
Cultured primary human islets provide a relevant platform for the study of 
early changes in gene expression upon viral infection due to the similarities in 
gene profile to the infection of primary human islets engrafted in mice. 
Stimulations of cultured human islets with other innate immune pathway agonists 
can provide insights into β cell responses that are specific to this viral infection 
and independent of general IFN responses. To identify gene expression changes 
that are specific to CVB4 infection of cultured primary human islets from a single 
islet donor, I compared gene expression after infection with CVB4 or after 
stimulations with synthetic agonists of IFN signaling. I transfected the dsRNA 
mimetic, poly(I:C), which signals through MDA5 and IRF3 to induce IFNB 
expression238. I also transfected poly(dA:dT) as a synthetic activator of the DNA 
sensing pathways that include ZBP1/DAI and LRRFIP1 leading to IFN-I 
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expression239. I evaluated gene expression using the NSCS2 gene expression 
panel at 24 hours after infection or treatment.  
Cultured primary human islets stimulated with either poly(I:C) or 
poly(dA:dT) had many similar patterns of gene expression changes with those for 
CVB4 infection. These include robust expression of the ISGs CXCL10, ISG15, 
and IFIT2 (Fig. 3.4, C). Despite these similarities, some interesting differences 
were noted, including those in islet function genes INS and PDX1. INS 
expression is decreased -4.3 fold at 24 hpi in CVB4 infected islets (Fig 3.4, A), 
which is similar to the -7.6 fold decrease observed at 48 hpi (Figure 3.1, A). No 
decrease in INS gene expression is measured in either poly(I:C) or poly(dA:dT) 
treated islets (Figure 3.4, A) despite the presence of a robust IFN response 
(Figure 3.4, B-C). PDX1 is also decreased by CVB4 infection by -3.5 fold, while 
poly(I:C) and poly(dA:dT) have minimal effects on PDX1 expression (-1.06 and 
1.08 fold change respectively). These changes in gene expression after CVB4 
infection may represent changes in islet function genes that are independent of 
the general IFN responses induced by synthetic nucleic acid analogs.  
IFN production is critically important in controlling viral replication and 
accumulating evidence points to IFN signaling as a contributor to the 
development of T1D104,177,178. Since differences in expression in islet function 
genes are observed with nucleic acid stimulants compared to CVB4 infection, 
different IFN genes stimulated under these conditions could mediate the 
differential responses. By adding probes specific for IFN-I, IFN-II, and IFN-III 
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genes, we are able to interrogate which genes are involved in the response of 
cultured primary human islets. In line with the induction of IFNB expression at 48 
hpi and secretion of IFN-β and IFN-α into supernatants (Fig. 3.1, B & C), IFNA16 
and IFNB1 are among the highest IFN-I genes induced by poly(I:C) and CVB4 
infection. CVB4-infected islets also increased the IFN-III gene, IFNL3 (IL28B) 
(Fig. 3.3, B). ISGs are increased at 24 hpi in all treatments.  
3.3.5: Infection and gene expression in SC-β cells 
To reduce the contribution of genetic variability in responses to viruses in 
islets from donors of primary human islets, I used cells that were directionally 
differentiated into pancreatic endocrine cells from human stem cells, called SC-β 
cells33. Multiple endocrine cell types are present in these cell clusters, but the 
majority of the cells are insulin-producing β-cells. First, I infected these cells with 
a GFP-expressing strain of CVB3, CVB4 or stimulation with transfected poly(I:C) 
from a single batch of SC-β cells. In mock-treated cells at 13 h, the cell clusters 
remained intact and had very few cells that were not associated with clusters 
(Fig. 3.5, A). Transfection of poly(I:C) resulted in more free-floating cells and 
some of the clusters appeared to be less tightly-associated, indicating some 
toxicity (Fig. 3.5, B). Infection with CVB4 at an MOI of 10 exhibited the highest 
CPE at 13 hpi, while infection with CVB3-eGFP at an MOI of 10 had slightly less 
CPE (Fig. 3.5, C-D). I also visualized GFP expression in these cells upon 
infection with CVB3-eGFP at three different MOI to evaluate the capacity of virus 
to replicate in SC-β cells and gauge relative infection efficiency (Fig. 3.5, E). The 
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13 hpi by brightfield microscopy at 25x magnification. (E) GFP expression was 
evaluated by microscopy at 100x magnification at 13hpi for CVB3-eGFP at MOIs 
of 0.1, 1, and 10. Gene expression was evaluated in untreated, stimulated with 
100 µg/ml poly(I:C) or infection of CVB4 at MOI of 1 at 16 hpi using the 
NanoString CodeSet (NSCS2) for the same genes as selected in Figure 3.3 
plotted as relative copies for each of the three conditions (F) CVB genome 
copies, (G) INS, (H) GCG, (I) PDX1, (J) PCSK1, (K) SLC2A2, (L) IFNA16, (M) 
IFNB1, (N) CXCL10, and (O) ISG15.
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mock-treated cells did not have any visible GFP expression, and a dose-
dependent increase in GFP production following CVB3-eGFP infection was 
observed with MOIs of 0.1, 1, and 10. The CPE observed in Figure 3.4, C 
correlates with the viral infection evaluated by GFP expression.  
In agreement with the expression of GFP in CVB3-eGFP-infected SC-β 
cells and the CPE observed in CVB4-infected islets, CVB genomes are detected 
in RNA extracted from infected SC-β cells by the NanoString probe. No CVB 
genomic RNA is present in mock or poly(I:C) treated cells (Fig. 3.5, F).  
To compare gene expression changes upon treatment with poly(I:C) and 
CVB4 infection in SC-β with the changes in cultured primary human islets, I 
measured gene expression by NanoString gene expression assay (NSCS2). 
While expression of many genes changed, I here focus on β cell function or 
innate immune genes that are modulated in infected cultured primary human 
islets. Upon treatment with poly(I:C) or CVB4 infection for 16 hpi, no changes in 
INS, GCG, PDX1, PCSK1, or SLC2A2 are seen (Fig. 3.5, G-K). IFNA16 gene 
expression is slightly increased with CVB4 infection, but not with poly(I:C) 
treatment (Fig. 3.5, L). IFNB1 gene expression is greatly increased after 
treatment with poly(I:C), and a similar, although less robust increase is observed 
with CVB4 infection (Fig. 3.5, M). The ISGs CXCL10 and ISG15 both increase 
with each treatment. However, gene expression is higher with poly(I:C) treatment 
than with CVB4 infection for each gene (Fig. 3.5, N-O).  
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3.3.6: CVB infection and replication in EndoC-βH1 cells 
Infection of SC-β cells can provide interesting insights into changes in 
gene expression from cells derived from a clonal stem cell population. This 
provides the advantage of reducing the inter-experimental variability caused by 
variability in donor genetics in primary human islet studies. However, these cells 
still are a mixed cell type population. To better define the infection, replication, 
and gene expression specifically in human β cells, I also used the recently 
developed EndoC-βH1 cell line237.  
EndoC-βH1 cells grow as an adherent monolayer on ECM-coated culture 
dishes (Fig. 3.6, A-top row). Following CVB4-infection (MOI 1), a progressive 
increase in CPE is observed over time, which is characterized by cell rounding 
and detachment from the culture surface. At 4 hpi, minimal viral CPE is evident. 
By 24 hpi, approximately 40% of the cells are rounded or separated from 
neighboring cells. By 48 hpi, almost all of the cells become rounded and begin to 
detach from the culture surface (Fig. 3.6, A-bottom row). The kinetics of the 
development of CPE are dose-dependent based on the input MOI of CVB4. At a 
low MOI of 0.01, 50% CPE is not reached until after 48 hpi. Infection with an MOI 
of 0.1 reaches 50% CPE between 24 and 32 hpi. CVB4-infection with an MOI of 
1 reaches 50% CPE before 24 hpi, and approaches 100% CPE by 48 hpi (Figure 
3.6, B). To further evaluate the kinetics of viral replication, I measured the 
production of CVB4 viral copies in RNA extracts from EndoC-βH1 cells at 0, 2, 4, 
6, 10, and 24 hpi at an MOI of 10 by qRT-PCR. Upon adsorption with the virus 
for 1 h, 3.5e7 copies/µl RNA are present, indicating that virus is either attached to 
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0, 2, 4, 6, 10, and 24 hpi evaluated by qRT-PCR. Flow cytometry of EndoC-βH1 
cells infected with CVB4 (MOI = 10) at 6 and 24 hpi for (D) dead cells or (E) VP1. 
(F) Immunofluorescence staining of EndoC-βH1 cells infected with CVB4 (MOI = 
10) at 6 hpi for DAPI (blue), VP1 (green), and insulin (red) images acquired with 
a 630x.
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or internalized by EndoC-βH1 cells. Between 0 and 10 hpi, the number of viral 
copies increased by nearly 2-logs, indicating a rapid and robust replication of 
CVB4 in EndoC-βH1 (Fig. 3.6, C). The capacity of CVB to produce viral RNA and 
proteins demonstrates that CVB4 is able to infect and replicate specifically in 
these human β cells.  
To further evaluate the replication capacity of CVB in human β cells, I 
stained infected cells for CVB capsid viral protein 1 (VP1) and cell death by flow 
cytometry. 62% of EndoC-βH1 cells infected with CVB4 at an MOI of 10 are 
positive for VP1 staining at 6 hpi. This decreases slightly to 29% by 24 hpi (Fig. 
3.6, D). CVB4-infected EndoC-βH1 cells have a similar proportion of dead cells 
compared to mock treated cultures at 6 hpi. By 24 hpi, an increase to 74% dead 
cells after CVB4 infection is present (Fig. 3.6, E). To visualize viral protein in 
addition to insulin in CVB4-infected EndoC-βH1, I stained cells infected with 
CVB4 at an MOI of 10 at 6 hpi with anti-VP1- (green) and anti-insulin- (red) 
specific antibodies. Under these conditions, VP1 was readily detected and 
colocalization with insulin staining is present (yellow) (Fig. 3.6, F). It is unclear 
from the image analysis if CVB4-infected EndoC-βH1 cells have reduced insulin 
protein compared to mock-treated cells as insulin staining intensity is not 
significantly different between the two treatments (data not shown). Taken 
together, production of CPE and increases in viral RNA and protein shows that 
CVB4 is able to infect and replicate specifically in human β cells. 
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3.3.7: Gene expression in CVB4-infected EndoC-βH1 cells 
Since CVB4 productively replicates in EndoC-βH1 cells, I measured the 
gene expression in these cells in response to infection. EndoC-βH1 cells infected 
with CVB4 at an MOI of 10 in three independent experiments have reproducibly 
high numbers of viral genomic copies at both 6 and 24 hpi (Fig 3.7, A). Only a 
slight increase is observed between these two time points, which is expected 
based on the viral replication kinetics established in Figure 3.6, C.  
CVB4-infection of EndoC-βH1 cells causes a slight, but statistically 
significant decrease in INS gene expression (Fig. 3.7, B). However, no change in 
PDX1 gene expression is observed at 6 hpi. At 24 hpi PDX1 gene expression is 
slightly but significantly increased (Fig. 3.7, C). Both IFNB1 and CXCL10 gene 
expression are increased following infection. IFNB1 expression is increased 
slightly at 6hpi and further increased by 24 hpi, however neither of these 
increases reached statistical significance (Fig. 3.7, D). Similarly, CXCL10 
expression is increased between 6 and 24 hpi, and again statistical significance 
was not reached (Fig. 3.7, E).
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3.4: Discussion 
3.4.1: Comparison of CVB4 infection of engrafted and cultured primary 
human islets 
The first goal of this chapter is to compare the gene expression changes 
upon CVB4 infection in either in vivo or cultured cells. The gene expression in 
mice with engrafted primary human islets upon CVB4 infection as described in 
Figure 2.6 serve as the comparator for other infection platforms. The in vivo 
studies provide a physiologically relevant model for the gene expression changes 
in primary human islets upon viral infection that is associated with hyperglycemia 
in these animals. The comparison model is cultured primary human islets 
infected with CVB4 for 48 hours. One of the major differences in these two 
experimental designs is the time frame. Gene expression in the engrafted human 
islets is not evaluated until the endpoint of the experiment is reached, which is a 
mean of 38 days post infection. This scenario provides an endpoint gene 
expression profile for the long-term viral replication and associated 
hyperglycemia. The gene expression of infection in the cultured islets is 
measured at 48 hpi. The earlier changes in gene expression offer insights into 
the pathways involved in reaching the endpoint gene expression profile observed 
in the mouse model.  
Surprisingly, there are many similarities in the genes with both the largest 
increases and decreases in both engrafted and cultured islets upon CVB4 
infection. Expression for ISGs is similarly increased upon viral infection in both 
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experimental setups. CXCL10, MX1, OAS2, and IFIH1 are all increased at 48 hpi 
in the cultured islets, and are sustained in the engrafted islets until the endpoint 
of the experiments (Fig. 3.2, A). Differences in IFN gene expression do indicate 
that there is eventually a reduction of IFN production at terminal time points in the 
infected islets in mice. IFNB1 and IFNG expression are not increased in primary 
human islets engrafted in mice, but at 48 hpi in cultured primary human islets 
expression of these genes is robust. One possibility for this is that prolonged 
exposure to virus in the islets engrafted in mice eventually exhausts or destroys 
the cells responsible for the IFN production that is present at 48 hpi in culture. 
Another possibility is that there are changes in the virus that make them less 
recognizable to pattern recognition receptors like MDA5 and therefore less 
stimulatory for IFN gene expression. Persistent infection is associated with 
terminal deletions in the 5’ UTR of virus, which may make them less 
stimulatory240. CVB proteins can also inhibit IFN production through the cleavage 
of MAVS by the protease 3C143. However, I have not investigated the changes in 
the virus or contributions of viral proteins in suppressing IFN signaling.  
The genes with the largest decrease in both experimental designs are 
associated with endocrine cell function. INS, PDX1, and SST are similarly 
decreased in engrafted and cultured islets upon CVB4 infection. It is interesting 
that both INS and PDX1 gene expression decrease by 48 hpi in cultured primary 
human islets, because the kinetics of the development of hyperglycemia in the 
mouse model of engrafted human islets indicates a slow, progressive loss in β 
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cell function upon CVB4 infection. There may be a delay in the virus reaching the 
engrafted human islets in the systemic infection of CVB4 administered by IP 
injection. However, in an independent infection of mice engrafted with primary 
human islets, VP1 protein is present at 7 days post infection (data not shown)241. 
Since the cultured primary human islets are infected in a low volume for 1 h to 
allow the virus to adsorb to cells, the local concentration of virus may be much 
higher than for the systemic infection, which may accelerate the β cell 
dysfunction.  
The pattern of differentially expressed genes did not completely overlap 
between the ex vivo and in vivo studies. The gene expression pattern of cultured 
human islets 48 h post-infection reflects early responses to viral infection similar 
to those reported by others242. In contrast, the in vivo gene profile in terminal 
graft samples reflects prolonged consequences of viral infection, and is 
dominated by downstream cytokines and ER stress-related unfolded protein 
response genes. Increases in gene expression for DDIT3, which encodes CHOP, 
and EIF2AK3, which encodes PERK, are observed; whereas the expression of 
XBP1 is decreased. Increased CHOP levels, but not XBP- 1 protein levels, are 
reported in islets from tissue sections of T1D patients243. TXNIP is also highly 
stimulated in grafts from infected mice. In the virus-induced BBDR rat model of 
diabetes, the IRE1 and PERK ER stress pathways are activated244; both of these 
pathways induce TXNIP to promote programmed cell death under unresolvable 
ER stress245.  
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3.4.2: Insulin staining of CVB3-eGFP-infected dispersed primary human 
islets 
Infection of dispersed primary human islets with a GFP-expressing strain 
of CVB3 indicates that these cells can be infected and they support active 
replication. Insulin staining of these cells reveals that viral GFP often co-
localizes. GFP does not always overlap with insulin staining, so other cell types 
represented in human islets may also support CVB replication. However, it is 
also possible that these cells produced insulin prior to infection and the staining 
is decreased after infection.  
3.4.3: Genes associated with β cell function are decreased after CVB4 
infection 
Early gene expression changes after CVB4 infection in cultured primary 
human islets indicate pathways that may be involved in the dynamic changes in 
antiviral response and β cell function. The earliest time point after viral infection 
that I measured was 6 hpi, and only four genes had greater than 3-fold increase 
in gene expression. CXCL10 consistently has the highest increase in gene 
expression across all time points measured upon CVB4 infection. Interestingly, 
treatment of primary human islets with CXCL10 inhibits β cell function. Treated 
islets have a decrease in insulin secretion in response to glucose stimulation190. 
Therefore, the production of CXCL10 in response to CVB4 infection may be 
contributing to changes in β cell functions of insulin secretion. However, this 
suppression of insulin is not likely due to a decrease in insulin translation since 
stimulations of islets with innate immune agonists, poly(I:C) and poly(dA:dT) 
produce robust levels of CXCL10 (Fig. 3.4, C), but they do not decrease INS and 
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PDX1 mRNA upon stimulation (Fig3.4, A). Thus, multiple factors contribute to β 
cell dysfunction during viral infection, including host gene responses and virus-
specific factors. These factors could be elucidated by expression of individual 
viral proteins or transfection of immune stimulatory viral RNA.  
Other genes associated with proper β cell function are decreased in 
primary islets upon CVB4 infection between 6 and 24 hpi. PCSK1, which 
encodes for prohormone convertase 1, is responsible for converting proinsulin 
into the mature hormone246. PCSK1 gene expression is also decreased upon 
CVB5 infection of primary human islets247. Additionally, SLC2A2, which encodes 
for the glucose transporter GLUT2, is decreased upon CVB4 infection of primary 
human islets. The import of glucose into β cells is a necessary step in sensing 
blood glucose concentrations and responding by secreting insulin246. These 
differences in insulin hormone processing and glucose transporter function could 
help to explain the reduction in insulin secretion in response to glucose 
stimulation upon viral infection233-235. Since these genes are involved in multiple, 
non-redundant pathways involved in normal β cell function, differential effects on 
individual pathways by various viruses may lead to some of the heterogeneity in 
their inhibition of insulin secretion.  
Despite these potentially exciting findings, these experiments need to be 
repeated in multiple primary human islet donors. Due to the heterogeneity of 
genetics in human islet donors, multiple donors must be evaluated to determine if 
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these observed results are due to donor specific genetics or if there are more 
generalized responses to CVB infections.  
3.4.4: Innate immune gene expression in primary human islets infected with 
CVB4 or treatment with poly(I:C) or poly(dA:dT) 
IFN production could contribute to the development of T1D in contributing 
to poor β cell function in response to glucose or through interactions with the 
adaptive immune system that progress to autoimmunity. IFN and downstream 
cytokine production are associated with β cell dysfunction190,248. The presence of 
IFN in serum or in sections of tissue from recent onset T1D patients is also often 
associated with the development of T1D104,177,178. Therefore, understanding the 
IFN production capacity of primary human islets is important for understanding 
the development of T1D.  
Many IFN genes increase in expression by 96 hpi in response to CVB4 
infection, but IFN-I genes are among the first to increase. IFNA16 is the first IFN 
gene to have a greater than 3-fold increase after CVB4 infection. This response 
is mediated through activation of the dsRNA sensor MDA5 through an interaction 
with MAVS168. Expression of IFNA16 could be driving the antiviral response at 
these early time points. However, at later time points viral proteins may suppress 
IFN signaling through a cleavage of both MAVS and TRIF by the viral protease 
3C143.  
Along with IFN-I expression upon CVB4 infection, IFNL3 gene expression 
is expressed 5.7-fold higher than in mock-infected islets at 48 hpi. Infections of 
primary human islets with other serotypes of CVB also trigger the production of 
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IFN-III247. Interestingly, some heterogeneity in IFN-III receptor distribution is 
observed on islet cells. Human α cells express both receptor subunits (IFNλ-R1 
and IL-10R2), while β cells only express a single receptor subunit (IL-10R2)249. 
Cell type differences in IFN receptor expression, so response to IFN could help 
reconcile the specificity for β cells in the ultimate autoimmune manifestation of 
T1D. CVB-infected β cells could produce and respond to IFN and downstream 
signaling to APCs differently from other CVB-infected cells in the pancreas. This 
could portend the production of autoimmunity to develop only against β cells. 
These cell type differences will be further explored in Chapter V.  
Despite subtle differences in the induction of IFN genes in CVB4 infection, 
and treatments with either poly(I:C) or poly(dA:dT), the ISG response is very 
similar increased upon treatment (Fig. 3.4, C). As in other experiments of viral 
infections of primary human islets CXCL10 expression was among the genes 
with highest increase in gene expression. This indicates that islet cells are 
capable of producing robust antiviral responses, but again it is unclear if there 
are cell-type specific differences in the production of these responses.   
3.4.5: Comparison of SC-β to primary human islets 
Treatment of SC-β cells with poly(I:C) or infected with CVB resulted in 
CPE comparable to cultured primary human islets. Both SC-β cells and primary 
human islets are comprised of mixed cell populations. Therefore it is difficult to 
determine if one cell type is more susceptible to treatment than others. Infection 
of SC-β cells with CVB3-eGFP resulted in dose-dependent production of GFP by 
13 hpi. The intensity and distribution of infected cells seemed similar to infections 
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of primary human islets. Thus SC-β cells (CXADR copies = 148) appear to have 
virus receptor expression similar to primary human islets (CXADR copies = 76) to 
allow for virus entry.  
Unexpectedly, SC-β gene expression of islet function genes INS, PDX1, 
PCSK1, and SLC2A2 did not decrease upon infection with CVB4. This finding is 
not consistent with observations in CVB4-infected cultured primary human islets. 
Factors of virus dose and replication kinetics in these two different cell sources 
could explain this discrepancy. Primary human islets have on average ~200 cells 
per IEQ, so primary human islets were infected with an effective MOI of 50. 
CVB4 MOIs of 1 and 10 in SC-β cells were substantially lower than that for 
cultured primary human islets. MOI-dependent differences in the fate of cells 
infected with CVB could explain some of the differences observed in islet function 
gene expression between the two cell sources250. Despite the differences in initial 
dose, CVB replicated to similar levels in SC-β and primary human islet cells. 
CVB4-infected SC-β cells at express 3.1e5 genome copies at 16 hpi, which at 
similar to the 5e5 genome copies of CVB measured in primary human islets at 24 
hpi. To better compare the outcomes of CVB4 infection on β cell function genes, 
a more comparable dose of CVB4 should be used and later time points should 
also be evaluated to account for possible differences in kinetics of response 
between the SC-β and cultured primary human islets.  
The cell composition of SC-β cells is different from primary human islets: 
the majority of hormone positive cells, 35% of total cells in SC-β clusters, 
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produce C-peptide, approximately 1% in these clusters also produce either 
glucagon or somatostatin, and another 10% produce more than one hormone33. 
In primary human islets, the majority of hormone-producing cells make insulin, 
with ~65% of total cells staining positive for insulin. In contrast to SC-β cells, 
primary human islets have higher proportions of α and δ cells, with ~30% and 
~5% of each, respectively251. Opposed to the cultured primary human islets, 
resident immune cells that contribute to the immune response should not be 
present in SC-β cells. Infections of SC-β cell clusters with CVB4 support the 
argument that cells other than APCs are producing IFN-I. The IFN and ISG gene 
response to treatment with poly(I:C) or infection with CVB4 is similar to infections 
of primary human islets. These cells may provide a new alternative to studying 
IFN signaling in human islets. Since these cells can be derived from clonal stem 
cells, they are more genetically tractable than primary human islet cells. The 
ability to modulate gene expression of innate immune sensors or IFN-I receptors 
may provide further insights into the innate immune responses in β cells upon 
CVB infection.  
3.4.6: EndoC-βH1 cell infections 
The species-specific differences in gene expression, structure, and 
function of β cells among different species places major caveats on studies of 
viral infections in rodent β cell lines in their relevance to human disease. The 
development of the human β cell line, EndoC-βH1, is an exciting advancement 
for studying viral infection in the context of species-specific interactions and 
responses. CVB4 productively replicates in EndoC-βH1 cells with a dose-
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dependent CPE. The kinetics of the development of CPE in these cells was 
somewhat surprising given the extended timeline for the development of 
hyperglycemia in mice engrafted with primary human islets. Engrafted islets may 
possibly receive growth and survival factors from other engrafted cells or mouse 
tissues. These could modulate the antiviral response and support the persistent 
infection and slow progression to hyperglycemia observed in these mice.  
Gene expression in EndoC-βH1 cells upon infection with CVB4 mirrors 
infection of primary human islets in some respects. In these cells there is a small 
but significant decrease in INS gene expression between 6 and 24 hpi. This is 
also observed in infections of cultured primary human islets, but the decrease is 
much more pronounced in this case. IFNB1 and CXCL10 production are both 
increased upon CVB4 infection, similar to primary human islets. In contrast to 
infections of cultured primary human islets, the gene expression for the 
transcription factor, PDX1, did not decrease between 6 and 24 hpi in EndoC-βH1 
cells. The reason for this discrepancy is unclear, but it is possible that the 
process used to immortalize these cells has made PDX1 gene regulation more 
resistant to stress conditions induced by viral replication.  
3.4.7: Conclusions:  
Gene expression changes in engrafted primary human islets are similar to 
cultured primary human islets upon CVB4 infection. These similarities point to 
important pathways that are involved in β cell dysfunction during CVB4 infection. 
The decrease of both INS and PDX1 gene expression between 6 and 24 hpi in 
cultured primary human islets indicates that the effects of viral replication on β 
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cell function occur early. The early role of changes in PDX1 on β cell function will 
be further addressed in Chapter IV. Although, differences between INS gene 
expression decrease between cultured primary human islets and both SC-β and 
EndoC-βH1 cells raises questions about direct effects of this decrease caused by 
CVB4 infection. The strategy of sorting different cell types from primary human 
islets using flow cytometry methodologies discussed in Chapter V aimed to 
address these discrepancies.  
Infections of cultured primary human islets are advantageous in the ability 
to easily evaluate the kinetics of gene expression in CVB4-infection. The time 
course of gene expression changes help to identify key players in the 
mechanistic changes in infected human islets. Specifically changes in innate 
immune genes after CVB4 infection further implicate a signaling pathway of 
detection of viral dsRNA replication intermediates by MDA5 (IFIH1) that leads to 
the production of IFN-β and downstream cytokine CXCL10. The innate immune 
cytokine production directly by β cells could potentiate the production of 
autoimmunity against these cells. However, from these studies the relative 
contributions of different cell types to the overall antiviral response are difficult to 
define. Flow cytometry-sorted primary human islet cells will be explored in 
Chapter V to further evaluate these differences.  
The sources of human β cells implicate a role for intrinsic viral interactions 
in β cells in cellular dysfunction. These cell types address experimental 
complications of primary human islets that include donor variability and 
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limitations in culture viability and cell availability. CVB4 productively replicates in 
SC-β cells and produces a similar IFN profile to infections of primary human 
islets. EndoC-βH1 cells also support viral replication and confirm that β cells are 
a source of IFN production upon viral infection. Either of these two sources of 
human β cells could be used in place of primary human islets in an in vivo model 
of viral induction of hyperglycemia described in Chapter II. The potential for 
developing these new models will be discussed in detail in the general discussion 
(Chapter VI).  
3.5: Materials and methods 
3.5.1: Virus strains 
The prototypical CVB4 laboratory strain JVB (#VR-184; American Type 
Culture Collection) was grown in HeLa cells230. Virus was purified by 
ultracentrifugation on a sucrose cushion as previously described252. eGFP-CVB3 
plasmid was gift from L. Whitton, Scripps Research Institute, La Jolla, CA. Virus 
was produced by transfection of in vitro transcribed RNA into HeLa cells as 
described previously231. 
3.5.2: Human islets for ex vivo Studies  
Primary human islets from three independent donors (Prodo Laboratories, 
Inc) were cultured in supplemented CMRL-1066 media and were challenged with 
poly(I:C) (InvivoGen) or CVB4-JVB (1e6 pfu/100IEQ). Supernatants were 
collected at 48 h. TRIzol reagent (Life Technologies) was added for RNA 
extraction at 48h. (Figure 3.1) 
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Primary islets from a fourth independent donor was cultured in RPMI 1640 
supplemented with 5.5mM glucose, 10% FBS, 1% L-glutamine, and antibiotics. 
These islets were infected with sucrose purified CVB4-JVB (1e6 pfu/100IEQ), 
transfected with poly(I:C) (100 µg/ml) (InvivoGen), poly(dA:dT) (100 µg/ml) 
(InvivoGen), or cultured in media alone. CVB4-infected and corresponding mock-
infected islets were collected at 6, 24, 48, and 96 hpi for total RNA extraction by 
TRIzol reagent (Life Technologies). Additionally poly(I:C) and poly(dA:dT) treated 
islets were collected at 24 hours (Fig 3.3 & 3.4). 
3.5.3: SC-β culture and infection 
SC-β cells were a kind gift from Doug Melton and their production has 
been described previously33. 500,000 cells were plated in 24 well plates and left 
untreated, transfected with 100µg/ml poly(I:C) (InvivoGen) using Lipofectamine 
2000 reagent (ThermoFisher Scientific), or infected with CVB3-eGFP or CVB4-
JVB at MOI 0.1, 1.0 or 10. Images were acquired at 13 h after treatment as 
described below, and total RNA was collected by TRIzol reagent (Life 
Technologies).  
3.5.4: EndoC-βH1 culture and infection 
EndoC-βH1 cells were cultured as previously described237. For infection 
studies, cells were plated into 24well plates. Titered stocks of CVB4-JVB were 
added to cells at indicated MOI in a minimal volume for 1 h to allow for 
adsorption. Following this incubation period, cells were washed with PBS and 
complete culture media was replaced. At indicated time points, cells were either 
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fixed for immunofluorescence staining or TRIzol reagent (Life Technologies) was 
added for extraction of total RNA.  
3.5.5: Gene expression profiling (Figure 3.1) 
The NSCS1 used in Figure 2.6 allowed for direct measurement of mRNA 
copies without the need for amplification. Probes were designed to target human 
genes in a species-specific manner. The CodeSet included type I IFN, cytokines, 
apoptosis, endocrine, endoplasmic reticulum (ER) stress, T1D-associated loci, 
and other human genes, plus seven housekeeping genes for normalization of 
data. A probe for a conserved CVB sequence targeting the same region as the 
quantitative RT-PCR primer was included105. 100 ng of RNA extracted from 
tissue was hybridized, processed, and analyzed per the manufacturer’s 
procedure. Data were normalized using the nSolver Analysis Software (version 
1.1). Fold changes in gene expression were the ratio of normalized gene 
expression in CVB4-infected samples versus those in mock-infected samples. 
Averages of fold changes were calculated by averaging the log10 of the fold 
change followed by a transformation of 10x. Values <1 were transformed by -1/x.  
3.5.5: Gene expression profiling (Fig 3.2, Fig 3-3, Fig 3.4) 
The NanoString CodeSet #2 (NSCS2) was developed for genes 
associated with IFN-1 (18), IFN-II (3), IFN-III (5), IFN regulated genes (20), β cell 
function (24), endocrine (9), apoptosis (8), cytokines (7), inflammation (8), ER 
stress (20), type 1 diabetes susceptibility genes (12), other human genes (4), the 
CVB-specific probe as described above, and housekeeping genes (7) for 
normalization of data for a total of 146 genes. Probes were designed to target 
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human genes in a species-specific manner. 100 ng of RNA extracted from 
cultured islets and was hybridized, processed, and analyzed per the 
manufacturer’s procedure. Data were normalized using the nSolver Analysis 
Software (version 2.6). Fold changes in gene expression were the ratio of 
normalized gene expression in CVB4-infected samples versus those in mock-
infected samples. Values <1 were transformed by -1/x. Limit of detection was 
determined by the highest value from the internal negative control probes for 
each assay run. Heatmaps of transformed fold changes were produced with 
Gitools v2.2.3 (http://gitools.org/).  
3.5.6: ELISA  
Human IFN-α and IFN-β ELISA (PBL Assay Science) for supernatants 
collected from primary human islets.  
3.5.7: Widefield microscopy 
Live cell culture images acquired on a Zeiss AxioVert 200 microscope 
equipped with an EXFO X-cite 120 fluorescent light source and an AxioCamMR 
camera running AxioVision SE64 v4.9.0.0 software. EC Plan-Neofluar objective 
lenses 5x/0.16 M27 or 10x/0.30 Ph1 were used where indicated. Images were 
adjusted with ImageJ v2.0.0-rc-39/1.50f232 
3.5.8: Immunofluorescence 
EndoC-βH1 cells were cultured on coverslips and infected with CVB4 at 
an MOI of 10 for 24 hours. Cells were fixed with 4% PFA for 30min at room 
temperature. Fixed cells were permeablized and stained in PBS-AT (PBS+2% 
BSA +0.5% Triton X-100) with the following primary antibodies guinea pig 
antibody to insulin (1:1000; Dako) and mouse antibody to VP1, clone 5-D8/1 
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(1:500; Dako). The following fluorophore conjugated secondary antibodies at 
1:1,000 dilution Alexa Fluor-594 goat antibody to guinea pig IgG and Alexa Fluor-
488 goat antibody to mouse IgG (catalog #A11076 and #A11029, respectively; 
Life Technologies) for 1 hour. Coverslips were mounted with ProLong Gold 
Antifade Reagent with DAPI (Life Technologies). Immunofluorescence was 
imaged on a Leica SP8 confocal microscope with a 63x HC PL APO CS2 
objective (1.4 oil) running Leica Advanced Fluorescence software (version 
3.3.0.10134.1). Images were adjusted using FIJI software (version 1.48p) where 
necessary232. 
3.5.9: Flow cytometry 
EndoC-βH1 cells were trypsinized to obtain a single cell suspension at 
indicated time points. Dead cells were stained using LIVE/DEAD™ Fixable Blue 
Stain (1:1000) (Invitrogen) for 20 minutes. Cells were then fixed and 
permeablized using BD Cytofix/Cytoperm reagents (BD Biosciences). Cells were 
then stained with mouse antibody to VP1, clone 5-D8/1 (1:1000; Dako) and Alexa 
Fluor-488 goat antibody to mouse IgG (1:1000; Life Technologies). Staining was 
analyzed on an LRB LSRII A equipped with Trigon and Blue 488nm lasers 
running BD FACS Diva software (version 8.0.1) and analyzed using FlowJo 
(version 10.1r5).  
3.5.10: Gene expression qRT-PCR 
Total RNA collected from CVB4-infected EndoC-βH1 cells was extracted 
using TRIzol reagent (Life Technologies). 1 µg of total RNA was reverse 
transcribed using the QuantiTect Reverse Transcription Kit (Qiagen). The 50ng 
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of the resulting cDNA was used as the template for QuantiFAST SYBR Green 
quantitative PCR kit using the following QuantiTect Primer Assay targets: 
GAPDH (QT00079247), INS (QT01531040), PDX1 (QT00201859), 
IFNB(QT00203763), and CXCL10 (QT01003065) (Qiagen). PCR was preformed 
on a Bio-RAD CFX96 Real-Time system and cut-offs were determined 
automatically. Relative gene expression was calculated by calculating the ΔCt for 
target genes relative to GAPDH followed by ΔΔCt calculation for treatment 
relative to mock-infected cells at each time point. This was then plotted as 2ΔΔCt 
using GraphPad Prism 6.0h software.  
3.5.11: CVB genome qRT-PCR 
Total RNA collected from CVB4-infected EndoC-βH1 cells was extracted 
using TRIzol reagent (Life Technologies). cDNA was generated using the High 
Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems) followed by 
quantitative PCR using the Platinum Quantitative PCR SuperMix-UDG Kit (Life 
Technologies). Enterovirus-specific primers and probe were used for 
quantification of viral RNA105. A standard curve was established using the eGFP-
CVB3 plasmid as a template to interpolate absolute copies per microliter of input 
RNA (a gift from L. Whitton, Scripps Research Institute, La Jolla, CA)231.  
3.5.12: Statistical Methods  
To assess the significance of the fold-change of NanoString gene 
expression, a standard one-sample t test was used to determine the significance 
compared with zero. Significance for qRT-PCR gene expression evaluated by 
unpaired, two-tailed t-test.
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CHAPTER IV: CVB4 INFECTION INDUCES CHANGES IN PDX1 
LOCALIZATION IN HUMAN Β CELLS  
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4.1: Abstract 
 β cells are the sole insulin-producing cells in the human body and the 
production of this hormone is critical in maintaining blood glucose levels. In the in 
vivo model in which mice engrafted with primary human islets are infected with 
CVB4, human INS gene expression is greatly decreased. Similarly, INS gene 
expression is decreased between 6 and 24 hpi in cultured primary human islets 
infected with CVB4. In parallel, gene expression of the transcription factor PDX1 
is also decreased in both models upon CVB4 infection. PDX1 is a critical 
transcription factor in the production of insulin and the overall function of β cells. 
Yet treatment of cells with the innate immune agonists poly(I:C) and poly(dA:dT) 
does not induce a decrease of INS or PDX1. Therefore, I sought to determine 
how CVB4 infection specifically affects PDX1 function and whether a change in 
PDX1 contributes to the loss in INS expression. PDX1 protein expression is 
sequestered to the nucleus in EndoC-βH1 cells. However, upon infection with 
CVB viruses, PDX1 staining intensity is decreased in the nuclei of infected cells. 
Surprisingly, this effect on PDX1 localization is not replicated in infections with 
vesicular stomatitis virus or respiratory syncytial virus. The changes in PDX1 
localization upon CVB infection do not require β cell specific factors, as 
overexpression of PDX1 in an irrelevant cell type is also excluded from the 
nucleus in infected cells. Taken together, these early changes in PDX1 
localization could be contributing to the decreased insulin gene expression.  
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4.2: Introduction 
4.2.1: Overview 
The gene expression for the transcription factor pancreatic duodenal 
homeobox 1 (PDX1) is highly decreased following CVB4-infection of either 
primary human islets engrafted in mice or cultured primary human islets (Fig. 2.6, 
3.1). PDX1 is a critical transcription factor in β cell development, function, and 
survival. Therefore, I further investigated the role of the reduction in PDX1 gene 
expression in β cell dysfunction upon CVB infection.  
4.2.2: PDX1 function 
PDX1 expression must be tightly regulated for the proper development of 
the pancreas. In people, homozygous frame-shift mutations in PDX1 are 
associated with pancreatic agenesis253. The levels of expression are also 
important in the function of differentiated β cells. Heterozygous mutations of 
PDX1 are linked to maturity-onset diabetes of the young 4 (MODY4)254. 
Missense mutations in PDX1 identified in clusters of patients cause late onset 
type 2 diabetes255. In addition to its important role in β cell function, PDX1 is also 
found in the proximal duodenum, pyloric glands of the distal stomach, occasional 
expression in submucosal layer of the duodenum and spleen256. However, the 
effects of PDX1 mutations are largely unknown in these tissues. The mutations 
and their associated diabetic manifestations highlight the importance of PDX1 in 
pancreatic development and blood glucose homeostasis in humans.  
PDX1 contributes to transcriptional control of a wide range of genes 
involved in islet cell function (Fig 4.1). PDX1 is a transactivator of insulin 
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transcription through binding to the insulin promoter257. Insulin transcription by 
PDX1 is further modulated through co-activators, p300 and Bridge-1258. PDX1 
also contributes to transcriptional regulation of other proteins that are important in 
β cell function. Genes encoding glucokinase (GK)259, islet amyloid polypeptide 
(IAPP)260, and glucose transporter type 2 (SLC2A)261 all have PDX1 regulatory 
sites in their promoters. PDX1 is important for maintaining the β cell program in 
differentiated cells, and loss of PDX1 can cause a shift to an α cell phenotype262. 
Additionally, ectopic expression of PDX1 during development can suppress the 
differentiation of α cells leading to a reduction in glucagon expression263.  
4.2.3: Control of PDX1 transcriptional function 
Because of its diverse function in development, function and survival of β 
cells, PDX1 is regulated through a variety of transcriptional, post-translational 
mechanisms. PDX1 is transcribed as a 2573 bp mRNA (NM_000209.3) and 
three transcript variants (XR_941578.1, XR_941579.1, XR_941580.1) are 
predicted. In humans the PDX1 promoter contains a distal enhancer region along 
with three enhancer regions that are conserved between human and mouse, 
referred to as PH1-3. A conserved promoter region is also present proximal to 
the transcription start site264. Transcription of PDX1 is induced by several 
transcription factors in addition to autoregulation by PDX1 itself (Fig. 4.1). HNF3β 
(FOXA2) binds to two enhancer regions in the promoter of PDX1 (PH1&2), and 
PDX1 itself binds to another enhancer region (PH1)265. The transcription factor 
HNF1α also binds to PH1 to promote PDX1 transcription266. These transcription 
factors promote PDX1 gene expression though binding to the distal enhancer 
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region of the PDX1 promoter at -2.7 to -1.9 kb. Furthermore, USF2 contributes to 
PDX1 transcription and provides β cell specificity for expression through binding 
to a E box site proximal to the transcription start site at -107 to -102267. The 
expression of PDX1 mRNA can also be negatively regulated. ATF3 is an 
inducible transcription factor in response to proinflammatory cytokines, nitric 
oxide, and ER stress268. ATF3 inhibits PDX1 transcription by binding to the 
ATF/CRE responsive element in the PDX1 promoter269. The combination of 
positive and negative regulators of transcription underscores the importance of 
the dynamic PDX1 expression to maintain homeostasis in response to the needs 
of the organism.  
In addition to transcriptional control, PDX1 function can be regulated 
through protein-protein interactions or post-translational modifications that can 
affect DNA chromatin remodeling, protein stability, and sub-cellular localization 
(Fig. 4.1). The PDX1 protein is translated from two exons. The N-terminal portion 
of the protein contains the activation domain and the C-terminal portion contains 
the homeodomain, which binds to DNA. Several potential protein-protein 
interacting domains can modulate PDX1 activity264. Since PDX1 does not contain 
intrinsic chromatin remodeling activity, it exerts its transcriptional activity through 
interactions with cofactors. These include members of the ATPase-containing 
Swi/Snf family of cofactors270. Interactions with these and other cofactors 
influence PDX1 DNA binding to modulate insulin production in response to 
glucose271. Interactions with other proteins can inhibit PDX1 function by 
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increasing protein degradation, altering transcriptional activity, or changing PDX1 
nuclear localization. Direct interaction of PDX1 with PCIF1 (SPOP) targets PDX1 
for ubiquitination and proteasome degradation272. SREBP-1c (SREBF1) belongs 
to a family of transcription factors that regulate genes associated with lipid 
synthesis, and expression of SREBP-1c in β cells impairs insulin secretion273. 
Under lipotoxic conditions, SREBP-1c binds directly to PDX1, which disrupts the 
binding of PDX1 to the distal promoter site inhibiting the autoregulation of PDX1 
transcription274. Changes in environmental conditions and cell stress can alter the 
proteins available to interact with PDX1. These modulatory proteins add an 
additional layer of control to allow for context-dependent PDX1 activity.  
Post-translational modifications to PDX1 can also modulate its activity in 
response to changes in glucose or environmental stress. Glucose response is 
associated with several post-translational modifications. Glycosylation increases 
the DNA binding activity of PDX1275. Sumoylation facilitates localization of PDX1 
to the nucleus and increases its stability276. Phosphorylation is also important in 
the glucose responsive behavior of PDX1. Glucose induces the phosphorylation 
of PDX1 through the activation of ERK2, which increases the transactivating 
activity of PDX1277. These modifications allow for rapid response to glucose to 
help maintain homeostasis. 
Cell stress conditions caused by environmental triggers also require rapid 
response to mitigate damaging effects. ER stress can occur under normal 
conditions when β cells are required to increase their protein production following 
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high-fat or high-glucose meals. If these conditions are temporary, ER stress can 
be resolved without detrimental effects to the cell. For example, PDX1 
contributes to β cell survival in mice fed a high-fat diet. This survival is mediated 
through the ER stress response212. To maintain cell function under temporary ER 
stress or proinflammatory cytokines associated with stress, PDX1 mRNA 
expression is maintained278. The presence of PDX1 directly promotes 
transcription of ER stress associated genes Atf4 and Wfs1212. However, 
unresolved ER stress can lead to apoptotic cell death. Under apoptotic 
conditions, the proapoptotic factor MST1 phosphorylates Thr11 of PDX1279. This 
leads to proteasome degradation of PDX1. Depending on the environmental 
stress and the protein factors present in the cell, PDX1 activity can be either 
maintained or inhibited.  
Under oxidative stress conditions, phosphorylation inhibits PDX1 activity 
by decreasing its abundance in the cell though proteasome degradation. 
Oxidative stress induces phosphorylation of PDX1 at Ser61 and Ser66 through the 
activation of glycogen synthase kinase 3 (GSK3)280. This targets PDX1 for 
protein degradation through the proteasome. Oxidative stress also induces 
translocation of PDX1 from the nucleus to the cytoplasm through activation of 
JNK. The presence of JNK causes nuclear export through a nuclear export signal 
(NES) that overrides the nuclear localization signal (NLS) that targets PDX1 to 
the nucleus281. Changes in subcellular localization can quickly reduce the 
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transcriptional activity by sequestering PDX1 to the cytoplasm followed by 
degradation of the protein.  
4.2.4: PDX1 in viral infection 
Despite the importance of PDX1 in islet cell development, function, and 
survival, very little has been reported on the effects of viral infection on PDX1. 
Ductal cells of the pancreas express PDX1 at low levels, and are susceptible to 
CVB4 infection. CVB4 persists in a human ductal cell line for up to 37 weeks 
after infection, leading to an impaired expression of PDX1 gene expression215. 
However, a mechanism for inhibition of PDX1 mRNA production in these 
persistently infected cells is unknown. CVB infections are associated with stress 
responses that are associated changes in PDX1 regulation described above. In 
cardiomyocytes, oxidative stress is activated though cross-talk with macrophages 
in CVB3-infected mice282. CVB also promotes cytokine and IFN expression, and 
CVB-induced cell death pathways may contribute to decreases in PDX1 
expression.  
4.2.5: Goals 
PDX1 is important in β cell function, and CVB directly infects β cells 
leading to β cell dysfunction. Since PDX1 is it is among the most highly 
decreased genes in both engrafted and cultured primary human islets, it is likely 
that CVB infection is directly mediating changes in PDX1 expression. To test the 
β cell specific effects of CVB on PDX1 expression and localization I used the 
EndoC-βH1 cell line. The goals of this chapter are to 1) determine the kinetics of 
decrease in PDX1 mRNA and protein upon CVB infection, 2) quantify the kinetics 
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of gene expression changes in factors that regulate PDX1 expression and 
transcriptional targets of PDX1, 3) demonstrate specificity of changes in PDX1 
nuclear localization in CVB-infection, and 4) determine a role for β cell-specific 
regulatory factors in the changes in PDX1 expression upon CVB infection.  
4.3: Results 
4.3.1: Changes in expression of genes in the PDX1 transcriptional network 
In cultured primary human islets infected with CVB4, PDX1 gene expression 
decreases between 6 and 24 hpi. To further evaluate the kinetics and 
consequences of CVB4 infection on PDX1 transcriptional targets, I focused on 
expression of select genes evaluated by NanoString from the same experimental 
data set as presented in Figure 3.3. Upon CVB4 infection PDX1 expression 
decreases by 1.3-fold at 6 hpi and 3.5-fold at 24 hpi compared to mock infected 
islets. In agreement with this data, genes that are at least partially controlled by 
PDX1 at the transcriptional level are decreased at 24 hpi: SST, INS, IAPP, 
MAFA, and SLC2A2 all decrease by more than 3-fold. GCG gene expression, 
which is inhibited by PDX1, slightly increases at 24 hpi. Two ER stress-
associated genes induced by PDX1, ATF4 and WFS1, are minimally changed 
upon CVB4 infection: ATF4 is only 1.6-fold increased over mock, and WFS1 is 
decreased by 1.7-fold (Fig. 4.2). These data reinforce the hypothesis that loss of 
PDX1 expression of primary human islets is a key mechanism of β cell 
dysfunction during CVB4 infection.  
I also measured expression of genes that contribute to the regulation of 
PDX1 using the NanoString gene expression assay. While PDX1 has an auto-
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regulatory role in promoting its own transcription, several independent 
transcription factors enhance its transcription. Decreases in these transcription 
factors would suggest their epistatic role in decreasing PDX1 expression upon 
CVB4 infection. However, gene expression for the transcription factors, FOXA2 
(HNF-3β), HNF1A, and NEUROD1, which have been previously described to 
regulate PDX1 transcription265,266, are all maintained at levels similar to mock 
treated cultured islets at 6 and 24 hpi (Fig. 4.2). Several proteins, including 
SPOP and SREBF1, negatively regulate PDX1 expression or function by either 
binding directly to PDX1 or its promoter to inhibit transcription272,274. SPOP and 
SREBF1 gene expression levels do not change between 6 and 24 h after CVB4 
infection. ATF3 is a transcription factor that binds to the PDX1 promoter to inhibit 
transcription269. After CVB4 infection, ATF3 gene expression is increased 2.9-fold 
at 6 hpi and 4.2-fold at 24 hpi compared to uninfected islets (Fig 4.2). Since this 
factor had the highest change in gene expression prior to the decrease in PDX1 
expression, it may be contributing to the rapid decrease in PDX1 mRNA.  
4.3.2: Changes in PDX1 protein localization upon CVB4 infection in EndoC-
βH1 cells 
The decrease in PDX1 gene expression and its importance in β cell 
function led me to investigate the kinetics of the expression and localization of 
PDX1 protein in human β cells after CVB4 infection. The heterogeneity of cell 
types and complex three-dimensional architecture of primary human islets 
complicate the acquisition and analysis of imaging protein expression and 
localization by immunofluorescence. Specifically, the heterogeneity of PDX1 
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staining makes differentiation between a cell that does not express PDX1 due to 
its cell-type properties and a cell that has lost PDX1 expression secondary to 
virus infection difficult. The availability of the EndoC-βH1 human β cell line 
provides a convenient platform to mitigate this problem. Since these cells are 
homogenous in PDX1 expression preceding infection, changes in PDX1 staining 
can be attributed to the virus infection. Additionally, since the cells are adherent 
and grown on a monolayer, they are more amenable to virus infection and 
immunofluorescent evaluation of protein expression and localization on a single 
cell basis. 
EndoC-βH1 cell infection with CVB4 does not result in the decrease in 
PDX1 mRNA observed in cultured primary human islets (Fig. 3.3 & 3.7). 
However, the regulation of protein localization and function may be separate from 
PDX1 mRNA production. It is possible that during the transformation process of 
these cells, physiologic regulation of PDX1 was altered to help promote the 
survival of the cell line. Alternatively, the rapid cell death kinetics after CVB4 
infection in EndoC-βH1 removes cells with low PDX1 mRNA from the analysis so 
it seems that global decreases in mRNA are not captured. The NanoString gene 
expression assay was also used to profile gene expression changes in CVB4-
infected EndoC-βH1 cells, but technical issues in several of the samples made 
the results of this experiment uninterpretable (data not shown). Despite this 
discrepancy, findings of the regulation of PDX1 at the protein level may be 
contributing to both models and contributing to β cell dysfunction.  
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PDX1 staining is robust and mostly retained in the nucleus in uninfected 
EndoC-βH1 cells (Fig 4.3, A & B). EndoC-βH1 cells infected with CVB4 at an 
MOI of 1 can be identified by VP1 staining at 6 hpi (Fig. 4.3, A & C). In contrast to 
adjacent uninfected cells, CVB4-infected cells have less PDX1 staining in the 
nucleus at 6 hpi (Fig 4.3, A & C). The staining is lower than one standard 
deviation below the mean staining intensity of mock-treated cells in 51% of 
CVB4-infected cells. However, whether or not total PDX1 protein levels are 
decreased at this time point is unclear. PDX1 staining in an independent infection 
of EndoC-βH1 cells with CVB4 at an MOI of 10 yielded similar amounts of PDX1 
as at 6 hpi. Under these conditions, 51% of cells are positive for VP1 (Fig. 4.3, 
D). This agrees with flow cytometry quantification of VP1 in CVB4-infected 
EndoC-βH1 cells under similar conditions a minimal number of cells stained with 
a cell death marker (Fig. 3.6, D). Quantification of nuclear PDX1 of uninfected 
(VP1-negative) or CVB4-infected (VP1-positive) cells confirmed a significant 
decrease in nuclear PDX1 staining intensity in CVB4-infected cells compared to 
uninfected cells. PDX1 staining intensity decreased from a mean of 3.86 in 
uninfected cells to 2.21 in CVB4-infected cells (Fig. 4.3, D). This reduction in 
nuclear PDX1 staining in CVB4-infected cells is specific to the infected cells, as 
uninfected cells in the same field retain PDX1 staining (Fig. 4.3, A & D).  
4.3.3: PDX1 nuclear localization is also decreased after infection with other 
serotypes of CVB in EndoC-βH1 cells 
To identify if the changes in PDX1 protein localization in EndoC-βH1 cells 
infected with CVB4 are specific to this coxsackievirus serotype, I infected cells 
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with two other serotypes to evaluate their ability to change PDX1 localization. I 
infected EndoC-βH1 cells with prototypical lab strains for CVB1 (strain Conn-5) 
and CVB5 (strain Faulkner). At 6 hpi, 33% and 17% of EndoC-βH1 cells are VP1-
positive following infection with CVB1 or CVB5, respectively, at an MOI of 10 
(Fig. 4.4, A). Nuclear staining is identified by DAPI (white rings) and PDX1 (red) 
appears robust in mock-infected EndoC-βH1 (Fig. 4.4, B). In contrast, nuclear 
staining of PDX1 for CVB1 and CVB5 is reduced at 6 hpi. Cells infected with 
respective viruses stain positive for VP1 (green) (Fig. 4.4, C & D). Quantification 
of nuclear PDX1 staining intensity is significantly lower in both CVB1 and CVB5-
infected cells compared to mock-infected cells (Fig. 4.4, E). Overall PDX1 
nuclear staining is low in CVB1-infected cells, likely due to the high proportion of 
these cells being infected. Since cells are not separated into infected and 
uninfected categories in this experiment, the differences in infection efficiency 
between CVB1 and CVB5 likely account for the variation in PDX1 nuclear 
staining in these conditions. Taken together, the reduction in PDX1 nuclear 
localization is not a specific feature of CVB4-JVB and may be a broad effect of 
enterovirus infection or antiviral responses in general. 
4.3.4: Changes in PDX1 localization are not a generalized virus response 
The interesting finding of changed PDX1 localization in CVB4-infected cells at 6 
hpi introduced the possibility that this could be a general β cell response to 
increased protein production that occurs during a viral infection or a generalized 
antiviral response. I transfected EndoC-βH1 cells with a plasmid encoding GFP 
under the control of the CMV promoter to investigate if increased protein burden
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EndoC-βH1 cells were infected with CVB1 or CVB5 at an MOI of 10. (A) Flow 
cytometry of VP1 staining to evaluate the proportion of cells infected at 6 hpi 
(gray bars) or 24 hpi (black bars). Immunofluorescence staining of (B) mock, (C) 
CVB1-infected, or (D) CVB5-infected EndoC-βH1 cells at 6 hpi. Cells are stained 
for DAPI (white circles drawn in ImageJ), VP1 (Green), or PDX1 (red) and 
images are obtained at 400x magnification. (E) Quantification of PDX1 nuclear 
staining intensity as defined by DAPI staining. Nuclear PDX1 staining intensity in 
all cells from mock-infected (n=735 cells), CVB1-infected (n=799 cells), or CVB5-
infected (n=931 cells) conditions. Error bars represent S.E.M. ****, P < 0.0001, 
two-tailed t test.
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on these cells would induce a change in PDX1 localization. In this experiment, 
GFP was expressed in 39% (9 of 23) cells at 24 hours after transfection. 
Overexpression of GFP alone did not have any effect on PDX1 nuclear 
localization compared to untransfected cells (Fig. 4.5, A). Quantification of 
nuclear PDX1 staining intensity confirmed that no significant change occurred 
upon overexpression of GFP (Fig. 4.5, D).  
Numerous changes occur in virally-infected cells in addition to increased protein 
production. Viral modification of host gene expression and antiviral responses 
might contribute to changes in PDX1 nuclear localization. Thus, I infected 
EndoC-βH1 cells with two non-CVB GFP-expressing viruses to determine if the 
reduction in PDX1 nuclear localization was due to a generalized antiviral 
response. EndoC-βH1 cells are permissive to infection with vesicular stomatitis 
virus (VSV), as infection with VSV-GFP at MOI of 0.5 resulted in the 89% of the 
cells expressing GFP at 24 hpi (Fig. 4.5, E). Respiratory syncytial virus (RSV) 
also infected EndoC-βH1 cells, albeit with much lower efficiency than VSV. At 24 
hpi only 8% of cells express GFP (Fig. 4.5, F). Despite the infection of EndoC-
βH1 cells by VSV and RSV, no change in PDX1 nuclear localization was 
observed (Fig 4.5, B & C) and no significant change in PDX1 nuclear staining 
intensity was noted for either of these viruses (Fig. 4.5, E & F). Since no change 
in PDX1 nuclear localization upon infection with either of these single stranded, 
negative sense RNA viruses was seen, I concluded that the phenotype observed 
in CVB infection is not likely due to a generalized antiviral response. 
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4.3.5: Changes in PDX1 localization in non-β cells 
 The change in PDX1 nuclear localization upon CVB infection, but 
not negative sense viruses, prompts the possibility that CVB is directly causing 
this change. However, regulation of PDX1 expression in β cells is complicated. 
PDX1 expression in auto-regulated and also influenced by a variety of β cell 
transcription factors for proper physiological responses. As an alternative model 
for investigating the mechanisms of CVB-mediated changes in PDX1 nuclear 
localization, I overexpressed PDX1 in an irrelevant, more genetically tractable 
cell type that could be readily infected with CVB but in which many of the β cell 
specific regulatory factors may not be present. This could help me determine if 
the changes in expression are due to transcriptional or post-translational 
regulation of gene expression or stability (HeLa: GSK3b protein expression is 
high, PCIF1-low RNA - Human Protein Atlas). 
I transduced HeLa cells with an adenoviral construct that expresses the 
mouse Pdx1 gene under the control of the CMV promoter described previously 
(pAd-Pdx1)283. The pAd-Pdx1 construct also encodes for nuclear localized GFP 
(nGFP) under the control of an IRES as a marker for cells that are transduced 
with the virus. Cells transduced with this construct co-express nGFP and Pdx1 in 
46% of cells. Overexpressed Pdx1 is primarily nuclear as evaluated by 
immunofluorescence staining at 24 hours after transduction (Fig. 4.6, A & B). 
Upon infection of Pdx1-expressing HeLa cells with CVB4 at an MOI of 1, 27% of 
cells stain positive for VP1 at 6 hpi. Under these conditions, 12% of cells are both 
transduced with pAd-Pdx1 and infected with CVB4. Similar to observations in 
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Expression of PDX1 in HeLa cells by transduction of an adenovirus vector that 
co-expresses nGFP. Cells were cultured for 24 h after transduction followed by 
challenge with CVB4 virus at MOI of 1. Cells were fixed and stained 6 hpi. 
Immunofluorescence staining was performed for DAPI (cyan circles), nGFP 
(blue), VP1 (green), and PDX1 (red). (A) Whole field images were acquired at 
400x magnification with individual examples in white boxes. (B) Image of a 
representative cell that is overexpressing the PDX1 construct alone, (C) a cell 
that infected with CVB4 only, or (D) a cell that is both overexpressing Pdx1 and 
infected with CVB4. (E) Quantification of nuclear PDX1 staining as defined by 
DAPI staining. Transduced cells were identified by the presence of nGFP, and 
CVB4-infected cells were identified by VP1 staining. Non-transduced and 
uninfected (n=279 cells); transduced and uninfected (n=245 cells); non-
transduced and infected (n=108 cells); transduced and infected (n=85 cells). 
Error bars represent S.E.M. ****, P < 0.0001, two-tailed t test. 
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CVB4-infected EndoC-βH1 cells, Pdx1 is excluded from the nucleus of Pdx1-
expressing HeLa cells infected with CVB4 (Fig 4.6, A & D). Quantification 
revealed that nuclear Pdx1 staining in cells that are both transduced with pAd-
Pdx1 and infected with CVB4 is significantly lower than cells that were only 
transduced with the pAd-Pdx1 construct (Fig. 4.6, E). In contrast to CVB4-
infected EndoC-βH1 cells, Pdx1 accumulates in the cytoplasm of CVB4-infected 
HeLa-Pdx1 cells. The nuclear localization of nGFP also disperses throughout the 
cell upon CVB4 infection (Fig. 4.6, D). Despite the differences in regulation in 
overexpression of Pdx1 in an irrelevant cell type, CVB4-infection still changes the 
nuclear localization of Pdx1. This provides further support for a viral-specific 
mechanism for changes in PDX1 in human β cell infection. 
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4.4: Discussion 
In primary human islets infected with CVB4, PDX1 mRNA decreases. This 
decrease is consistent between islets engrafted in mice and in islets infected in 
culture. While it is difficult to determine the kinetics of PDX1 decrease in CVB4-
infected islets engrafted in mice, the expression decreases most dramatically 
between 6 and 24 hpi in cultured islets (Fig. 4.2). PDX1 orchestrates many 
functions in β cell development, function, and survival. Because of its critical role 
in these functions, a better understanding of the mechanisms of PDX1 decrease 
after CVB infection will provide insights into dysfunction in infected β cells. This 
could aid in developing therapies to maintain β cell function upon CVB infection, 
and possibly prevent the development of autoimmunity.  
The idea that reduction of PDX1 in CVB4-infected primary human islets 
has a profound impact on β cell function is supported by the changes in gene 
expression of downstream transcriptional targets. Gene expression for the β cell 
function genes, INS, IAPP, MAFA, and SLC2A2 are all at least partly enhanced 
by PDX1. By 24 hpi all of these genes have a greater than 3-fold decrease in 
gene expression. PDX1 also contributes to the expression of SST in δ cells, and 
gene expression is similarly decreased upon CVB4 infection. Interestingly, GCG, 
which is negatively regulated by PDX1 in α cells, is slightly increased at 24 hpi 
(Fig. 4.2). In other models, the reduction of PDX1 alleviates the suppression of 
an α cell program, which leads to phenotypic and gene expression patterns that 
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resemble α cells262. However, I have not explored the possibility of a change from 
β to α cell phenotype in CVB4-infected cells.  
One interesting finding in PDX1 expression in primary human islets is that 
PDX1 gene expression does not decrease upon treatments with poly(I:C) or 
poly(dA:dT) at 24 hours post treatment (Fig. 3.4, A). Since these synthetic IFN-I 
agonists did not decrease PDX1 to the same levels as CVB4 infection, the 
mechanisms involved may be IFN-I independent. To confirm this, recombinant 
IFN could be added to EndoC-βH1 cells followed by evaluation of nuclear PDX1 
localization. While gene expression is maintained in treatments of poly(I:C) and 
poly(dA:dT), I have not investigated if PDX1 nuclear localization changes with 
these treatments.  
In an effort to identify other factors that may be contributing to the changes 
in PDX1 gene expression upon CVB4 infection, I measured the gene expression 
of factors that either promote or inhibit PDX1 mRNA production. Transcription 
factors that promote PDX1 expression were all unchanged at 6 hpi. However, the 
functions of these transcription factors may not be regulated at the level of gene 
expression. Protein-protein interactions or post-translational modifications of 
these transcription factors may reduce PDX1 production and would not be 
detected through the NanoString gene expression assay.  
Of various factors assessed that could potentially inhibit PDX1 function, 
only ATF3 was highly expressed in CVB4 infected islets compared to mock (Fig. 
4.2). ATF3 represses PDX1 expression by binding to the PDX1 promoter269. 
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ATF3 expression is induced in stress conditions through NF-κB and JNK/SAPK 
pathways268. Treatment of primary human islets with either poly(I:C) or 
poly(dA:dT) also increased ATF3 expression 2.5-fold and 5.6-fold, respectively, 
at 24 hours post treatment (Fig. 3.4, A). Since ATF3 is expressed at comparable 
levels with these treatments as with CVB4-infection while PDX1 expression is 
maintained, ATF3 cannot be the only factor contributing to the PDX1 phenotype 
in CVB4-infected islets. The inhibitory effects of ATF3 on PDX1 are likely 
compounded by changes in PDX1 nuclear localization upon CVB infection. This 
likely further reduces PDX1 expression through the auto-regulatory mechanisms 
of PDX1 in promoting its own mRNA production265. These findings point to 
multiple mechanisms that could concomitantly produce the decrease in PDX1 
expression in CVB4-infected primary human islets.  
While a reproducible decrease in PDX1 gene expression in engrafted and 
primary human islets at 24 hpi was observed, the same decrease did not occur in 
SC-β or EndoC-βH1 (Fig. 3.5, I & 3.7, C). In SC-β cells differences in infection 
efficiency or the kinetics might account for this. In infections of EndoC-βH1 cells 
with CVB4 at MOI of 10, approximately 50% of cells are infected at 6 hpi. 
Despite, active replication in these cells, PDX1 gene expression slightly but 
significantly increased at 24 hpi when compared to 6 hpi (Fig. 3.7, C). Since 
many environmental factors contribute to the regulation of PDX1, the other cells 
present in primary human islets could contribute to the phenotype. Cytokine 
production or reactive oxygen species produced in response to viral infection by 
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nearby cells could enhance the decrease of PDX1 mRNA in primary human 
islets. Alternately, the maintenance of PDX1 expression in EndoC-βH1 cells 
could be due to mutations acquired during the passage or immortalization 
processes of these cells in establishing the cell line. Given that these cells are 
derived from human fetal islets, differences in transcriptional regulation in these 
cells may account for the findings distinct from those in β cells. Some of these 
differences will be further explored in studies of flow cytometry-sorted primary 
human islets discussed in Chapter V. Regardless of the differences in PDX1 
gene expression between primary human islets and EndoC-βH1 cells, infections 
of EndoC-βH1 cells provide a platform for exploring PDX1 protein localization 
changes that would be difficult in primary human islets.  
EndoC-βH1 cells infected with CVB1, CVB4, or CVB5 have a decrease in 
nuclear PDX1 staining at 6 hpi (Fig, 4.3 & 4.4). Changes in PDX1 localization are 
one mechanism for decreasing its transcriptional activity. While some specificity 
in viruses leads to a change in PDX1 localization, perhaps a mechanism shared 
at least within the Coxsackie B virus group. This could provide a mechanistic 
insight into the broad range of enteroviruses that inhibit glucose stimulated 
insulin secretion after infection234. It will be interesting to determine if other 
enteroviruses change PDX1 localization. Specifically, CVA9 or CVB4 strain 
VD2921, which do not produce CPE in primary human islets, would be 
interesting to study234,235. The reduction of PDX1 in CVB-infected β cells might 
also be shared with other cell types that express PDX1. SST expression 
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decreases in infections of primary islets, suggesting that PDX1 might also be 
altered in δ cells. Previous studies of CVB infection in ductal cells also reported a 
decrease in PDX1 gene expression in persistently-infected cells215. Further 
identification of viruses that affect PDX1 and possible cell-type differences could 
provide insights into what makes some strains diabetogenic and what confers the 
β cell specificity in T1D autoimmunity.  
PDX1 localization is retained in the nucleus in EndoC-βH1 cells infected 
with both VSV-GFP and RSV-GFP. Both of these viruses belong to the order 
Mononegavirales. These single-stranded negative sense RNA viruses differ in 
their genomic structure to CVB viruses, which are single-stranded but positive 
sense. They also utilize different mechanisms for altering host gene expression 
and stimulated innate immune function. VSV blocks host transcription, mRNA 
export from the nucleus, and host translation. RSV blocks RIG-I signaling and 
INF-I production (reviewed here 284). Despite all these affects on cell function, 
neither virus changes the nuclear localization of PDX1 upon infection. This could 
partly explain why some pancreatropic viruses are able to productively replicate 
in β cells, but do not result in hyperglycemia or the development of T1D.  
Several possible regulatory mechanisms of PDX1 nucleo-cytoplasmic 
transition are unlikely due to the specificity of the phenotype to CVB viruses. It is 
unlikely that it is mediated through IFN or cytokine responses, ER stress, or 
apoptotic mechanisms. One possibility is oxidative stress conditions impact 
PDX1. CVB3 infection of cardiomyocytes is associated with the induction of 
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oxidative stress282. Oxidative stress in β cells prompts PDX1 phosphorylation and 
a change in localization from the nucleus to the cytoplasm280,281. Therefore, virus 
induction of oxidative stress may be causing the change in PDX1 localization. 
However, this hypothesis has not been tested yet in this model. Treatment with 
small molecule oxidative stress inhibitors could be tested for their efficacy in 
preventing PDX1 translocation upon CVB infection. Mutation of the Ser61 and 
Ser66 phosphorylation sites to make a PDX1 mutant that is resistant to oxidative 
stress-induced changes in PDX1 localization would be of interest, too. 
The results presented here only show the change in PDX1 localization 
upon CVB infection by immunofluorescence in EndoC-βH1 cells. Other methods 
for determining the changes in PDX1 localization include Western blot of 
subcellular protein fractions. These methods were used previously to show the 
change in PDX1 localization in response to oxidative stress conditions281. A flow 
cytometry approach could also be used to evaluate the presence of PDX1 in β 
cells upon CVB infection. Both of these methods would be helpful in translating 
the results presented here to cultured primary human islets, since microscopy is 
of limited utility in intact islets.   
In CVB4-infected HeLa cells overexpressing Pdx1, the amount of 
cytoplasmic staining of PDX1 is higher than in EndoC-βH1 cells. This could be 
due to the lack of autoregulatory activity of this construct. Since PDX1 production 
is under the control of the CMV promoter, PDX1 protein is continually produced 
even though it is being excluded from the nucleus. This also helps confirm that 
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the loss in nuclear staining is at least partly independent of transcriptional 
mechanisms.  
The overexpression of Pdx1 in HeLa cells provides further mechanistic 
insights into the changes in PDX1 localization upon CVB infection. First, PDX1 is 
excluded in an environment that is free of β cell-specific regulatory mechanisms 
of PDX1. Endogenously, HeLa cells do not expresses transcription factors 
involved in PDX1 production FOXA2 (0), HNF1A (0), NEUROD1 (0). They do 
express factors that inhibit PDX1 function at low levels of ATF3 (6), MST1 (2); or 
moderate levels of SREBF1 (37), SPOP (19), GSK3 (14), and JNK (24). Values 
are fragments per kilobase of exon per million reads mapped (FPKM) from RNA-
Seq data available from the Human Protein Atlas cell line data 
(www.proteinatlas.org).  
Other proteins in addition to PDX1 might be similarly excluded from the 
nucleus of CVB infected cells. However, I have not stained for the change in 
localization in other transcription factors important in β cell function. Surprisingly, 
the nGFP protein co-expressed in HeLa cells transduced with the pAd-Pdx1 
construct also is dispersed throughout the cell upon CVB infection. How both of 
these proteins change localization despite the presumptive lack of similar post-
translational regulatory features in nGFP is unknown. A generalized exclusion of 
proteins from the nucleus in these cells may occur. In CVB-infection of other cell 
types, other nuclear proteins are excluded from the nucleus through cleavage of 
nuclear pore complexes285,286.  
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Another possibility is a direct cleavage of the PDX1 target protein by one 
of the viral proteinases. CVB viruses do directly cleave several cellular proteins 
during infection, including eIF4G, PABP, MAVS and TRIF, to inhibit 
signaling137,139,143. In poliovirus infection, the lupus antigen is excluded from the 
nucleus through the cleavage of the lupus antigen nuclear localization signal 
within 3 hpi287,288.A similar mechanism may exclude PDX1 from the nucleus in 
both EndoC-βH1-infected cells and HeLa cells overexpressing Pdx1. To test if 
the viral protease is contributing to the change in PDX1 localization, infected cells 
could be treated with the small molecule inhibitor AG7088 that prevents protease 
3C activity289.  
Despite these interesting findings in the change in PDX1 localization, I 
was not able to directly link this phenomenon to the reduction in INS gene 
expression. To further evaluate this direct role, I could co-express PDX1 and a 
luciferase reporter under the control of the INS promoter. These cells could be 
infected and I could measure the production of INS as a measure of the change 
of PDX1 transcriptional activity under the influence of CVB infection.  
Conclusions:  
1) PDX1 mRNA expression is decreased at 24 hpi upon CVB4 infection 
compared to 6 hpi; this decrease is not observed upon challenge with activators 
of IFN-I signaling. 2) PDX1 transcriptional target gene expression is reduced at 
24 hpi, strengthening the association between PDX1 decrease and β cell 
dysfunction. 3) ATF3 gene expression increases prior to the decrease in PDX1 
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gene expression following CVB4 infection, which suggests a role for ATF3 in 
reducing PDX1 transcription. 4) Nuclear PDX1 localization decreases upon 
infection with three different CVB serotypes, but infections with VSV and RSV do 
not generate the same decrease in PDX1 nuclear localization in EndoC-βH1 
cells. 5) Ectopic expression of Pdx1 in HeLa cells, which do not express 
transcriptional regulatory factors for PDX1 expression, also have decreased 
nuclear Pdx1 staining upon CVB4 infection. Other nuclear proteins may be 
similarly excluded from the nucleus. Since PDX1 is a crucial factor in β cell 
function and CVB-infection at least somewhat specifically affects its gene 
expression and localization, this is a potential mechanism for the β cell 
dysfunction observed in enterovirus-infected primary human islets.  
4.5: Materials and methods 
4.5.1: Cell culture and infection 
EndoC-βH1 cells were cultured as previously described237. HeLa cells 
were cultured by standard protocols. For microscopy studies, cells were plated 
into 24 well plates with a coverslip. Titered stocks of virus were added to cells at 
indicated MOI in a minimal volume for 1 h to allow for adsorption. Following this 
incubation period, cells were washed with PBS and complete culture media was 
replaced. At indicated time points, cells were fixed for immunofluorescence or 
flow cytometry staining with 4% paraformaldehyde. 
4.5.2: Virus sources 
The CVB4 strain JVB, CVB1 strain Conn-5, and CVB5 strain Faulkner (# 
VR-184, VR-28, and VR-185 respectively; American Type Culture Collection) 
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grown in HeLa cells230. Virus was purified by ultracentrifugation on a sucrose 
cushion where indicated as previously described252. 
VSV-GFP, a gift from S. Whelan, was propagated as previously 
described290. 
rgRSV224 (RSV-GFP) was a kind gift from Peter Collins and Mark 
Peeples. Virus was and propagated in HEp-2 cells as previously described291. 
4.5.3: Gene expression profiling  
The NanoString CodeSet #2 (NSCS2) was developed for genes 
associated with IFN-1 (18), IFN-II (3), IFN-III (5), IFN regulated genes (20), β cell 
function (24), endocrine (9), apoptosis (8), cytokines (7), inflammation (8), ER 
stress (20), type 1 diabetes susceptibility genes (12), other human genes (4), the 
CVB-specific probe as described above, and housekeeping genes (7) for 
normalization of data for a total of 146 genes. Probes were designed to target 
human genes in a species-specific manner. One hundred nanograms of RNA 
extracted from cultured islets and was hybridized, processed, and analyzed per 
the manufacturer’s procedure. Data were normalized using the nSolver Analysis 
Software (version 2.6). Fold changes in gene expression were the ratio of 
normalized gene expression in CVB4-infected samples versus those in mock-
infected samples. Values <1 were transformed by -1/x. Heatmaps of transformed 
fold changes were produced with Gitools v2.2.3 (http://gitools.org/). 
4.5.4: Immunofluorescence 
Cells were cultured on coverslips and infected with CVB4 at an MOI of 10 
for 24 h. Cells were fixed with 4% PFA for 30min at room temperature. Fixed 
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cells were permeablized and stained in PBS-AT (PBS+2% BSA +0.5% Triton X-
100) with the following primary antibodies guinea pig antibody to mouse antibody 
to VP1, clone 5-D8/1 (1:500; Dako) and rabbit polyclonal antibody against PDX1 
(Abcam Ab47267). The following fluorophore conjugated secondary antibodies at 
1:1,000 dilution; Alexa Fluor-488 or Alexa Fluor-594 goat antibody to mouse IgG 
(catalog #A11029 and #A11032, respectively; Life Technologies) and Alexa 
Fluor-594 or Alexa Fluor-647 goat antibody to rabbit IgG (Catalog #A11012 and 
#A31573, respectively; Life Technologies) for 1 h. Coverslips were mounted with 
ProLong Gold Antifade Re-agent with DAPI (Life Technologies). 
Immunofluorescence was imaged on a Leica SP8 confocal microscope with a 
40x (1.3 oil) or 63x (1.4 oil) HC PL APO CS2 objectives running Leica Advanced 
Fluorescence software (version 3.3.0.10134.1).  
4.5.5: Image quantification 
Brightness and contrast were adjusted and PDX1 nuclear staining 
intensity was quantified by FIJI software (version 1.48p)232. Briefly, automatic 
thresholding of DAPI staining and used to mark nuclei as regions of interest 
(ROI) and counted. Staining intensity of the PDX1 channel was measured as 
integrated density of each nuclear ROI. The resulting integrated density 
measurement for each measurement was scaled by dividing by 10,000 to 
generate single digit numbers and reported as PDX1 staining intensity. Where 
indicated, each cell was also scored as infected or not infected by VP1 staining.  
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4.5.6: Flow cytometry 
EndoC-βH1 cells were trypsinized to obtain a single cell suspension at 
indicated time points. Cells were fixed and permeablized using BD 
Cytofix/Cytoperm reagents (BD Biosciences). Cells were then stained with 
mouse antibody to VP1, clone 5-D8/1 (1:1000; Dako) and Alexa Fluor-488 goat 
antibody to mouse IgG (1:1000; Life Technologies). Staining was analyzed on an 
LRB LSRII A equipped with Trigon and Blue 488nm lasers running BD FACS 
Diva software (version 8.0.1) and analyzed using FlowJo (version 10.1r5). 
4.5.7: Overexpression of Pdx1 in HeLa cells 
pAd PdxI-I-nGFP was a gift from Douglas Melton (Addgene plasmid 
#19411) and recombinant adenovirus was produced in 293A cells as previously 
described 283. HeLa cells were transduced with pAd PdxI-I-nGFP virus at a virus 
concentration that was empirically determined to maximize the number of PDX1 
positive cells at 24 h post-transduction. Transduced HeLa cells were infected 
with CVB4-JVB at an MOI of 1 for 6 h. Cells were then fixed and stained for 
PDX1 and VP1 immunofluorescence as described below.  
4.5.8: Statistical Methods  
To assess the significance of the quantification of nuclear PDX1 staining, 
a standard unpaired, two-tailed t test was used to determine the significance.
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5.1: Abstract 
 T1D is caused by a progressive loss in β cell mass due to autoimmune 
destruction directed at these cells. The development of this cell type-specific 
autoimmune reaction continues to be a poorly understood component in the 
pathogenesis of the disease. One area of interest is the functional differences of 
various endocrine cell types in response to environmental insults. β cells may be 
specifically affected in their ability to produce insulin upon CVB infection, while 
neighboring α cells may continue to produce glucagon. Additionally, divergences 
in the strength or type of antiviral response in individual cell types could affect the 
clearance of virus, creating an environment that fosters the development of 
autoimmunity. To address these possibilities, I developed a flow cytometry 
strategy to sort live cells into enriched populations of insulin-producing, glucagon-
producing, and non-hormone producing cells. Stimulation of these sorted cell 
types with innate immune stimuli revealed cell type-specific variations in the 
magnitude of responses. These findings provide insights into the initiating factors 
of the autoimmune targeting of β cells in T1D.
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5.2: Introduction 
An interesting component of the pathogenesis and development of T1D is 
the specificity for the autoimmune reaction against β cells. While the ultimate 
destruction mediated by T cells is characterized16, the processes that precipitate 
autoimmunity in a specific cell types are poorly understood. This specificity is 
particularly interesting in the context of viral triggers of T1D. Viruses could trigger 
autoimmune progression by several mechanisms. β cells could be particularly 
sensitive to viral infection leading to disproportionate presentation of β cell 
antigens to the adaptive immune system. Another possibility is that β cells 
produce or respond to innate immune signals differently than other cells. This 
could again shift the balance of antigen presentation from these cells to adaptive 
immune cells and drive autoimmunity. Understanding the differential responses 
of various islet cell types to viral infection could provide insights into the β cell 
specificity of T1D autoimmunity.  
 Viruses may have a selective β cell effect due to cell type-specific virus-
host interactions. The expression of the viral receptor, cell-specific expression of 
viral restriction factors, and differences in the cell intrinsic antiviral responses all 
contribute to cell type virus tropism. Previous histological studies in pancreas 
from individuals with T1D show that CVB is detected in β but not α cells, which 
suggests that CVB does not infect human α cells104,292-295. One possibility for the 
absence viral proteins in α cells is the lack of the requisite viral receptor on the 
cell surface. CAR protein expression is required for CVB infection and its 
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expression is absent in mouse β cells119,129. However, rat β and α cells both 
express CAR protein296. This correlates with studies of sorted human islet cells, 
where CXADR (which encodes CAR) gene expression is detected in both β and 
α cells297. Furthermore, pretreatment with anti-CAR antibody reduces CVB 
infection in both β and α cells of cultured primary human islets200. So while some 
species-specific expression differences of CAR in some cell types may exist, 
human β and α cells both produce the viral receptor making them susceptible to 
viral attachment and entry.  
Intracellular restriction factors can inhibit viral replication. The adenosine-
uridine (AU)-rich element RNA binding factor 1 (AUF1) can destabilize mRNAs 
and target them for degradation. This activity also destabilizes viral RNA in CVB 
infection and can inhibit viral replication if the virus is unable to cleave the 
protein298. Such cell type-specific restriction factors can prevent viral replication if 
no mechanism exists for the virus to subvert the inhibitory effect of the host 
factor. Other restriction factors may affect viral transcription, translation, or 
assembly of viral particles. Some of these factors may also contribute to cell 
intrinsic innate immune response signaling.  
The recognition of viral RNA by cytosolic RLRs leads to an antiviral state 
through the production of IFN, which generates an antiviral state by regulating 
thousands of downstream genes. In flow cytometry-sorted rat β and α cells, 
CVB5-infected α cells express higher levels of the RLR gene Ifih1 (which 
encodes MDA5) than β cells296. Therefore, α cells can respond more vigorously 
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to CVB-infection than β cells, perhaps preventing efficient viral replication in α 
cells. This response could be mediated through higher basal expression of other 
genes in the IFN production pathway in rat α cells. Basal expression of the 
transcription factor downstream of IFN signaling, Stat1, is also higher in rat α 
than in β cells296.  
The findings that rat α cells prevent viral replication through higher basal 
innate immune gene expression may not hold true to infections of human α cells. 
Notable differences in gene expression between rodent and human β cells have 
been documented, with 1540 genes differentially expressed between mouse and 
human β cells299. Furthermore, basal gene expression in sorted human β cells is 
higher for both IFIH1 and STAT1 than in α cells297; the immune response in these 
sorted human cells was not evaluated. Despite these differences in gene 
expression, other mechanisms of innate immune gene regulation could mediate 
a differential immune response in β compared to α cells.  
Gene expression studies of sorted primary human islet cells could be used 
to identify differentially expressed, cell-type specific immune responses. While 
high purification of β and α cells is possible using sorting by cell surface staining, 
this method could interfere with downstream treatments and gene expression. 
Adding antibodies to the cells could inhibit viral infection through steric hindrance 
of virus-receptor interactions. Antibody binding may also induce modest 
activation of innate immune signaling, which would affect the basal gene 
expression in sorted cells. This would not be ideal for evaluating gene expression 
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following treatment with poly(I:C). To mitigate these potential pitfalls, I use a cell 
sorting strategy based on intrinsic autofluorescence and side scatter properties of 
human islet cells. Previous attempts to sort human cells based on 
autofluorescence in the FITC channel are limited due to higher accumulation of 
lipofuscin in human β cells300. Despite this technical limitation, utilizing additional 
excitation and emission characteristics now available on flow cytometry 
machines could circumvent these issues.  
The goals of this chapter are to 1) develop a cell sorting strategy based on 
cell intrinsic autofluorescence and side scatter properties for primary human islet 
cells, 2) evaluate the purity of the sorted cell populations by flow cytometry and 
gene expression, 3) compare basal gene expression in β cells compared to α 
cells, and 4) evaluate the induction of innate immune genes in sorted cells in 
response to treatment with poly(I:C).  
5.3: Results 
5.3.1: Development and analysis of human primary islet cells sorted based 
on autofluorescence characteristics. 
Since cell sorting of human primary islets is reported to be problematic 
based on FITC autofluorescence characteristics alone due to the accumulation of 
lipofuscin in β cells300, I developed an alternative sorting strategy based on 
additional autofluorescence parameters. I dissociated primary human islets and 
identified live cells based on 7-Aminoactinomycin D (7-AAD) exclusion. From this 
population of live cells, I sorted populations based on autofluorescence and side-
scatter characteristics. Cells that have high autofluorescence in the fluorescein 
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(FITC) spectrum (488nm excitation, 530/30 filter) and high side scatter are 
enriched for β cells. I sorted the remaining cells based on the Pacific BlueTM 
spectrum (405nm excitation, 450/50 filter) and FITC or side scatter. Cells that are 
low in Pacific BlueTM and FITC are enriched for α cells, and cells that are lowest 
in side scatter are enriched for hormone negative cells (HN) (Fig 5.1, A). 
Following the sorting procedure, I cultured the sorted cell populations for 24 h.  
5.3.2: Evaluation of sorted populations by flow cytometry and gene 
expression profiling 
Following the overnight culture of the sorted populations, I evaluated the 
enrichment of the three major endocrine cell populations based on fluorescent 
antibody staining followed by flow cytometry analysis. I dissociated and stained a 
parallel sample from the same human islet donor that did not undergo any flow 
cytometry-sorting. Of these cells, referred to as “staining control sample”, 22% 
are β cells, 42% are α cells, 6% are δ cells, and 30% are hormone non-producing 
cells based on staining for insulin, glucagon, somatostatin, or the absence of all 
three respectively (Fig 5.1, B). To assess survival of cells following sorting or 
dispersion and overnight culture, I treated cells the same as in other sorted 
populations, but only collected live cells based on 7-AAD exclusion. This 
population is roughly equivalent to the proportions of β (17%), α (35%), δ (9%), 
or HN (39%) as the staining control sample (Fig, 5.1, B).
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the percentage of hormone positive cells was calculated for each sorted 
population. The staining control was a sample of islets from the same donor 
cultured for 48 h that was dissociated just prior to staining. (C) Viability of sorted 
cell populations after overnight culture evaluated based on Zombie VioletTM 
staining. Percentage of dead cells was calculated based on total cells gated on 
forward and side scatter. Gene expression was evaluated in a parallel culture of 
sorted islet cells using the NanoString gene expression assay. (D) Raw gene 
counts for the seven housekeeping genes that are used for normalization. (E) 
Gene expression of hormone genes normalized to the panel of housekeeping 
genes.
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The sorting strategy described above yielded a β cell population that is 
enriched from 17% in the unsorted sample to 53% insulin positive cells. 
Glucagon positive and HN cells are depleted from 35% to 29% and 39% to 9%, 
respectively, from the unsorted population to the sorted β cell population. 
However, somatostatin positive cells still represent 9% of the cells in this 
population. The sorted α cell population is enriched from 35% to 69% glucagon 
positive cells from the unsorted to the α cell population. This population is 
depleted for the other populations with only 7% of cells positive for insulin, 2% 
positive for somatostatin, and 21% HN. The sorted HN population is enriched 
from 39% to 73% for cells that do not stain for insulin, glucagon, or somatostatin. 
The hormone producing cells in the HN population are all depleted with only 3% 
insulin positive, 20% glucagon positive, and 4% somatostatin positive (Fig 5.1, 
B). While many of the cells maintained hormone staining after 24h culture as 
single cells, these conditions were detrimental to their survival. I evaluated cell 
death by identifying dead cells with Zombie VioletTM dye, which is excluded from 
live cells. 37% of cells are dead in the staining control sample where primary 
human islets were maintained in islet clusters until just prior to staining and not 
subjected to flow cytometry-sorting. Cell death is higher in all sorted populations 
cultured for 24h after sorting. 70% of cells are dead in the unsorted sample. This 
is comparable to the sorted β, α, and HN populations where 81%, 74%, and 67% 
of cells are dead, respectively (Fig. 5.1, C).  
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As a secondary means of validating enrichment in the sorted islet cell 
populations, I measured expression of hormone genes. I processed a portion of 
sorted cells that were cultured for 24 h in parallel to cells evaluated for hormone 
production by flow cytometry for gene expression. I used the NanoString gene 
CodeSet 2 (NSCS2), which includes housekeeping genes and the hormone 
genes, INS, GCG, and SST. Since there is some variation in cell survival after 24 
h, I evaluated the raw gene counts for the seven housekeeping genes. The RNA 
counts for the unsorted population and sorted β or α cells were similar for 
housekeeping genes (Fig. 5.1, D). The sorted HN population, which has the 
highest survival, also has the highest gene counts for the housekeeping genes. 
Because the survival and gene expression of housekeeping genes correlates, I 
can more confidently use these genes to normalize the data set. Gene 
expression of the hormone genes is an independent method for confirming the 
enrichment of the islet cell types in the sorted populations measured by flow 
cytometry. The normalized gene copies for the INS, GCG, and SST in the sorted 
islet populations correlates well with the staining data. The β cell population has 
more INS copies than the unsorted population. The α cell population is enriched 
for GCG gene expression. The HN population has lower gene expression for all 
three hormone genes than in the unsorted population (Fig. 5.1, E & 5.2, A). 
Therefore, the sorted populations of human islet cells both stain and express 
their associated hormone genes, and thus I can evaluate the differences in these 
cell populations at baseline and when treated with immune-stimulatory agents.
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5.3.3: Comparison of basal gene expression in sorted human islet 
populations 
In addition to the hormone genes expressed in the sorted populations of 
primary human islets, the NanoString also measured a variety of genes 
associated with islet cell function and viral innate immune function. I evaluated 
the basal expression of these genes to assess for differential levels in each cell 
population. Such differences could influence β cell dysfunction in engrafted or 
cultured primary human islets upon CVB infection. 
The gene expression in sorted human islet populations for other islet 
function genes help to confirm the enrichment of specific cell types in sorted 
populations. As expected, gene expression for proteins involved in β cell function 
is enriched in the sorted β cell population. This includes enrichment of INS (12-
fold), PDX1 (18-fold), MAFA (9-fold), IAPP (38-fold), and PCSK1 (2.7-fold) in β 
cells compared the sorted α cells (Fig. 5.2, A & C). These genes are also 
enriched in β cells compared to the unsorted population and the sorted HN cells. 
Genes associated with δ cell function, SST and HHEX, are both enriched in the β 
cell population by 69-fold and 20.8-fold, respectively (Fig. 5.2, A & C). The sorted 
α cell population is slightly enriched for GCG (1.15-fold) expression compared to 
the other populations (Fig. 5.2, A & C). This indicates contamination of the sorted 
β cells with δ cells, but not α cells. The HN population has lower expression for 
most of the islet function genes, except for a slightly higher expression of ATF3 
(Fig. 5.2, A). Taken together, β and α cells are enriched in their respective 
populations while the HN population is depleted in hormone producing cells.  
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The normalized gene counts for genes involved in CVB infection for the 
unsorted, β, α, or HN populations under basal conditions have some cell-type 
variation. The basal expression of genes involved in CVB infection in different 
cell types may contribute to the cell-type specific nature of T1D. The viral 
receptor for CVB is CAR, which is encoded by the gene, CXADR129. CXADR 
expression is highest in the HN population and the lowest in α cells. Expression 
of IFIH1 is highest in β cells and lowest in α cells. The IFNB1 is expressed at 
very low levels in all populations basally, but is slightly higher in β cells. The 
genes encoding the type I (IFNAR1, IFNAR2) and type III (IFNL1, IL10RB) IFN 
receptors are all expressed at nearly equivalent levels in all three sorted cell 
populations(Fig. 5.2, B). These gene expression differences indicate the 
possibility of differential responses to viral infection in these cell types.  
5.3.4: Gene expression profiling poly (I:C) stimulation of sorted human islet 
populations  
To better understand the cell-type specific differences in antiviral immune 
response in primary human islet cells, I quantified gene expression after 
stimulation with poly(I:C) in unsorted cells or populations enriched for α and HN 
cells. While sorted β cells were also treated with poly(I:C), these data are not 
available for analysis due to the technical failure of probe hybridization during 
gene expression quantification. Similar to treatment of intact primary human 
islets with poly(I:C) (Fig. 3.4, A) only small differences in genes associated with 
islet function are observed in the unsorted population (Fig. 5.3, A). In the α cell 
population after treatment with poly(I:C), a large increase in genes not normally 
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associated with α cells is observed. SST, IAPP, INS, and PDX1 are all increased 
greater than 5-fold. Similar to the unsorted population, islet function genes are 
generally unaffected in the sorted HN cells.  
IFN genes are highly expressed in all cell populations upon treatment with 
poly(I:C). The highest expression is in the IFN-I gene IFNB1, and the IFN-III 
genes IFNL1, IFNL2, and INFL3. The highest stimulation is in the sorted α cells. 
IFNB1 fold change is 3.4-fold higher than the unsorted cells and 2.5-fold higher 
than in the HN cells. Similarly, IFNL1 fold change is 15.5-fold higher than the 
unsorted population, and 2.9-fold higher than the HN cells. In the HN population, 
the expression for IFNA21 and IFNE1 are higher than the other two populations. 
IFNA21 is induced 5.5-fold compared to 1.1-fold and 1.2-fold in the unsorted and 
sorted α cells respectively. IFNE1 is upregulated 5.4-fold in HN cells compared to 
reductions of -1.1-fold and -1.2-fold in unsorted and α cells respectively (Fig 5.3, 
B). While the general trend of IFN-induction by poly(I:C) may be similar in 
unsorted cells compared to sorted α or HN cells, there are some cell-type specific 
responses. These could be partly due to the basal expression of immune related 
genes described in Figure 5.2.  
In line with the findings that IFN genes are highly stimulated upon poly(I:C) 
treatment, ISGs are also increased. CXCL10 is increased the most upon 
poly(I:C) treatment in all cell populations.
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Like IFN gene expression, α cells also have higher CXCL10 expression 
compared to the unsorted population and sorted HN cells. CXCL10 fold-increase 
is 2.1-fold higher than in unsorted cells and 2.3-fold higher than in sorted HN 
cells (Fig. 5.3, C).  
5.4: Discussion 
5.4.1: Primary human islet sorting and culture 
β, α, and HN cells are enriched to 53%, 69% and 73% respectively using 
a sorting strategy combining autofluorescence in the FITC and Pacific BlueTM 
channels (Fig. 5.1, B). The current sort strategy provides the highest enrichment 
for β and α cells that I have tested. Despite this progress, the purity of each 
population does not reach that achieved in flow cytometry-sorted rat islet cells, 
for which β and α cells are each >90% pure296. The major contaminating cell type 
in the β and HN populations is α cells. It is possible that other sorting strategies 
or autofluorescence characteristics will aid in excluding these cells. Other sorting 
strategies are available for live human islet cells utilizing surface staining with the 
antibodies HPi2 and HPa2. This strategy can highly purify β and α cells as 
evaluated by the gene expression of INS and GCG, although similar to my 
results, δ cells are largely maintained in the β cell population297. Both sorting 
techniques have limitations in reducing the number of δ cells in the sorted β cell 
population.  
Resident immune cells of primary human islets could be major 
contributors to the immune responses measured here. Since I did not stain for 
these cells, it is unclear in which sorted population these cells reside. Adding cell 
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surface staining for CD45 could indicate if these cells are present in unequal 
proportions in the enriched populations. If CD45+ cells are a potential 
confounding factor to measure the intrinsic responses of endocrine cells, it may 
be possible to deplete these cells during the cell sorting process. The exclusion 
of CD45+ cells by the addition of an anti-CD45 antibody could be used to remove 
these cells prior to treatment.  
Under the current culture conditions of the sorted human islet cells, 
viability is low even after only 24h of culture. The percentage of dead cells varies 
between 67% and 81% for the sorted cells (Fig. 5.1, C). Modifying the culture 
conditions could increase viability of dispersed, sorted cells. Culture of dispersed 
primary human islets on temperature-responsive polymer, poly(N-
isopropylacrylamide), culture dishes coated with rat laminin-5 increases cell 
viability and glucose responsiveness301. This culture surface, in addition to 
optimizing glucose and nutrient concentrations in the media will likely allow for 
better cell survival.  
5.4.2: Basal gene expression provides insights into cell-type specific viral 
responses 
The evaluation of cell purity based on gene expression indicates that β 
and α are enriched based on the expression of INS and GCG respectively. HN 
cells have a predictably lower expression of INS, GCG, and SST (Fig 5.1, E). 
These findings help validate the specificity of the autofluorescence-based sorting 
strategy. However, similar to the staining results, GCG expression remains high 
in the sorted β and HN cells. This is likely the reason for the paltry 1.15-fold 
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enrichment of GCG expression in β cells compared to α cells (Fig. 5.2, C). 
Further optimizing the sorting procedure will likely enhance this enrichment. 
Despite the presence of contaminating cells in the sorted β cell population, IAPP, 
PDX1, and MAFA are also enriched in these sorted cells. The presence of these 
β cell specific genes in these cells further validates the sorting strategy based on 
autofluorescence in human islet cells. 
The gene for the CVB receptor, CXADR, is expressed in sorted β and α 
cells. Additionally HN cells also express the gene for CAR (Fig 5.2, B). CXADR 
expression in both β and α cells therefore removes cell-type specific receptor 
restriction as a factor in human β cell specificity of CVB infections. Therefore, 
other restriction factors may contribute to low replication of CVB in human α cells.  
Marroqui et al. argue that the differences in CVB replication between β 
and α cells is because α cells produce a more robust immune response due to 
higher basal expression of immune genes296. In sorted primary human islet cells 
presented here, I also observe some cell-type specific differences in basal innate 
immune gene expression, albeit many of these genes are enriched in β cells, not 
α cells. This finding is more in agreement with basal gene expression of human 
islet cells sorted based on cell surface staining297. These species-specific 
differences raise questions about the translatability of these mechanisms in rat 
islets to treatment of human disease. However, cells from additional human 
donors will need to be evaluated to determine the full range of the findings of 
sorted primary human islets.  
 178 
5.4.3: Gene expression for ISGs is higher in sorted α cells 
Gene expression is generally higher for IFN and ISG gene expression 
upon poly(I:C) treatment in sorted α cells compared to the unsorted population 
and sorted HN cells (Fig. 5.3) Unfortunately, due to a technical issue the gene 
expression in sorted β cells upon poly(I:C) treatment cannot be evaluated. The 
absence of this data set makes drawing definitive conclusions about the cell-type 
specific gene expression of antiviral response genes difficult. Despite this 
shortcoming, the presence of any differences between the sorted α cells and the 
HN population is surprising. This is especially interesting since the HN population 
potentially contains resident immune cells from the primary islets. However, cell 
surface staining for hematopoietic surface markers needs to be evaluated to 
determine if these cells are actually present in this sorted population.  
Consistent with findings described in Chapter III of the changes in islet 
function gene expression upon treatment with poly(I:C), most genes in this 
category did not change in sorted α of HN cells. Interestingly the expression of 
SST and IAPP increased 48.2-fold and 15.1-fold respectively in sorted α cells. 
The cause for this increase in expression of genes from cells that are depleted in 
this sorted population is unclear, but could be explained by a differential effect on 
cell survival in α cells treated with poly(I:C). This could cause a relative 
enrichment in the other contaminating cell types in this population. Future studies 
of the cytotoxic effects of this treatment could help explain these findings.  
Even after stimulation of the sorted cells with poly(I:C), expression of 
many IFN genes remained low. However, robust production of IFNB1, IFNL1, 
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IFNL2, and IFNL3 is present. In addition to the increase in expression of these 
genes in the unsorted population of islet cells, the sorted α and HN cells also 
expressed these genes upon poly(I:C) stimulation. Interestingly, the α cells 
consistently had the highest expression of these genes. α cells had a 2.5x higher 
fold change than HN cells for IFNB1, and a 2.9x higher fold change for IFNL1 
(Fig. 5.3, B). Corresponding with this higher expression of IFN-I and IFN-III 
expression, ISGs are also induced to higher levels in α cells than HN cells. 
CXCL10, IFIT2, ISG15, and IFIH1 expression have 2.3x, 8.5x, 2.7x, and 3.75x 
higher fold-changes in α cells than in HN cells. While expression could not be 
compared with β cell expression of these genes after poly(I:C) treatment, these 
findings are consistent with findings that rat α cells produce a robust antiviral cell 
intrinsic response296. However, cell type differences in transfection efficiency of 
the poly(I:C) cannot be excluded as a confounding factor in this experiment. 
Further characterization of the mechanisms of this robust response could help us 
understand the differences in response to viral infection in α cells compared to 
neighboring β cells.  
The robust production of an antiviral response in α cells could be affecting 
the function and survival of nearby β cells. Treatment of β cells with cytokines 
inhibits insulin release190,302. Therefore, if α cells in fact mount the most efficient 
cell-autonomous antiviral immune response, cytokine production in α cells could 
also be signaling to β cells and inhibiting their function. Another possibility is that 
an inefficient immune response occurs in HN cells compared to α cells. This 
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could allow for CVB infection to persist in pancreas cells. While the β cell 
response to poly(I:C) is not directly compared here, part of the β cell specificity in 
T1D could be due to protracted infection in β cells due to inefficient viral 
clearance in these cells. The low intrinsic immune response to prevent apoptosis 
and cell death of these important cells could lead to inefficient clearance, while α 
cells have a more robust immune response and efficiently clear the virus. Further 
exploration of these mechanisms will need to be investigated to fully understand 
the role of differential immune responses in the development of T1D.  
5.4.4: Future directions 
The interpretations of the results presented here are restricted by the 
limited ability to purify individual endocrine cell types and the single human donor 
of the cells. Methods of obtaining higher cell-type purity are possible, but require 
the fixation of cells prior to sorting303. This would limit the experimental design of 
studies of viral infections to infecting intact islets followed by sorting. Efforts to 
evaluate the gene expression of single sorted cells by RNA-seq may provide 
alternatives to both my current soring strategy and other available strategies. 
However, the depth of sequencing of single cells is still a limiting factor with 
technologies that are currently available.  
5.4.5: Conclusions 
Enriched populations of primary human cells can be obtained by flow 
cytometry-sorting cells based on intrinsic autofluorescence characteristics. Basal 
gene expression indicates that cell type-specific expression of innate immune 
genes may mediate differences in antiviral responses. Furthermore, sorted α 
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cells treated with poly(I:C) have higher expression of innate immune genes than 
unsorted cells or sorted HN cells. Further dissecting these cell type differences in 
innate immune signaling to viral infections will help to understand the 
development of β cell specific autoimmunity in T1D.  
5.5: Materials and methods 
5.5.1: Culture and dissociation of human islets 
Primary human islets from a normal human donor were cultured in 
supplemented Primary Islet Medium (PIM(S) – Prodo Labs) overnight. Islets were 
dissociated into a single cell suspension using TrypLE (Invitrogen) and filtered 
through a 35 µM cell strainer. Single cells were kept on ice in DMEM medium 
with 2.8mM glucose and 1% BSA for a minimal time until flow cytometry-sorting.  
5.5.2: Flow cytometry sorting 
Cells were sorted on a BD FACSAria IIu Cell Sorter installed in a Baker 
BioProtect IV biosafety cabinet running on BD FACSDiva Software (version 8.0, 
firmware version 1.8). Live cells were gated on 7-AAD (488nm excitation, 695/40 
filter). A sample of unsorted, live cells was collected prior to sorting as a control. 
Cells were then sorted three ways based on forward scatter, side scatter, FITC 
(488nm excitation, 530/30 filter), and Pacific BlueTM (405nm excitation, 450/50 
filter) as outlined in Figure 5.1.  
5.5.3: Culture and treatment of sorted cells 
After sorting, 15,000 cells were transferred to 96 well plates for each of the 
sorted populations and the unsorted, live population. These cells were either 
untreated or transfected with 100 µg/ml of poly(I:C) (InvivoGen) by Lipofectamine 
2000 reagent (Invitrogen). After overnight culture, a portion of untreated cells was 
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stained for flow cytometry analysis described below. Parallel samples of 
untreated or poly(I:C) treated cells were washed with PBS and lysed with RLT 
buffer (Qiagen). These samples were then directly analyzed by NanoString assay 
as described below.  
5.5.4: Flow cytometry analysis 
A portion of the original sample of primary human islets was not run 
through the flow cytometry-sorted and instead cultured for an additional day (two 
days total culture). Just prior to staining all samples, these cells were dissociated 
with TrypLE (Invitrogen). These cells served as staining controls. The staining 
controls and sorted cells were first stained by Zombie VioletTM to stain dead cells 
(BioLegend 423113). Cells were then fixed with 4% paraformaldehyde and 
permeabilized by 0.1% saponin. Antibodies against glucagon (Sigma, G2654) 
and somatostatin (Lifetech, 7G5) were conjugated with Zenon 568 or 488 kits 
respectively (Invitrogen). The insulin antibody is conjugated to Alexa Fluor 647 
(Cell Signaling, #9008). Stained cells were then analyzed on a BD LSRII SORP 
running BD FACSDiva Software (version 8.0, firmware version 1.8). Proportions 
were calculated based on total cells identified by forward and side scatter as the 
denominator.  
5.5.5: NanoString gene expression profiling 
The NanoString CodeSet (NSCS2) used in these studies was developed 
to include human genes associated with IFN-I (18), IFN-II (3), IFN-III (5), IFN 
regulated genes (20), β cell function (24), endocrine (9), apoptosis (8), cytokines 
(7), inflammation (8), ER stress (20), T1D susceptibility genes (12), other human 
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genes (4), a CVB-specific probe, and housekeeping genes (7) for normalization 
of data for a total of 146 genes. Methods are the same as described in Chapter 
III.
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CHAPTER VI: DISCUSSION 
6.1: Overview 
The role of viruses as environmental triggers for the development of T1D 
is a major question in the diabetes field. Broadly, I sought to characterize two 
aspects of enterovirus infection of human β cells. The first is how CVB infection 
directly disrupts β cell function of insulin production. The second is to define how 
innate immune signaling in β cells following CVB challenge may contribute to the 
pathogenesis and autoimmune activation of T1D in people. A summary of the 
findings for changes in insulin and PDX1 expression and innate immune 
responses for each model system described are summarized in Table 6.1. A 
better understanding of these aspects of viral infection could be used to identify 
early markers for the progression to T1D, which could be used in clinical 
diagnosis and towards prevention of T1D. Biomarkers that identify patients who 
develop autoimmunity against β cells after a viral infection could aid in preventing 
disease. These same pathways could also be targeted for drug design to prevent 
the development of T1D.  
In Chapter II, results from the in vivo infection model of mice engrafted 
with primary human islets indicate that a loss of insulin production causes 
hyperglycemia and that an islet intrinsic innate immune response to the viral 
infection occurs. In Chapter III, infections with various cultured human β cells 
indicate that the reduction in insulin gene expression occurs between 6 and 24 
hpi. A robust IFN-I response followed by induction of downstream ISGs occurs in 
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these cells in response to poly(I:C) treatment or infection with CVB4. In Chapter 
IV, I identified a shift in nuclear PDX1 localization in CVB-infected EndoC-βH1 
cells at 6 hpi. Infection with viruses other than CVB did not result the same shift 
in localization. These results indicate a potential early mechanism in β cell 
dysfunction upon CVB infection. Finally, in Chapter V, immune responses in 
populations of flow cytometry-sorted cells are evaluated upon poly(I:C) 
stimulation. These results indicate that IFN and ISG responses are different in α 
cells compared to hormone-negative cells. Cell type differences in innate immune 
responses could identify factors that are important in the cell type specificity of 
the autoimmune reaction against β cells in T1D. As a whole, many changes in 
gene expression are observed in CVB4-infected β cells compared to uninfected 
control, and it is likely that some or all of these changes act in concert to initiate a 
cascade that contributes to the autoimmune destruction of β cells and the 
development of T1D.  
6.2: β cell dysfunction and innate immune signaling in an in vivo model 
In Chapter II, I utilized an in vivo model of primary human islets engrafted 
into immunodeficient mice with induced hyperglycemia to define effects of CVB4 
infection on β cell function and innate immune signaling. At a mean time of 28 
days post infection with CVB4, mice developed hyperglycemia due to reduced 
insulin production (Fig. 2.2). This finding was the impetus for further exploring β 
cell dysfunction after CVB4 infection. CVB4 infection of engrafted primary human 
islets also produces a strong innate immune gene response that is indicative of 
the induction of IFN-I. The dsRNA sensor IFIH1, which initiates IFN-I responses 
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and is itself an ISG, and the IFN-inducible cytokine CXCL10 are both significantly 
increased following infections.  
This in vivo model could be modified in several ways to further understand 
β cell dysfunction and innate immune responses after virus infection. Drugs could 
be used to modulate viral replication or immune responses, other virus strains 
could be evaluated, and human immune cells could be added to the system. 
Each is discussed below in further detail. 
The above-described in vivo model could be extended through drug 
modification of viral replication or cellular responses. The antiviral drug, 
pleconaril, suppresses CVB4 replication by binding to VP1 and interfering with 
the uncoating of the virus in cultured primary human islets304. So treatment of 
infected mice with this drug may also reduce viral replication, increase viral 
clearance, and prevent hyperglycemia. Administration of drug after the 
development of hyperglycemia could help determine if the hyperglycemia is 
reversible. However, this recovery may be limited due to the poor proliferation of 
human β cells. It may also be possible to reduce β cell stress in infected mice to 
determine if hyperglycemia can be delayed or prevented. Modulations in viral 
replication or the ability of β cells to tolerate viral replication may extend the time 
until hyperglycemia develops.  
Viral pathogens besides CVB could be used for infection to determine if 
they can cause hyperglycemia in the relative absence of immune cells. While 
other viruses can infect and replicate in β cells, including VSV and RSV, they 
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may not be able to promote hyperglycemia similar to CVB4. Because VSV and 
RSV do not impact PDX1 localization in the same manner as CVB4 in EndoC-
βH1 cells (see Chapter IV), these viruses might not affect insulin or induce 
hyperglycemia in these mice. If they do promote the development of 
hyperglycemia, they may do so more rapidly or through different mechanisms. 
Another potentially interesting virus to try is CVA9, which reportedly infects and 
replicates in cultured primary human islets, but does not affect insulin 
secretion233,234. This could provide the opportunity to compare gene expression 
through unbiased RNA-seq techniques to identify similarities and differences in 
these responses.  
Another means for expanding the in vivo model is to add back 
components of the human immune system to provide insight on the interaction of 
the innate immune signaling from infected islet cells to the adaptive immune 
system. Engraftment human fetal liver and thymus tissue to provide 
macrophages, T, and B cells could be transplanted along with autologous human 
fetal islets. Challenging these mice with virus would provide for a better 
understanding of the mechanisms behind development of beta cell dysfunction in 
human tissue in the context of adaptive immune responses. The infiltration of 
these cells into engrafted islets could further enhance the local inflammatory 
niche in the infected islets, potentially leading to a cytotoxic T cells response 
against β cells. This may accelerate the progression to hyperglycemia in this 
model. However, a major challenge is the significant dual morbidity of graft 
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versus host disease and virus infection in the model. 
6.3: Combining models 
Engraftment of either SC-β or EndoC-βH1 in mice can rescue 
hyperglycemia in mice33,237, i.e., these sources of human β cells can used in 
place of primary human islets in the in vivo model with viral challenge to induce 
diabetes. These alternative cells provide less genetic variability between 
experiments, greater availability of cells, and the possibility for genetic 
manipulation of the engrafted cells. Studying engraftment of these cells in mice 
provides advantages over culture given more physiologically relevant conditions 
and vascularization that maintains long-term viability.  
Two potential outcomes from these experiments are considered; each can 
be leveraged to reveal new insights on β cell biology and innate immune 
responses that precipitate autoimmunity. These mice become hyperglycemic 
after CVB challenge just as in the experiments with engrafted primary human 
islets. If this is the case, in vivo models of these engrafted cells could provide a 
more reproducible model with more genetic stability between experiments to test 
other strains of CVB4 or other viruses implicated in T1D. This also provides for a 
genetically tractable system for testing components of the type IFN-I pathway in 
the development of hyperglycemia after viral infection, given that candidate 
genes can be targeted using CRISPR-Cas9 approach. Knockouts for IFIH1 or 
type I interferon receptor (IFNAR) would be candidates for suppressing IFN-I 
signaling following CVB4 challenge and could help to dissect the relative 
contributions of direct viral effects and innate immune responses on the 
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production or secretion of insulin.  
A second potential outcome is that mice engrafted with either SC-β or 
EndoC-βH1 cells do not revert to hyperglycemia following CVB4 infection. 
Differences in insulin gene expression of these cells compared to cultured 
primary human islets following in vitro challenge with virus have been observed. 
Since insulin mRNA production is maintained in SC-β and EndoC-βH1 cells, it is 
possible that these cells may be resistant to the mechanisms that suppress 
insulin expression in cultured primary human islets. These artificial β cell sources 
lack some of the cellular diversity in cultured primary human islets. Cultured and 
engrafted islets include resident immune cells, endothelial cells, ductal cells, and 
low levels of exocrine cells, which may be contributing to the decrease in insulin 
gene expression via an undefined mechanism during infection. If hyperglycemia 
were induced by CVB4 in SC-β or EndoC-βH1 cell-engrafted mice, this would 
suggest that the non-endocrine cells are non-essential in the mechanism. RNA-
seq of infected cultured primary human islets could be compared with that of SC-
β or EndoC-βH1 to identify genetic factors that many be absent in the later two 
cell types. The differential gene expression could identify pathways involved in 
the loss of INS and PDX1 gene expression and islet dysfunction in CVB4 
infection.  
Altogether, these alternative sources of β cells in the mouse model could 
provide new insights into virus-host interactions between CVB and human β 
cells. Results could be leveraged to gain insights into β cell dysfunction after viral 
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infection and the innate immune responses induced in response to viral infection.  
6.4: Potential extensions of viral infections of EndoC-βH1 cells 
Because a β cell line derived from human cells has only recently become 
available, most of the information about β cell changes after virus infection is 
from experiments carried out in rodent β cell lines. Because of limitations in 
translating the findings in rodent models into therapies for human disease, these 
species-specific differences are critical. The availability of EndoC-βH1 cells and 
their permissiveness to CVB infection allow for investigation of other aspects of 
the virus-host relationship. The effects on aspects of insulin secretion and 
changes in viral genome in adaptation to β cells should be evaluated. This 
platform also provides a system for identifying and characterizing early 
biomarkers of viral infection and β cell function that could be translated into 
diagnostic assays.  
In addition to decreases in INS gene expression after CVB infection, other 
aspects of the insulin response may be disrupted including insulin translation, 
maturation in secretory granules, or secretion. In the mouse β cell line, MIN6, 
CVB5 infection directly impairs glucose-stimulated insulin secretion by reducing 
the amount of insulin in secretory granules305. This may also contribute to the β 
cell dysfunction observed in engrafted primary human islets after infection that 
results in hyperglycemia (Chapter II). In addition to reduction in insulin production 
or packaging, CVB infection may interfere with aspects of insulin secretion. The 
increase in intracellular calcium upon glucose sensing is required for release of 
insulin granules docked that the plasma membrane for immediate release. The 
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CVB viral proteins 2B and 2BC integrate into ER and golgi membranes and 
increase calcium efflux145. This could interfere with the normal calcium control in 
β cells and reduce their ability to release insulin in response to glucose. The 
combination of these factors in disruption of insulin responses might explain the 
loss of glycemic control in the in vivo model. These possibilities for additional 
mechanisms of β cell dysfunction may help explain why infections with CVB are 
often associated with the development of T1D.  
The persistence of viral infection in our in vivo engrafted primary human 
islet model was surprising and raises questions about possible changes in the 
viral genome over the course of the infection. Conditions of CVB3 persistent 
infection are associated with deletions in the 5’ UTR121. These viruses are poorly 
replicative and less cytopathic. Evaluating virus present in the engrafted primary 
human islets of infected mice for mutations and deletions acquired over the 
course of persistent infection would be of interest. RNA-seq on samples from the 
engrafted primary human islets could reveal if 5’ UTR deletions are present; viral 
genome populations from the input inoculum virus could be compared to the 
viruses that remain during persistent infection. These data may provide insights 
into viruses that are slowly replicating and well adapted to the β cells, and are 
consistent with the hypothesis that persistent enteroviruses may precipitate T1D 
development by promoting persistent inflammatory conditions in the islets306. 
Another method to explore the changes in virus genome after adaptation 
to human β cells is to serially passage CVB4 in EndoC-βH1 cells to see if this 
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reduces the virulence and CPE induced by these viruses and to determine if 
these viruses become more β cell tropic. This may lead to increased the 
penetrance of virus infection in the in vivo model, which is currently ~50% 
(Chapter II). Adaptation of CVB5 to MIN6 cells allowed for a more β cell tropic 
virus in infections of mice307. A similar approach could be applied to CVB in 
human β cells. In addition to passaging CVB in human β cells, selective 
pressures could be added to learn more why viruses selected under different 
conditions may or may not induce hyperglycemia in vivo. For example, CVB 
could be passaged in the presence of recombinant IFN-I. This IFN-I resistant 
strain could upset the balance of viral replication and innate immune control in 
the engrafted primary human islets, and would be predicted to be more likely to 
precipitate hyperglycemia in mice.  
Infections of EndoC-βH1 cells provide an attractive platform for discovery 
of biomarkers that could be used clinically to identify enterovirus infections 
affecting β cells that could lead to the induction of T1D. These cells have the 
advantage of being a monoculture, so the changes measured will be β cell-
specific. Infections of non-β cell types could help identify markers for the 
production of secreted or cell-intrinsic factors induced upon CVB infection. 
Proteomics of supernatants from CVB-infected EndoC-βH1 cells would identify 
factors secreted or released from infected cells. Furthermore, samples at 
different time points could identify factors that identify early or late markers for β 
cell infection. 
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6.5: Conclusions 
Overall, I hypothesized that CVB4 infection of human β cells results in β 
cell dysfunction characterized by reduced insulin production and innate immune 
responses, including induction of IFNB and CXCL10 gene expression. Further 
insights into these responses will help to better identify, diagnose, treat, and 
prevent the development of T1D in genetically predisposed people.  
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APPENDIX I: CHANGES IN MOUSE GENE EXPRESSION UPON CVB4 
INFECTION 
In Chapter II, I describe the response of primary human islets engrafted 
into diabetic, immunodeficient mice. To differentiate the gene expression 
changes after CVB4 infection, I utilized the NanoString gene expression assay. 
This allowed for the design of species-specific probes to determine if the 
changes in gene expression were because of viral responses in the engrafted 
human tissue or the surrounding mouse kidney tissue.  
The species-specificity of the probes can be evaluated based on the 
expression of endocrine genes that should not be expressed in mouse kidney 
tissue. The human-specific NanoString detected robust expression of endocrine 
genes including INS, SST, and GCG. In contrast, the gene expression from these 
same samples using the mouse-specific NanoString had RNA copies below the 
level of detection for Ins2 and Sst. Some cross-reactivity may occur between 
some of the probes because the probe that was designed to be specific for 
mouse Gcg detects at high levels.  
The human-specific NanoString showed many genes that are decreased 
after CVB4 infection in the engrafted islets (Fig. 2.6, A). In the same samples 
from Experiment 1 where diabetes was induced by STZ treatment, there are very 
few mouse genes that decrease after CVB4 infection, and none of these changes 
reach statistical significance (Fig. A1, A). Comparison of human genes increased 
after CVB4 infection (Fig. 2.6, B) with increased mouse-specific genes shows
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 that several of the genes with the highest increases are the same. Ccl5, Oas, 
Mx1, Cxcl10, Ifih1, and Stat1 are all significantly increased in both human-
specific and mouse-specific probe sets (Fig. A1, B). However, in general the fold 
increases are lower with the mouse-specific probes. Several genes are 
significantly increased with the mouse-specific probes that are not significantly 
changed with the human-specific probes, including Ifi16, Irf7, Ifng, Tlr7, and Tlr9 
(Fig. A1, B). These genes may represent species-specific differences or tissue-
type specificity. These differences could help to understand the innate immune 
responses to CVB infection between different cell types, and why infection of β 
cells could trigger autoimmunity.  
 While some response to the CVB-infection in the mouse tissue is 
observed, the gene signature is unique from that of the engrafted primary human 
islets. The response in mouse tissue also seems to be weaker than the human 
gene response. However, it is unclear how much the expression of these genes 
from mouse tissue influences the function and response of the engrafted primary 
human islets.  
When these experiments were conducted, it was not possible to 
specifically recover the engrafted primary human islet cells from the mouse 
tissue. Recently, methods have been developed that will allow the separation of 
the human cells from the mouse tissue. This will further mitigate the 
complications of cross-reactive probes. However, these techniques will not 
account for the potential for cross-species signaling that may occur during the 
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viral infection. The response of the mouse dendritic cells, macrophages, and 
granulocytes, which are still present in NSG mice, could be mediating some of 
the changes in gene expression in human cells in this model. It is encouraging 
that in cultured islets, which are devoid of any mouse tissue or cells, the gene 
expression patterns are similar to the islets engrafted in mice. Therefore, it is 
likely that the gene expression changes in this model of viral infection of primary 
human islets are due to cell-intrinsic responses to the virus and not due to 
responses to mouse immune cells.  
Appendix I: Materials and methods 
Culture and dissociation of human islets 
A portion of the human islets that were engrafted in mice was collected at 
the time of sacrifice from Experiment 1 (STZ-treatment) from CVB4-infected mice 
(n=7) and mock-infected mice (n=5). TRIzol reagent (Life Technologies) was 
used for RNA extraction from the tissue. Probes were designed to target mouse 
genes in a species-specific manner against the same genes as described for 
NanoString CodeSet #1 (NSCS1), which included type I IFN, cytokines, 
apoptosis, endocrine, endoplasmic reticulum (ER) stress, T1D-associated loci, 
and other human genes, plus seven housekeeping genes for normalization of 
data. One hundred nanograms of RNA extracted from tissue was hybridized, 
processed, and analyzed per the manufacturer’s procedure. Data were 
normalized using the nSolver Analysis Software (version 1.1). Fold changes in 
gene expression were the ratio of normalized gene expression in CVB4-infected 
samples versus those in mock-infected samples. Averages of fold changes were 
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calculated by averaging the log10 of the fold change followed by a transformation 
of 10x. Values <1 were transformed by -1/x. Statistical significance was 
determined by Student’s t-test.  
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